US3948254A
(en)
*
|
1971-11-08 |
1976-04-06 |
Alza Corporation |
Novel drug delivery device
|
US3996933A
(en)
*
|
1972-10-02 |
1976-12-14 |
Morton Gutnick |
Intrauterine contraceptive devices and processes
|
US4325388A
(en)
*
|
1973-02-05 |
1982-04-20 |
Louis Bucalo |
Apparatus for collecting and processing body fluids
|
US3971376A
(en)
*
|
1973-02-26 |
1976-07-27 |
Ceskoslovenska Akademie Ved |
Method and apparatus for introducing fluids into the body
|
US4177256A
(en)
*
|
1973-04-25 |
1979-12-04 |
Alza Corporation |
Osmotic bursting drug delivery device
|
US4111196A
(en)
*
|
1973-07-27 |
1978-09-05 |
Lionel C. R. Emmett |
Intrauterine contraceptive device of c or omega form with tubular inserter and method of placement
|
GB1465684A
(en)
*
|
1973-07-27 |
1977-02-23 |
Emmett L |
Contraceptive device
|
US4018220A
(en)
*
|
1974-07-19 |
1977-04-19 |
Lionel C. R. Emmett |
Method of insertion for intrauterine device of C or omega form with tubular inserter
|
US4172446A
(en)
*
|
1974-12-20 |
1979-10-30 |
Louis Bucalo |
Apparatus for collecting body fluids
|
US4135514A
(en)
*
|
1974-12-23 |
1979-01-23 |
Alza Corporation |
Osmotic releasing system for administering ophthalmic drug to eye of animal
|
US3946734A
(en)
*
|
1975-02-19 |
1976-03-30 |
The United States Of America As Represented By The Secretary Of State |
Apparatus for controlling the release of a drug
|
ZA761193B
(en)
*
|
1975-03-19 |
1977-02-23 |
Procter & Gamble |
Controlled release articles
|
US4034758A
(en)
*
|
1975-09-08 |
1977-07-12 |
Alza Corporation |
Osmotic therapeutic system for administering medicament
|
US3977404A
(en)
*
|
1975-09-08 |
1976-08-31 |
Alza Corporation |
Osmotic device having microporous reservoir
|
US4036228A
(en)
*
|
1975-09-11 |
1977-07-19 |
Alza Corporation |
Osmotic dispenser with gas generating means
|
US3987790A
(en)
*
|
1975-10-01 |
1976-10-26 |
Alza Corporation |
Osmotically driven fluid dispenser
|
US4077407A
(en)
*
|
1975-11-24 |
1978-03-07 |
Alza Corporation |
Osmotic devices having composite walls
|
US4031202A
(en)
*
|
1975-12-08 |
1977-06-21 |
The Procter & Gamble Company |
Controlled release contraceptive article
|
US4073833A
(en)
*
|
1975-12-08 |
1978-02-14 |
The Procter & Gamble Company |
Encapsulation process
|
US4008719A
(en)
*
|
1976-02-02 |
1977-02-22 |
Alza Corporation |
Osmotic system having laminar arrangement for programming delivery of active agent
|
US4058122A
(en)
*
|
1976-02-02 |
1977-11-15 |
Alza Corporation |
Osmotic system with laminated wall formed of different materials
|
US4014334A
(en)
*
|
1976-02-02 |
1977-03-29 |
Alza Corporation |
Laminated osmotic system for dispensing beneficial agent
|
US4203439A
(en)
*
|
1976-11-22 |
1980-05-20 |
Alza Corporation |
Osmotic system with volume amplifier for increasing amount of agent delivered therefrom
|
US4207890A
(en)
*
|
1977-01-04 |
1980-06-17 |
Mcneilab, Inc. |
Drug-dispensing device and method
|
US4218433A
(en)
*
|
1977-03-03 |
1980-08-19 |
Nippon Kayaku Kabushiki Kaisha |
Constant-rate eluting tablet and method of producing same
|
US4160452A
(en)
*
|
1977-04-07 |
1979-07-10 |
Alza Corporation |
Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
|
US4182330A
(en)
*
|
1977-07-25 |
1980-01-08 |
Alza Corporation |
Means for administering amphipathic medicament
|
US4190642A
(en)
*
|
1978-04-17 |
1980-02-26 |
Alza Corporation |
Ocular therapeutic system for dispensing a medication formulation
|
US4265874A
(en)
*
|
1980-04-25 |
1981-05-05 |
Alza Corporation |
Method of delivering drug with aid of effervescent activity generated in environment of use
|
US4344929A
(en)
*
|
1980-04-25 |
1982-08-17 |
Alza Corporation |
Method of delivering drug with aid of effervescent activity generated in environment of use
|
SE448203B
(sv)
*
|
1980-09-10 |
1987-02-02 |
Johan Alfred Olof Johansson |
formkropp framstelld av agar och/eller agaros och/eller ett derivat derav innehallande farmakologiskt verksamt emne
|
US4439195A
(en)
*
|
1980-10-14 |
1984-03-27 |
Alza Corporation |
Theophylline therapy
|
US4455145A
(en)
*
|
1981-07-10 |
1984-06-19 |
Alza Corporation |
Dispensing device with internal drive
|
US4740201A
(en)
*
|
1981-10-09 |
1988-04-26 |
Alza Corporation |
Intravenous system for delivering a beneficial agent
|
USRE34365E
(en)
*
|
1981-07-13 |
1993-08-31 |
|
Intravenous system for delivering a beneficial agent
|
US4985017A
(en)
*
|
1981-07-13 |
1991-01-15 |
Alza Corporation |
Parenteral therapeutical system comprising drug cell
|
US4857052A
(en)
*
|
1981-07-13 |
1989-08-15 |
Alza Corporation |
Intravenous system for delivering a beneficial agent
|
US4973307A
(en)
*
|
1981-07-13 |
1990-11-27 |
Alza Corporation |
Method for administering drugs to a patient
|
US4790820A
(en)
*
|
1981-07-13 |
1988-12-13 |
Alza Corporation |
Parenteral agent dispensing equipment with drug releasing member
|
US4511353A
(en)
*
|
1981-07-13 |
1985-04-16 |
Alza Corporation |
Intravenous system for delivering a beneficial agent
|
US4740198A
(en)
*
|
1981-10-09 |
1988-04-26 |
Alza Corporation |
Method of administering intravenous drug using rate-controlled dosage form
|
US5069671A
(en)
*
|
1981-07-13 |
1991-12-03 |
Alza Corporation |
Intravenous medication
|
US4552555A
(en)
*
|
1981-07-31 |
1985-11-12 |
Alza Corporation |
System for intravenous delivery of a beneficial agent
|
US4994031A
(en)
*
|
1981-07-13 |
1991-02-19 |
Alza Corporation |
Intravenous system for delivering a beneficial agent
|
US4432756A
(en)
*
|
1981-11-27 |
1984-02-21 |
Alza Corporation |
Parenteral controlled therapy
|
GB2107191B
(en)
*
|
1981-07-31 |
1984-08-30 |
Alza Corp |
Parenteral delivery system
|
US4525162A
(en)
*
|
1981-07-31 |
1985-06-25 |
Alza Corporation |
Parenteral controlled delivery
|
US4871360A
(en)
*
|
1981-07-31 |
1989-10-03 |
Alza Corporation |
System for intravenous delivery of a beneficial drug at a regulated rates
|
US4439194A
(en)
*
|
1981-09-08 |
1984-03-27 |
Merck & Co., Inc. |
Water and drug delivery system for suppository use
|
US4740200A
(en)
*
|
1981-10-09 |
1988-04-26 |
Alza Corporation |
Intravenous system for delivering a beneficial agent
|
US4586922A
(en)
*
|
1981-10-09 |
1986-05-06 |
Alza Corporation |
Intravenous system for delivering a beneficial agent
|
US4740103A
(en)
*
|
1981-10-09 |
1988-04-26 |
Alza Corporation |
Intravenous system for delivering a beneficial agent
|
US4741734A
(en)
*
|
1981-10-09 |
1988-05-03 |
Alza Corporation |
Releasing means for adding agent using releasing means to IV fluid
|
US4740197A
(en)
*
|
1981-10-09 |
1988-04-26 |
Alza Corporation |
Intravenous system for delivering a beneficial agent via polymer delivery
|
US4740199A
(en)
*
|
1981-10-09 |
1988-04-26 |
Alza Corporation |
Intravenous system for delivering a beneficial agent
|
US4741735A
(en)
*
|
1981-10-09 |
1988-05-03 |
Alza Corporation |
Intravenous system for delivering a beneficial agent
|
US4416659A
(en)
*
|
1981-11-09 |
1983-11-22 |
Eli Lilly And Company |
Sustained release capsule for ruminants
|
US4484909A
(en)
*
|
1981-11-27 |
1984-11-27 |
Alza Corporation |
Parenteral therapy using solid drug
|
US4479794A
(en)
*
|
1981-11-27 |
1984-10-30 |
Alza Corporation |
System for intravenous therapy
|
US4479793A
(en)
*
|
1981-11-27 |
1984-10-30 |
Alza Corporation |
Parenteral administration using drug delivery device
|
US4493702A
(en)
*
|
1981-11-27 |
1985-01-15 |
Alza Corporation |
Parenteral administration using osmotically motivated delivery system
|
US4548599A
(en)
*
|
1981-11-27 |
1985-10-22 |
Alza Corporation |
Parenteral controlled therapy
|
US4552556A
(en)
*
|
1981-11-27 |
1985-11-12 |
Alza Corporation |
Parenteral controlled therapy
|
US4583981A
(en)
*
|
1981-11-27 |
1986-04-22 |
Alza Corporation |
Parenteral controlled therapy, using a porous matrix with parenteral agent
|
US4579553A
(en)
*
|
1981-11-27 |
1986-04-01 |
Alza Corporation |
Parenteral controlled therapy
|
US4484921A
(en)
*
|
1982-02-01 |
1984-11-27 |
Alza Corporation |
Theophylline therapy utilizing osmotic delivery
|
US4475916A
(en)
*
|
1982-03-18 |
1984-10-09 |
Merck & Co., Inc. |
Osmotic drug delivery system
|
US4439196A
(en)
*
|
1982-03-18 |
1984-03-27 |
Merck & Co., Inc. |
Osmotic drug delivery system
|
US4449983A
(en)
*
|
1982-03-22 |
1984-05-22 |
Alza Corporation |
Simultaneous delivery of two drugs from unit delivery device
|
US4455143A
(en)
*
|
1982-03-22 |
1984-06-19 |
Alza Corporation |
Osmotic device for dispensing two different medications
|
US4664650A
(en)
*
|
1982-05-24 |
1987-05-12 |
Alza Corporation |
Apparatus for parenteral infusion of fluid containing beneficial agent
|
US4908019A
(en)
*
|
1982-05-24 |
1990-03-13 |
Alza Corporation |
Apparatus comprising dual reservoirs for parenteral infusion of fluid containing beneficial agent
|
US4515585A
(en)
*
|
1982-05-24 |
1985-05-07 |
Alza Corporation |
System for parenteral administration of agent
|
US4489056A
(en)
*
|
1982-06-30 |
1984-12-18 |
Merck & Co., Inc. |
Acid anhydrides as rate controlling agent for the erosion of polymers which latter polymers have beneficial substances dispersed throughout their matrix or where the polymer matrix surrounds the beneficial substance
|
US4519801A
(en)
*
|
1982-07-12 |
1985-05-28 |
Alza Corporation |
Osmotic device with wall comprising cellulose ether and permeability enhancer
|
US4553973A
(en)
*
|
1982-07-12 |
1985-11-19 |
Alza Corporation |
Process for preparing osmotic device
|
US4539004A
(en)
*
|
1982-09-22 |
1985-09-03 |
Alza Corporation |
Self-driven pump assembly and method of operation
|
US4522625A
(en)
*
|
1982-09-29 |
1985-06-11 |
Alza Corporation |
Drug dispenser comprising wall formed of semipermeable member and enteric member
|
US4552561A
(en)
*
|
1982-12-23 |
1985-11-12 |
Alza Corporation |
Body mounted pump housing and pump assembly employing the same
|
US4859667A
(en)
*
|
1983-01-21 |
1989-08-22 |
Merck Frosst Canada, Inc. |
Pharmaceutical compositions of phenothiazone derivatives and analogs
|
US4667032A
(en)
*
|
1983-01-21 |
1987-05-19 |
Merck Frosst Canada, Inc. |
Phenothiazone derivatives and analogs
|
US4576604A
(en)
*
|
1983-03-04 |
1986-03-18 |
Alza Corporation |
Osmotic system with instant drug availability
|
US4789516A
(en)
*
|
1983-04-15 |
1988-12-06 |
Damon Biotech, Inc |
Production of sustained released system
|
US4690682A
(en)
*
|
1983-04-15 |
1987-09-01 |
Damon Biotech, Inc. |
Sustained release
|
US4503030A
(en)
*
|
1983-06-06 |
1985-03-05 |
Alza Corporation |
Device for delivering drug to certain pH environments
|
US4610686A
(en)
*
|
1983-11-02 |
1986-09-09 |
Alza Corporation |
Controlled delivery of haloperidol by an osmotic delivery system
|
GB2150830B
(en)
*
|
1983-12-05 |
1987-08-19 |
Alza Corp |
Drug dispenser
|
US4844984A
(en)
*
|
1984-03-19 |
1989-07-04 |
Alza Corporation |
Dispensing system with means for increasing delivery of beneficial agent from the system
|
US4692336A
(en)
*
|
1984-03-19 |
1987-09-08 |
Alza Corporation |
Self controlled release device for administering beneficial agent to recipient
|
US4624945A
(en)
*
|
1984-03-19 |
1986-11-25 |
Alza Corporation |
Dispensing system with means for increasing delivery of beneficial agent from the system
|
US5000957A
(en)
*
|
1984-03-19 |
1991-03-19 |
Alza Corporation |
Dispenser comprising hydrophilic osmopolymer
|
US4612186A
(en)
*
|
1984-03-19 |
1986-09-16 |
Alza Corporation |
Method for establishing blood levels of biocide in animals
|
US4684524A
(en)
*
|
1984-03-19 |
1987-08-04 |
Alza Corporation |
Rate controlled dispenser for administering beneficial agent
|
US4717566A
(en)
*
|
1984-03-19 |
1988-01-05 |
Alza Corporation |
Dosage system and method of using same
|
US4729793A
(en)
*
|
1985-08-09 |
1988-03-08 |
Alza Corporation |
Composition for manufacturing wall of dispensing device
|
US4927633A
(en)
*
|
1984-03-19 |
1990-05-22 |
Alza Corporation |
Dispenser for delivering drug to livestock
|
US4663148A
(en)
*
|
1984-03-21 |
1987-05-05 |
Alza Corporation |
Dispenser comprising telescopically engaging members
|
US4663149A
(en)
*
|
1984-03-21 |
1987-05-05 |
Alza Corporation |
Dispenser comprising inner and outer walls functioning as cooperative unit
|
US4678467A
(en)
*
|
1984-03-21 |
1987-07-07 |
Alza Corporation |
Dispenser comprising capsule with volume displacing member
|
GB2155889B
(en)
*
|
1984-03-21 |
1988-03-02 |
Alza Corp |
Dispenser-capsule
|
US4716031A
(en)
*
|
1984-03-21 |
1987-12-29 |
Alza Corporation |
Drug dispenser comprising a multiplicity of members acting together for successfully dispensing drug
|
US4814180A
(en)
*
|
1984-03-21 |
1989-03-21 |
Alza Corporation |
Agent dispenser comprising a semipermeable wall surrounding single-piece or two-piece container
|
US4692326A
(en)
*
|
1984-03-21 |
1987-09-08 |
Alza Corporation |
Dispenser comprising inner positioned soft or hard capsule
|
US4615698A
(en)
*
|
1984-03-23 |
1986-10-07 |
Alza Corporation |
Total agent osmotic delivery system
|
US4511351A
(en)
*
|
1984-05-14 |
1985-04-16 |
Alza Corporation |
Parenteral delivery system utilizing a hollow fiber cellular unit
|
US4596555A
(en)
*
|
1984-05-14 |
1986-06-24 |
Alza Corporation |
Parenteral delivery system utilizing a hollow fiber cellular unit
|
US4511352A
(en)
*
|
1984-05-14 |
1985-04-16 |
Alza Corporation |
Parenteral delivery system with in-line container
|
US4968507A
(en)
*
|
1984-06-20 |
1990-11-06 |
Merck & Co., Inc. |
Controlled porosity osmotic pump
|
US4769027A
(en)
*
|
1984-08-15 |
1988-09-06 |
Burroughs Wellcome Co. |
Delivery system
|
AU592546B2
(en)
*
|
1984-12-03 |
1990-01-18 |
Baxter International Inc. |
Drug delivery apparatus preventing local and systemic toxicity
|
US4765985A
(en)
*
|
1985-03-05 |
1988-08-23 |
Ciba-Geigy Corporation |
Devices and methods for treating memory impairment
|
US4680172A
(en)
*
|
1985-03-05 |
1987-07-14 |
Ciba-Geigy Corporation |
Devices and methods for treating memory impairment
|
JPS61153350U
(US20080293856A1-20081127-C00127.png)
*
|
1985-03-13 |
1986-09-22 |
|
|
US4693886A
(en)
*
|
1985-04-22 |
1987-09-15 |
Alza Corporation |
Osmotic device with inert core
|
CA1309557C
(en)
|
1985-06-18 |
1992-10-27 |
Robert N. Young |
Leukotriene antagonists
|
US4717718A
(en)
*
|
1985-08-09 |
1988-01-05 |
Alza Corporation |
Device for the controlled delivery of a beneficial agent
|
US4717568A
(en)
*
|
1985-08-09 |
1988-01-05 |
Alza Corporation |
Laminar arrangement for increasing delivery of beneficial agent from dispenser
|
US4643731A
(en)
*
|
1985-08-16 |
1987-02-17 |
Alza Corporation |
Means for providing instant agent from agent dispensing system
|
US4963141A
(en)
*
|
1985-08-16 |
1990-10-16 |
Alza Corporation |
Dispensing system for administering beneficial agent formulation to ruminants
|
US4704118A
(en)
*
|
1985-08-16 |
1987-11-03 |
Alza Corporation |
Ruminant dispensing device with thermo-activated memory
|
US4865598A
(en)
*
|
1985-08-16 |
1989-09-12 |
Alza Corporation |
Dispensing system for administering beneficial agent
|
US4966767A
(en)
*
|
1985-08-16 |
1990-10-30 |
Alza Corporation |
Ruminant dispensing device comprising agent displacement member
|
US4883667A
(en)
*
|
1985-08-16 |
1989-11-28 |
Alza Corporation |
Process for forming dispensing device
|
US4871544A
(en)
*
|
1985-08-16 |
1989-10-03 |
Alza Corporation |
Ruminant dispensing device
|
US4955881A
(en)
*
|
1985-08-16 |
1990-09-11 |
Alza Corporation |
Ruminant dispensing device
|
US5098425A
(en)
*
|
1985-08-16 |
1992-03-24 |
Alza Corporation |
Method of administering a ruminant dispensing device comprising density member dispersed in hydrogel member
|
US4675174A
(en)
*
|
1985-08-16 |
1987-06-23 |
Alza Corporation |
Veterinary dispenser delivering beneficial agent by gas power generated in situ
|
US4756314A
(en)
*
|
1985-10-28 |
1988-07-12 |
Alza Corporation |
Sweat collection patch
|
US4680266A
(en)
*
|
1985-11-21 |
1987-07-14 |
Contraves Ag |
Cell culture chamber with means for automatic replenishment of nutrient
|
US5008112A
(en)
*
|
1985-12-16 |
1991-04-16 |
International Minerals & Chem. Corporation |
Device for the extended delivery of diffusible agents
|
US4971790A
(en)
*
|
1986-02-07 |
1990-11-20 |
Alza Corporation |
Dosage form for lessening irritation of mocusa
|
US4867969A
(en)
*
|
1986-02-07 |
1989-09-19 |
Alza Corporation |
Hydrogel formulation for administering non-steroidal drugs
|
US4865845A
(en)
*
|
1986-03-21 |
1989-09-12 |
Alza Corporation |
Release rate adjustment of osmotic or diffusional delivery devices
|
DE3786030T2
(de)
|
1986-03-27 |
1993-12-02 |
Merck Frosst Canada Inc |
Tetrahydrocarbazole Ester.
|
US4755180A
(en)
*
|
1986-06-16 |
1988-07-05 |
Alza Corporation |
Dosage form comprising solubility regulating member
|
US4847093A
(en)
*
|
1986-06-19 |
1989-07-11 |
Alza Corporation |
Dosage form with means for governing rate of gas formation
|
US4838862A
(en)
|
1986-08-04 |
1989-06-13 |
Pharmetrix Corp. |
Portable controlled release osmotic infusion device
|
CH668187A5
(de)
*
|
1986-08-07 |
1988-12-15 |
Ciba Geigy Ag |
Therapeutisches system mit systemischer wirkung.
|
USRE34990E
(en)
*
|
1986-08-07 |
1995-07-04 |
Ciba-Geigy Corporation |
Oral therapeutic system having systemic action
|
EP0277092B1
(de)
*
|
1987-01-14 |
1992-01-29 |
Ciba-Geigy Ag |
Therapeutisches System für schwerlösliche Wirkstoffe
|
US4801461A
(en)
|
1987-01-28 |
1989-01-31 |
Alza Corporation |
Pseudoephedrine dosage form
|
US4915952A
(en)
*
|
1987-02-27 |
1990-04-10 |
Alza Corporation |
Composition comprising drug, HPC, HPMC and PEO
|
US5023076A
(en)
*
|
1987-02-27 |
1991-06-11 |
Alza Corporation |
Lamina comprising carboxyvinyl polymer
|
US4888416A
(en)
*
|
1987-03-30 |
1989-12-19 |
International Minerals & Chemical Corp. |
Method for stabilizing somatotropins
|
US4957494A
(en)
*
|
1987-06-25 |
1990-09-18 |
Alza Corporation |
Multi-layer delivery system
|
US5499979A
(en)
*
|
1987-06-25 |
1996-03-19 |
Alza Corporation |
Delivery system comprising kinetic forces
|
US5340590A
(en)
*
|
1987-06-25 |
1994-08-23 |
Alza Corporation |
Delivery system with bilayer osmotic engine
|
US5236689A
(en)
*
|
1987-06-25 |
1993-08-17 |
Alza Corporation |
Multi-unit delivery system
|
US5391381A
(en)
*
|
1987-06-25 |
1995-02-21 |
Alza Corporation |
Dispenser capable of delivering plurality of drug units
|
US5023088A
(en)
*
|
1987-06-25 |
1991-06-11 |
Alza Corporation |
Multi-unit delivery system
|
US4874388A
(en)
*
|
1987-06-25 |
1989-10-17 |
Alza Corporation |
Multi-layer delivery system
|
US5110597A
(en)
*
|
1987-06-25 |
1992-05-05 |
Alza Corporation |
Multi-unit delivery system
|
US5938654A
(en)
*
|
1987-06-25 |
1999-08-17 |
Alza Corporation |
Osmotic device for delayed delivery of agent
|
US4891223A
(en)
*
|
1987-09-03 |
1990-01-02 |
Air Products And Chemicals, Inc. |
Controlled release delivery coating formulation for bioactive substances
|
US4880631A
(en)
*
|
1987-09-24 |
1989-11-14 |
Merck & Co., Inc. |
Controlled porosity osmotic pump
|
US4886668A
(en)
*
|
1987-09-24 |
1989-12-12 |
Merck & Co., Inc. |
Multiparticulate controlled porosity osmotic pump
|
US4950486A
(en)
*
|
1987-10-02 |
1990-08-21 |
Alza Corporation |
Dosage form for treating cardiovascular diseases
|
US4816263A
(en)
*
|
1987-10-02 |
1989-03-28 |
Alza Corporation |
Dosage form for treating cardiovascular diseases comprising isradipine
|
US4946687A
(en)
*
|
1987-10-02 |
1990-08-07 |
Alza Corporation |
Dosage form for treating cardiovascular diseases
|
US4994273A
(en)
*
|
1987-11-02 |
1991-02-19 |
Merck & Co., Inc. |
Solubility modulated drug delivery device
|
US5030203A
(en)
*
|
1987-11-16 |
1991-07-09 |
Baxter International Inc. |
Ampule for controlled administration of beneficial agent
|
JP2590358B2
(ja)
*
|
1988-03-01 |
1997-03-12 |
正雄 五十嵐 |
子宮内膜症治療用の子宮内又は膣内投与製剤
|
US4837111A
(en)
*
|
1988-03-21 |
1989-06-06 |
Alza Corporation |
Dosage form for dispensing drug for human therapy
|
US4855141A
(en)
*
|
1988-03-25 |
1989-08-08 |
Alza Corporation |
Device comprising means for protecting and dispensing fluid sensitive medicament
|
US4959218A
(en)
*
|
1988-03-25 |
1990-09-25 |
Alza Corporation |
Method for delivering somatotropin to an animal
|
US4996060A
(en)
*
|
1988-03-25 |
1991-02-26 |
Alza Corporation |
Device comprising liner for protecting fluid sensitive medicament
|
US5019397A
(en)
*
|
1988-04-21 |
1991-05-28 |
Alza Corporation |
Aqueous emulsion for pharmaceutical dosage form
|
US4892739A
(en)
*
|
1988-04-25 |
1990-01-09 |
Ciba-Geigy Corporation |
Osmotic continuous dispensing oral delivery system containing a pharmaceutically acceptable active agent having a improved core membrane adhesion properties
|
US4931285A
(en)
*
|
1988-04-28 |
1990-06-05 |
Alza Corporation |
Aqueous based pharmaceutical coating composition for dosage forms
|
US5024842A
(en)
*
|
1988-04-28 |
1991-06-18 |
Alza Corporation |
Annealed coats
|
US5006346A
(en)
*
|
1988-04-28 |
1991-04-09 |
Alza Corporation |
Delivery system
|
US5160743A
(en)
*
|
1988-04-28 |
1992-11-03 |
Alza Corporation |
Annealed composition for pharmaceutically acceptable drug
|
US4859470A
(en)
*
|
1988-06-02 |
1989-08-22 |
Alza Corporation |
Dosage form for delivering diltiazem
|
US4966769A
(en)
*
|
1988-06-02 |
1990-10-30 |
Alza Corporation |
Method for delivering dosage form for diltiazem
|
US5028434A
(en)
*
|
1988-07-21 |
1991-07-02 |
Alza Corporation |
Method for administering nilvadipine for treating cardiovascular symptoms
|
GB8820353D0
(en)
*
|
1988-08-26 |
1988-09-28 |
Staniforth J N |
Controlled release tablet
|
US5612059A
(en)
*
|
1988-08-30 |
1997-03-18 |
Pfizer Inc. |
Use of asymmetric membranes in delivery devices
|
US5096716A
(en)
*
|
1988-09-01 |
1992-03-17 |
Alza Corporation |
Dosage form for administering calcium antagonist nicardipine
|
US5236714A
(en)
*
|
1988-11-01 |
1993-08-17 |
Alza Corporation |
Abusable substance dosage form having reduced abuse potential
|
US5030456A
(en)
*
|
1988-11-07 |
1991-07-09 |
Alza Corporation |
Dosage form for treating cardiovascular diseases
|
US5376383A
(en)
*
|
1988-11-21 |
1994-12-27 |
Merck & Co., Inc. |
Method for enhancing the lowering of plasma-cholesterol levels
|
US4997658A
(en)
*
|
1988-11-21 |
1991-03-05 |
Merck & Co., Inc. |
Method for enhancing the lowering of plasma cholesterol levels
|
US5135523A
(en)
*
|
1988-12-13 |
1992-08-04 |
Alza Corporation |
Delivery system for administering agent to ruminants and swine
|
US5059423A
(en)
*
|
1988-12-13 |
1991-10-22 |
Alza Corporation |
Delivery system comprising biocompatible beneficial agent formulation
|
US5037420A
(en)
*
|
1988-12-13 |
1991-08-06 |
Alza Corporation |
Delivery system comprising two sections for delivering somatotropin
|
US5728088A
(en)
*
|
1988-12-13 |
1998-03-17 |
Alza Corporation |
Osmotic system for delivery of fluid-sensitive somatotropins to bovine animals
|
US5174999A
(en)
*
|
1988-12-13 |
1992-12-29 |
Alza Corporation |
Delivery system comprising fluid ingress and drug egress
|
US5110596A
(en)
*
|
1988-12-13 |
1992-05-05 |
Alza Corporation |
Delivery system comprising means for delivering agent to livestock
|
US5057318A
(en)
*
|
1988-12-13 |
1991-10-15 |
Alza Corporation |
Delivery system for beneficial agent over a broad range of rates
|
US5034229A
(en)
*
|
1988-12-13 |
1991-07-23 |
Alza Corporation |
Dispenser for increasing feed conversion of hog
|
IL92966A
(en)
*
|
1989-01-12 |
1995-07-31 |
Pfizer |
Hydrogel-operated release devices
|
US5108756A
(en)
*
|
1989-01-12 |
1992-04-28 |
Pfizer Inc. |
Dispensing devices powered by lyotropic liquid crystals
|
US5030452A
(en)
*
|
1989-01-12 |
1991-07-09 |
Pfizer Inc. |
Dispensing devices powered by lyotropic liquid crystals
|
US5186942A
(en)
*
|
1989-01-30 |
1993-02-16 |
Alza Corporation |
Nicardipine therapy
|
DD295760A5
(de)
*
|
1989-01-31 |
1991-11-14 |
Martin-Luther-Universitaet Halle Wittenberg,De |
Arzneistoffreigabesystem mit kotrollierter wirkstoffreisetzung
|
US4969872A
(en)
*
|
1989-03-08 |
1990-11-13 |
Alza Corporation |
Intravenous system for delivering a beneficial agent with delivery rate control via permeable surface area variance
|
US5019396A
(en)
*
|
1989-05-12 |
1991-05-28 |
Alza Corporation |
Delivery dispenser for treating cardiac arrhythmias
|
US5776493A
(en)
*
|
1989-07-14 |
1998-07-07 |
Alza Corporation |
Oral osmotic device for delivery of nystatin with hydrogel driving member
|
US5021053A
(en)
*
|
1989-07-14 |
1991-06-04 |
Alza Corporation |
Oral osmotic device with hydrogel driving member
|
US5126142A
(en)
*
|
1989-07-18 |
1992-06-30 |
Alza Corporation |
Dispenser comprising ionophore
|
US5273752A
(en)
*
|
1989-07-18 |
1993-12-28 |
Alza Corporation |
Controlled release dispenser comprising beneficial agent
|
US5024843A
(en)
*
|
1989-09-05 |
1991-06-18 |
Alza Corporation |
Oral hypoglycemic glipizide granulation
|
US5035897A
(en)
*
|
1989-09-05 |
1991-07-30 |
Alza Corporation |
Dosage form for delivering soluble or insoluble drugs
|
US20020197309A1
(en)
*
|
1989-09-05 |
2002-12-26 |
Kuczynski Anthony L. |
Method for lowering blood glucose
|
US6361795B1
(en)
|
1989-09-05 |
2002-03-26 |
Alza Corporation |
Method for lowering blood glucose
|
US5091190A
(en)
*
|
1989-09-05 |
1992-02-25 |
Alza Corporation |
Delivery system for administration blood-glucose lowering drug
|
US5591454A
(en)
*
|
1989-09-05 |
1997-01-07 |
Alza Corporation |
Method for lowering blood glucose
|
US5112614A
(en)
*
|
1989-09-14 |
1992-05-12 |
Alza Corporation |
Implantable delivery dispenser
|
US5098714A
(en)
*
|
1989-11-16 |
1992-03-24 |
Alza Corporation |
Osmotic, oral dosage form for fertility control
|
US5200197A
(en)
*
|
1989-11-16 |
1993-04-06 |
Alza Corporation |
Contraceptive pill
|
US5474785A
(en)
*
|
1990-01-24 |
1995-12-12 |
Alza Corporation |
Delivery system comprising means for controlling internal pressure
|
US5071607A
(en)
*
|
1990-01-31 |
1991-12-10 |
Alza Corporatino |
Method and apparatus for forming a hole in a drug dispensing device
|
US5024663A
(en)
*
|
1990-02-21 |
1991-06-18 |
Alza Corporation |
Self-contained suction pump
|
US5178866A
(en)
*
|
1990-03-23 |
1993-01-12 |
Alza Corporation |
Dosage form for delivering drug to the intestine
|
US5242391A
(en)
*
|
1990-04-25 |
1993-09-07 |
Alza Corporation |
Urethral insert for treatment of erectile dysfunction
|
US5017381A
(en)
*
|
1990-05-02 |
1991-05-21 |
Alza Corporation |
Multi-unit pulsatile delivery system
|
US5190763A
(en)
*
|
1990-05-07 |
1993-03-02 |
Alza Corporation |
Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
|
US5192550A
(en)
*
|
1990-05-07 |
1993-03-09 |
Alza Corporation |
Dosage form for treating central nervous system disorders
|
US5221536A
(en)
*
|
1990-05-07 |
1993-06-22 |
Alza Corporation |
Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
|
US5057321A
(en)
*
|
1990-06-13 |
1991-10-15 |
Alza Corporation |
Dosage form comprising drug and maltodextrin
|
US5128145A
(en)
*
|
1990-06-13 |
1992-07-07 |
Alza Corporation |
Dosage form for Parkinson's disease, spasticity and muscle spasms
|
US5234693A
(en)
*
|
1990-07-11 |
1993-08-10 |
Alza Corporation |
Delivery device with a protective sleeve
|
US5238687A
(en)
*
|
1990-07-11 |
1993-08-24 |
Alza Corporation |
Delivery device with a protective sleeve
|
US5234692A
(en)
*
|
1990-07-11 |
1993-08-10 |
Alza Corporation |
Delivery device with a protective sleeve
|
US5234694A
(en)
*
|
1990-07-11 |
1993-08-10 |
Alza Corporation |
Method for increasing feed efficiency in animals
|
US5180591A
(en)
*
|
1990-07-11 |
1993-01-19 |
Alza Corporation |
Delivery device with a protective sleeve
|
US5147654A
(en)
*
|
1990-07-23 |
1992-09-15 |
Alza Corporation |
Oral osmotic device for delivering nicotine
|
DK0542926T3
(da)
*
|
1990-08-07 |
1995-05-15 |
Pfizer |
Brug af grænsefladepolymeriserede membraner i frigivelsesanordninger
|
US5589511A
(en)
*
|
1990-08-13 |
1996-12-31 |
Sepracor Inc. |
Method for treating migraine headaches using optically pure S(+) fluoxetine
|
US5104899A
(en)
*
|
1990-08-13 |
1992-04-14 |
Sepracor, Inc. |
Methods and compositions for treating depression using optically pure fluoxetine
|
US5156850A
(en)
*
|
1990-08-31 |
1992-10-20 |
Alza Corporation |
Dosage form for time-varying patterns of drug delivery
|
US5232705A
(en)
*
|
1990-08-31 |
1993-08-03 |
Alza Corporation |
Dosage form for time-varying patterns of drug delivery
|
US5246709A
(en)
*
|
1990-09-10 |
1993-09-21 |
Alza Corporation |
Antiemetic therapy
|
US5166145A
(en)
*
|
1990-09-10 |
1992-11-24 |
Alza Corporation |
Antiemetic therapy
|
DK0550641T3
(da)
*
|
1990-09-28 |
1994-08-22 |
Pfizer |
Dispenseringsanordning indeholdende et hydrofobt medium
|
US5151093A
(en)
*
|
1990-10-29 |
1992-09-29 |
Alza Corporation |
Osmotically driven syringe with programmable agent delivery
|
US5443459A
(en)
*
|
1991-01-30 |
1995-08-22 |
Alza Corporation |
Osmotic device for delayed delivery of agent
|
US5708035A
(en)
*
|
1991-02-04 |
1998-01-13 |
Sepracor Inc. |
Methods of use and compositions of R(-) fluoxetine
|
US5861166A
(en)
*
|
1991-03-12 |
1999-01-19 |
Alza Corporation |
Delivery device providing beneficial agent stability
|
US5208037A
(en)
*
|
1991-04-22 |
1993-05-04 |
Alza Corporation |
Dosage forms comprising polymers comprising different molecular weights
|
US5198229A
(en)
*
|
1991-06-05 |
1993-03-30 |
Alza Corporation |
Self-retaining gastrointestinal delivery device
|
US5227167A
(en)
*
|
1991-06-11 |
1993-07-13 |
Alza Corporation |
Long-term delivery device including hydrophobic loading dose
|
US5137727A
(en)
*
|
1991-06-12 |
1992-08-11 |
Alza Corporation |
Delivery device providing beneficial agent stability
|
US5801141A
(en)
*
|
1991-06-24 |
1998-09-01 |
American Cyanamid Company |
Implant compositions containing a biologically active protein, peptide or polypeptide
|
US5190765A
(en)
*
|
1991-06-27 |
1993-03-02 |
Alza Corporation |
Therapy delayed
|
US6764697B1
(en)
|
1991-06-27 |
2004-07-20 |
Alza Corporation |
System for delaying drug delivery up to seven hours
|
US5252338A
(en)
*
|
1991-06-27 |
1993-10-12 |
Alza Corporation |
Therapy delayed
|
US5160744A
(en)
*
|
1991-06-27 |
1992-11-03 |
Alza Corporation |
Verapmil therapy
|
US5178867A
(en)
*
|
1991-08-19 |
1993-01-12 |
Alza Corporation |
Dosage form for delivering drug in short-time period
|
US5240713A
(en)
*
|
1991-09-27 |
1993-08-31 |
Alza Corporation |
Dual rate agent delivery device
|
US5266331A
(en)
*
|
1991-11-27 |
1993-11-30 |
Euroceltique, S.A. |
Controlled release oxycodone compositions
|
US5200195A
(en)
*
|
1991-12-06 |
1993-04-06 |
Alza Corporation |
Process for improving dosage form delivery kinetics
|
US5266332A
(en)
*
|
1991-12-06 |
1993-11-30 |
Alza Corporation |
Method for administering anti-Parkinson drug
|
US5254349A
(en)
*
|
1991-12-06 |
1993-10-19 |
Alza Corporation |
Process for lessening irritation caused by drug
|
US5200194A
(en)
*
|
1991-12-18 |
1993-04-06 |
Alza Corporation |
Oral osmotic device
|
US5958459A
(en)
*
|
1991-12-24 |
1999-09-28 |
Purdue Pharma L.P. |
Opioid formulations having extended controlled released
|
US5478577A
(en)
*
|
1993-11-23 |
1995-12-26 |
Euroceltique, S.A. |
Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
|
US5968551A
(en)
*
|
1991-12-24 |
1999-10-19 |
Purdue Pharma L.P. |
Orally administrable opioid formulations having extended duration of effect
|
US5223265A
(en)
*
|
1992-01-10 |
1993-06-29 |
Alza Corporation |
Osmotic device with delayed activation of drug delivery
|
US5330762A
(en)
*
|
1992-02-27 |
1994-07-19 |
Alza Corporation |
Tandospiaine antidepressive therapy
|
US5858407A
(en)
*
|
1992-02-27 |
1999-01-12 |
Alza Corporation |
Method for administering tandospirone
|
US5688518A
(en)
*
|
1992-02-27 |
1997-11-18 |
Alza Corporation |
Antidepressive therapy
|
US5185158A
(en)
*
|
1992-02-27 |
1993-02-09 |
Alza Corporation |
Dosage form comprising succinimide drug for treating depressive disorders and composition comprising same
|
US5246711A
(en)
*
|
1992-02-27 |
1993-09-21 |
Alza Corporation |
Dosage form for treating dysthymia
|
US5246710A
(en)
*
|
1992-02-27 |
1993-09-21 |
Alza Corporation |
Dosage form for treating cyclothymia
|
US5248310A
(en)
*
|
1992-03-27 |
1993-09-28 |
Alza Corporation |
Oral osmotic device with hydrogel driving member
|
US5512299A
(en)
*
|
1992-03-30 |
1996-04-30 |
Alza Corporation |
Method of treating oral inflammatory disease
|
US5869097A
(en)
|
1992-11-02 |
1999-02-09 |
Alza Corporation |
Method of therapy comprising an osmotic caplet
|
US20080075781A1
(en)
*
|
1992-11-25 |
2008-03-27 |
Purdue Pharma Lp |
Controlled release oxycodone compositions
|
US5573776A
(en)
*
|
1992-12-02 |
1996-11-12 |
Alza Corporation |
Oral osmotic device with hydrogel driving member
|
US5358721A
(en)
*
|
1992-12-04 |
1994-10-25 |
Alza Corporation |
Antiviral therapy
|
AU6268894A
(en)
*
|
1993-02-22 |
1994-09-14 |
Alza Corporation |
Compositions for oral delivery of active agents
|
PT621032E
(pt)
*
|
1993-04-23 |
2001-01-31 |
Novartis Ag |
Dispositivo de distribuicao de libertacao controlada de farmaco
|
IL119660A
(en)
*
|
1993-05-10 |
2002-09-12 |
Euro Celtique Sa |
Controlled release formulation comprising tramadol
|
US6440457B1
(en)
|
1993-05-27 |
2002-08-27 |
Alza Corporation |
Method of administering antidepressant dosage form
|
US6287598B1
(en)
*
|
1993-05-28 |
2001-09-11 |
Alza Corporation |
Method for providing sustained antiepileptic therapy
|
US7740881B1
(en)
|
1993-07-01 |
2010-06-22 |
Purdue Pharma Lp |
Method of treating humans with opioid formulations having extended controlled release
|
IL110014A
(en)
*
|
1993-07-01 |
1999-11-30 |
Euro Celtique Sa |
Solid controlled-release oral dosage forms of opioid analgesics
|
US5410054A
(en)
*
|
1993-07-20 |
1995-04-25 |
Merck Frosst Canada, Inc. |
Heteroaryl quinolines as inhibitors of leukotriene biosynthesis
|
US5879705A
(en)
*
|
1993-07-27 |
1999-03-09 |
Euro-Celtique S.A. |
Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
|
US5498255A
(en)
*
|
1993-08-17 |
1996-03-12 |
Alza Corporation |
Osmotic device for protracted pulsatile delivery of agent
|
KR100354702B1
(ko)
*
|
1993-11-23 |
2002-12-28 |
유로-셀티크 소시에떼 아노뉨 |
약학조성물의제조방법및서방형조성물
|
US5891471A
(en)
*
|
1993-11-23 |
1999-04-06 |
Euro-Celtique, S.A. |
Pharmaceutical multiparticulates
|
DE4342173A1
(de)
*
|
1993-12-10 |
1995-06-14 |
Lohmann Therapie Syst Lts |
Pharmazeutische Formulierung zur Prophylaxe bzw. Vorbehandlung einer Vergiftung durch phosphororganische Cholinesterasehemmer
|
US5532003A
(en)
*
|
1994-01-18 |
1996-07-02 |
Alza Corporation |
Pentoxifylline therapy
|
US5540665A
(en)
*
|
1994-01-31 |
1996-07-30 |
Alza Corporation |
Gas driven dispensing device and gas generating engine therefor
|
US5770076A
(en)
*
|
1994-03-07 |
1998-06-23 |
The Regents Of The University Of California |
Micromachined capsules having porous membranes and bulk supports
|
US5985328A
(en)
*
|
1994-03-07 |
1999-11-16 |
Regents Of The University Of California |
Micromachined porous membranes with bulk support
|
US5798042A
(en)
*
|
1994-03-07 |
1998-08-25 |
Regents Of The University Of California |
Microfabricated filter with specially constructed channel walls, and containment well and capsule constructed with such filters
|
US5985164A
(en)
*
|
1994-03-07 |
1999-11-16 |
Regents Of The University Of California |
Method for forming a filter
|
US5843480A
(en)
*
|
1994-03-14 |
1998-12-01 |
Euro-Celtique, S.A. |
Controlled release diamorphine formulation
|
ZA953078B
(en)
*
|
1994-04-28 |
1996-01-05 |
Alza Corp |
Effective therapy for epilepsies
|
US20040191314A1
(en)
*
|
1994-04-28 |
2004-09-30 |
Frank Jao |
Antiepileptic dosage form and process for protecting antiepileptic drug
|
US5411745A
(en)
*
|
1994-05-25 |
1995-05-02 |
Euro-Celtique, S.A. |
Powder-layered morphine sulfate formulations
|
US6077533A
(en)
*
|
1994-05-25 |
2000-06-20 |
Purdue Pharma L.P. |
Powder-layered oral dosage forms
|
US5460826A
(en)
*
|
1994-06-27 |
1995-10-24 |
Alza Corporation |
Morphine therapy
|
US5698224A
(en)
*
|
1994-06-27 |
1997-12-16 |
Alza Corporation |
Tacrine therapy
|
US5529787A
(en)
*
|
1994-07-07 |
1996-06-25 |
Alza Corporation |
Hydromorphone therapy
|
US5914131A
(en)
*
|
1994-07-07 |
1999-06-22 |
Alza Corporation |
Hydromorphone therapy
|
US5633011A
(en)
*
|
1994-08-04 |
1997-05-27 |
Alza Corporation |
Progesterone replacement therapy
|
DE4431653C2
(de)
*
|
1994-09-06 |
2000-01-20 |
Lohmann Therapie Syst Lts |
Manteltablette zur kontrollierten Freisetzung von Wirkstoffen, ein Verfahren zu ihrer Herstellung und ihre Verwendung
|
US6491945B1
(en)
*
|
1994-09-16 |
2002-12-10 |
Alza Corporation |
Hydrocodone therapy
|
US5718700A
(en)
*
|
1994-09-20 |
1998-02-17 |
Alza Corporation |
Exit means in dosage form
|
US5614578A
(en)
*
|
1994-10-28 |
1997-03-25 |
Alza Corporation |
Injection-molded dosage form
|
GB9422154D0
(en)
*
|
1994-11-03 |
1994-12-21 |
Euro Celtique Sa |
Pharmaceutical compositions and method of producing the same
|
US5965161A
(en)
|
1994-11-04 |
1999-10-12 |
Euro-Celtique, S.A. |
Extruded multi-particulates
|
US5595759A
(en)
*
|
1994-11-10 |
1997-01-21 |
Alza Corporation |
Process for providing therapeutic composition
|
US5582838A
(en)
*
|
1994-12-22 |
1996-12-10 |
Merck & Co., Inc. |
Controlled release drug suspension delivery device
|
US6429221B1
(en)
*
|
1994-12-30 |
2002-08-06 |
Celgene Corporation |
Substituted imides
|
US5595997A
(en)
|
1994-12-30 |
1997-01-21 |
Sepracor Inc. |
Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine
|
US5651979A
(en)
*
|
1995-03-30 |
1997-07-29 |
Gel Sciences, Inc. |
Apparatus and method for delivering a biologically active compound into a biological environment
|
US5736159A
(en)
*
|
1995-04-28 |
1998-04-07 |
Andrx Pharmaceuticals, Inc. |
Controlled release formulation for water insoluble drugs in which a passageway is formed in situ
|
US5558879A
(en)
*
|
1995-04-28 |
1996-09-24 |
Andrx Pharmaceuticals, Inc. |
Controlled release formulation for water soluble drugs in which a passageway is formed in situ
|
US5912268A
(en)
*
|
1995-05-22 |
1999-06-15 |
Alza Corporation |
Dosage form and method for treating incontinence
|
US6124355A
(en)
*
|
1995-05-22 |
2000-09-26 |
Guittard; George V. |
Oxybutynin therapy
|
US6262115B1
(en)
|
1995-05-22 |
2001-07-17 |
Alza Coporation |
Method for the management of incontinence
|
US5674895A
(en)
*
|
1995-05-22 |
1997-10-07 |
Alza Corporation |
Dosage form comprising oxybutynin
|
US5817335A
(en)
*
|
1995-05-26 |
1998-10-06 |
Alza Corporation |
Osmotic device with high drug loading and delayed activation of drug delivery
|
US5869079A
(en)
*
|
1995-06-02 |
1999-02-09 |
Oculex Pharmaceuticals, Inc. |
Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
|
US5800422A
(en)
*
|
1995-06-02 |
1998-09-01 |
Alza Corporation |
Osmotic device with delayed activation of drug delivery and complete drug release
|
US5690952A
(en)
*
|
1995-06-07 |
1997-11-25 |
Judy A. Magruder et al. |
Implantable system for delivery of fluid-sensitive agents to animals
|
US5713852A
(en)
*
|
1995-06-07 |
1998-02-03 |
Alza Corporation |
Oral dosage and method for treating painful conditions of the oral cavity
|
US5798119A
(en)
*
|
1995-06-13 |
1998-08-25 |
S. C. Johnson & Son, Inc. |
Osmotic-delivery devices having vapor-permeable coatings
|
US6548084B2
(en)
*
|
1995-07-20 |
2003-04-15 |
Smithkline Beecham Plc |
Controlled release compositions
|
US5780058A
(en)
|
1995-07-21 |
1998-07-14 |
Alza Corporation |
Oral delivery of discrete units
|
US5840332A
(en)
*
|
1996-01-18 |
1998-11-24 |
Perio Products Ltd. |
Gastrointestinal drug delivery system
|
US6858589B2
(en)
|
1996-01-25 |
2005-02-22 |
Pharmacy And Therapeutic Advisory Consultancy Pty Ltd |
Methods of and compositions for potentiating the action of agents active on cell wall sites of the susceptible bacteria
|
EP0914097B1
(en)
*
|
1996-03-12 |
2002-01-16 |
Alza Corporation |
Composition and dosage form comprising opioid antagonist
|
US6096339A
(en)
*
|
1997-04-04 |
2000-08-01 |
Alza Corporation |
Dosage form, process of making and using same
|
US5902605A
(en)
*
|
1996-04-18 |
1999-05-11 |
Alza Corporation |
Drug delivery device with minimal residual drug retention
|
ES2195151T3
(es)
|
1996-06-18 |
2003-12-01 |
Alza Corp |
Dispositivo de mejora de aporte o de muestreo de agentes transdermicos.
|
CZ299810B6
(cs)
*
|
1996-08-12 |
2008-12-03 |
Celgene Corporation |
Substituovaná aromatická sloucenina a její použití pro snížení hladiny cytokinu
|
US6024721A
(en)
|
1996-10-18 |
2000-02-15 |
Alza Corporation |
Mixing system for an active agent delivery device
|
AU729905B2
(en)
*
|
1996-10-18 |
2001-02-15 |
Alza Corporation |
Multiple flow path device for oral delivery of discrete units
|
PT936894E
(pt)
|
1996-10-18 |
2002-02-28 |
Alza Corp |
Dispositivo para fornecimento de agentes activos
|
US6361796B1
(en)
|
1996-10-25 |
2002-03-26 |
Shire Laboratories, Inc. |
Soluble form osmotic dose delivery system
|
US6110498A
(en)
*
|
1996-10-25 |
2000-08-29 |
Shire Laboratories, Inc. |
Osmotic drug delivery system
|
US6919373B1
(en)
*
|
1996-11-12 |
2005-07-19 |
Alza Corporation |
Methods and devices for providing prolonged drug therapy
|
US5900421A
(en)
*
|
1997-02-11 |
1999-05-04 |
Sepracor Inc. |
Methods and compositions for treating allergic asthma and dermatitis using descarboethoxyloratadine
|
US5939426A
(en)
*
|
1997-02-28 |
1999-08-17 |
Sepracor Inc. |
Methods for treating urinary incontinence using descarboethoxyloratadine
|
US5948787A
(en)
*
|
1997-02-28 |
1999-09-07 |
Alza Corporation |
Compositions containing opiate analgesics
|
ES2185153T3
(es)
|
1997-03-07 |
2003-04-16 |
Vernalis Res Ltd |
Uso de mefloquina(+) para el tratamiento de la malaria.
|
EP1304105B1
(en)
*
|
1997-03-31 |
2006-07-19 |
Alza Corporation |
Diffusional implantable delivery system
|
CA2284058C
(en)
*
|
1997-03-31 |
2007-02-20 |
Alza Corporation |
Diffusional implantable delivery system
|
EP0984762B1
(en)
|
1997-05-16 |
2002-08-07 |
Alza Corporation |
Flow controller configurations for an active agent delivery device
|
US5994148A
(en)
|
1997-06-23 |
1999-11-30 |
The Regents Of University Of California |
Method of predicting and enhancing success of IVF/ET pregnancy
|
US6110499A
(en)
*
|
1997-07-24 |
2000-08-29 |
Alza Corporation |
Phenytoin therapy
|
US6245042B1
(en)
|
1997-08-27 |
2001-06-12 |
Science Incorporated |
Fluid delivery device with temperature controlled energy source
|
US6514530B2
(en)
|
1997-09-09 |
2003-02-04 |
Alza Corporation |
Dosage form comprising means for changing drug delivery shape
|
US7060734B1
(en)
|
1997-09-09 |
2006-06-13 |
Alza Corporation |
Pharmaceutical coating composition and method of use
|
ATE282407T1
(de)
*
|
1997-09-09 |
2004-12-15 |
Alza Corp |
Arzneimittel-überzugszubereitung und verfahren zu ihrer anwendung
|
ID24259A
(id)
|
1997-09-25 |
2000-07-13 |
Bayer Ag |
Formulasi obat yang memiliki pelepasan senyawa aktif terkontrol
|
US20040062799A1
(en)
*
|
1997-09-29 |
2004-04-01 |
Ayer Atul D. |
Therapeutic composition and delivery system for administering drug
|
US6607751B1
(en)
*
|
1997-10-10 |
2003-08-19 |
Intellipharamaceutics Corp. |
Controlled release delivery device for pharmaceutical agents incorporating microbial polysaccharide gum
|
AU1251499A
(en)
|
1997-11-26 |
1999-06-15 |
Cerebrus Limited |
(-)-mefloquine to block purinergic receptors and to treat movement or neurodegenerative disorders
|
ES2172944T3
(es)
|
1997-12-05 |
2002-10-01 |
Alza Corp |
Forma de dosificacion osmotica que comprende un primer y un segundo revestimiento.
|
US20060141036A1
(en)
*
|
1997-12-12 |
2006-06-29 |
Andrx Labs Llc |
HMG-CoA reductase inhibitor extended release formulation
|
US20040029962A1
(en)
*
|
1997-12-12 |
2004-02-12 |
Chih-Ming Chen |
HMG-COA reductase inhibitor extended release formulation
|
US20080219976A1
(en)
*
|
1997-12-19 |
2008-09-11 |
Naomi Balaban |
Methods and compositions for treatment and prevention of staphylococcal infections
|
US7323179B2
(en)
*
|
1997-12-19 |
2008-01-29 |
Naomi Balaban |
Methods and compositions for the treatment and prevention of Staphylococcus and other bacterial infections
|
SI1685839T1
(sl)
|
1997-12-22 |
2013-08-30 |
Euro-Celtique S.A. |
Farmacevtska oralna dozirna oblika, ki vsebuje kombinacijo opioidnega agonista in opioidnega antagonista
|
US6375957B1
(en)
|
1997-12-22 |
2002-04-23 |
Euro-Celtique, S.A. |
Opioid agonist/opioid antagonist/acetaminophen combinations
|
AU1623099A
(en)
|
1997-12-22 |
1999-07-12 |
Alza Corporation |
Rate controlling membranes for controlled drug delivery devices
|
AU1828599A
(en)
*
|
1997-12-29 |
1999-07-19 |
Alza Corporation |
Osmotic delivery system with membrane plug retention mechanism
|
AU1937099A
(en)
|
1997-12-31 |
1999-07-19 |
Alza Corporation |
Osmotic drug delivery monitoring system and method
|
US7098206B2
(en)
*
|
1998-01-21 |
2006-08-29 |
Smithkline Beecham Corporation |
Pharmaceutically active morpholinol
|
US6998400B2
(en)
*
|
1998-01-22 |
2006-02-14 |
Smithkline Beecham Corporation |
Pharmaceutically active morpholinol
|
AU2483599A
(en)
|
1998-01-29 |
1999-08-16 |
Sepracor, Inc. |
Pharmaceutical uses of optically pure (-)-bupropion
|
JP2002501891A
(ja)
|
1998-01-29 |
2002-01-22 |
セプラコア インコーポレーテッド |
光学的に純粋な(+)−ビュープロピオンの医薬用途
|
US6245357B1
(en)
|
1998-03-06 |
2001-06-12 |
Alza Corporation |
Extended release dosage form
|
US8524277B2
(en)
*
|
1998-03-06 |
2013-09-03 |
Alza Corporation |
Extended release dosage form
|
US6099859A
(en)
*
|
1998-03-20 |
2000-08-08 |
Andrx Pharmaceuticals, Inc. |
Controlled release oral tablet having a unitary core
|
AR018321A1
(es)
*
|
1998-03-26 |
2001-11-14 |
Alza Corp |
Una forma de dosificacion de liberacion prolongada que comprende oxibutinina y los usos de la oxibutinina y de la forma de dosificacion de liberacionprolongada.
|
US6462034B1
(en)
|
1998-04-03 |
2002-10-08 |
Theravance, Inc. |
Local anesthetic compounds and uses
|
AR014809A1
(es)
|
1998-04-03 |
2001-03-28 |
Advanced Medicine Inc |
Compuestos multiligazon, composicion farmaceutica, metodo para prepara dichos compuestos y uso de dichos compuestos para preparar medicamentos
|
US6196993B1
(en)
|
1998-04-20 |
2001-03-06 |
Eyelab Group, Llc |
Ophthalmic insert and method for sustained release of medication to the eye
|
US20010038855A1
(en)
*
|
1998-06-05 |
2001-11-08 |
Desjardin Michael A. |
Dosage form for administering prescribed dose
|
US6420354B1
(en)
|
1998-06-08 |
2002-07-16 |
Advanced Medicine, Inc. |
Sodium channel drugs and uses
|
US6897305B2
(en)
|
1998-06-08 |
2005-05-24 |
Theravance, Inc. |
Calcium channel drugs and uses
|
CZ20004736A3
(cs)
|
1998-06-15 |
2001-09-12 |
Sepracor, Inc. |
Farmaceutický prostředek
|
IL140118A0
(en)
|
1998-06-15 |
2002-02-10 |
Sepracor Inc |
Use of optically pure (+) norcisapride for treating apnea, bulimia and other disorders
|
US6369039B1
(en)
*
|
1998-06-30 |
2002-04-09 |
Scimed Life Sytems, Inc. |
High efficiency local drug delivery
|
US7890176B2
(en)
*
|
1998-07-06 |
2011-02-15 |
Boston Scientific Neuromodulation Corporation |
Methods and systems for treating chronic pelvic pain
|
TW407058B
(en)
|
1998-07-17 |
2000-10-01 |
Dev Center Biotechnology |
Oral cisapride dosage forms with an extended duration
|
US7772220B2
(en)
*
|
2004-10-15 |
2010-08-10 |
Seo Hong Yoo |
Methods and compositions for reducing toxicity of a pharmaceutical compound
|
EP1113785B1
(en)
|
1998-07-24 |
2005-04-13 |
Seo Hong Yoo |
Clear aqueous solutions of bile acids
|
US20050158408A1
(en)
*
|
1998-07-24 |
2005-07-21 |
Yoo Seo H. |
Dried forms of aqueous solubilized bile acid dosage formulation: preparation and uses thereof
|
US7303768B2
(en)
*
|
1998-07-24 |
2007-12-04 |
Seo Hong Yoo |
Preparation of aqueous clear solution dosage forms with bile acids
|
US6339106B1
(en)
|
1999-08-11 |
2002-01-15 |
Sepracor, Inc. |
Methods and compositions for the treatment and prevention of sexual dysfunction
|
US6331571B1
(en)
*
|
1998-08-24 |
2001-12-18 |
Sepracor, Inc. |
Methods of treating and preventing attention deficit disorders
|
US6974838B2
(en)
*
|
1998-08-24 |
2005-12-13 |
Sepracor Inc. |
Methods of treating or preventing pain using sibutramine metabolites
|
US6476078B2
(en)
*
|
1999-08-11 |
2002-11-05 |
Sepracor, Inc. |
Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
|
US6099862A
(en)
*
|
1998-08-31 |
2000-08-08 |
Andrx Corporation |
Oral dosage form for the controlled release of a biguanide and sulfonylurea
|
US6703050B1
(en)
*
|
1998-09-04 |
2004-03-09 |
The Regents Of The University Of Michigan |
Methods and compositions for the prevention or treatment of cancer
|
US6551613B1
(en)
*
|
1998-09-08 |
2003-04-22 |
Alza Corporation |
Dosage form comprising therapeutic formulation
|
US6174547B1
(en)
*
|
1999-07-14 |
2001-01-16 |
Alza Corporation |
Dosage form comprising liquid formulation
|
DK1112060T3
(da)
*
|
1998-09-09 |
2006-04-18 |
Alza Corp |
Doseringsform anvendende flydende formulering
|
US7906143B1
(en)
|
1998-10-05 |
2011-03-15 |
Intellipharmaceutics Corp |
Controlled release pharmaceutical delivery device and process for preparation thereof
|
US7101909B2
(en)
*
|
1998-10-12 |
2006-09-05 |
Theravance, Inc. |
Calcium channel drugs and uses
|
US6806294B2
(en)
|
1998-10-15 |
2004-10-19 |
Euro-Celtique S.A. |
Opioid analgesic
|
GB9822854D0
(en)
|
1998-10-21 |
1998-12-16 |
Reckitt & Colmann Prod Ltd |
Improvements in or relating to organic compositions
|
AU1238500A
(en)
|
1998-11-02 |
2000-05-22 |
Alza Corporation |
Controlled delivery of active agents
|
US6706282B1
(en)
|
1998-11-02 |
2004-03-16 |
Evangeline Cruz |
Controlled delivery of phenoxyethyl-substituted 1,2,4-triazolones
|
US6342533B1
(en)
|
1998-12-01 |
2002-01-29 |
Sepracor, Inc. |
Derivatives of (−)-venlafaxine and methods of preparing and using the same
|
US6342249B1
(en)
|
1998-12-23 |
2002-01-29 |
Alza Corporation |
Controlled release liquid active agent formulation dosage forms
|
US6797283B1
(en)
|
1998-12-23 |
2004-09-28 |
Alza Corporation |
Gastric retention dosage form having multiple layers
|
US6855820B2
(en)
|
1999-01-20 |
2005-02-15 |
Smithkline Beecham Corporation |
Pharmaceutically active morpholinol
|
US6734213B2
(en)
|
1999-01-20 |
2004-05-11 |
Smithkline Beecham Corporation |
Pharmaceutically active morpholinol
|
US6638727B1
(en)
*
|
1999-01-26 |
2003-10-28 |
Cytyc Health Corporation |
Methods for identifying treating or monitoring asymptomatic patients for risk reduction or therapeutic treatment of breast cancer
|
DE19906974C2
(de)
*
|
1999-02-19 |
2003-10-09 |
Lohmann Therapie Syst Lts |
Verwendung von Desoxypeganin zur Behandlung des Alkoholismus
|
CA2371822A1
(en)
|
1999-03-01 |
2000-09-08 |
Sepracor Inc. |
Methods for treating apnea and apnea disorders using optically pure r(+)ondansetron
|
US6337328B1
(en)
*
|
1999-03-01 |
2002-01-08 |
Sepracor, Inc. |
Bupropion metabolites and methods of use
|
US6342496B1
(en)
*
|
1999-03-01 |
2002-01-29 |
Sepracor Inc. |
Bupropion metabolites and methods of use
|
US6362202B1
(en)
|
1999-03-02 |
2002-03-26 |
Sepracor Inc. |
Methods and compositions using (−) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists
|
US6353005B1
(en)
|
1999-03-02 |
2002-03-05 |
Sepracor, Inc. |
Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist
|
US6835194B2
(en)
*
|
1999-03-18 |
2004-12-28 |
Durect Corporation |
Implantable devices and methods for treatment of pain by delivery of fentanyl and fentanyl congeners
|
US6541021B1
(en)
*
|
1999-03-18 |
2003-04-01 |
Durect Corporation |
Devices and methods for pain management
|
US6428818B1
(en)
|
1999-03-30 |
2002-08-06 |
Purdue Research Foundation |
Tea catechin formulations and processes for making same
|
US6410052B1
(en)
|
1999-03-30 |
2002-06-25 |
Purdue Research Foundation |
Tea catechins in sustained release formulations as cancer specific proliferation inhibitors
|
ES2305606T3
(es)
|
1999-04-06 |
2008-11-01 |
Sepracor Inc. |
Succinato de o-desmetilvenlafaxina.
|
DE19918325A1
(de)
|
1999-04-22 |
2000-10-26 |
Euro Celtique Sa |
Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
|
EP2030620A1
(en)
|
1999-05-07 |
2009-03-04 |
Wockhardt Limited |
(s)-benzoquinolizine carboxylic acids and their use as antibacterial agents
|
US6479498B1
(en)
|
1999-06-04 |
2002-11-12 |
Theravance, Inc. |
Sodium channel drugs and uses
|
US6214807B1
(en)
*
|
1999-06-22 |
2001-04-10 |
Cv Therapeutics, Inc. |
C-pyrazole 2A A receptor agonists
|
USRE47351E1
(en)
|
1999-06-22 |
2019-04-16 |
Gilead Sciences, Inc. |
2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
|
US6403567B1
(en)
|
1999-06-22 |
2002-06-11 |
Cv Therapeutics, Inc. |
N-pyrazole A2A adenosine receptor agonists
|
US6100274A
(en)
*
|
1999-07-07 |
2000-08-08 |
Schering Corporation |
8-chloro-6,11-dihydro-11- ](4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions
|
US6399826B1
(en)
|
1999-08-11 |
2002-06-04 |
Sepracor Inc. |
Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
|
BR0014166A
(pt)
*
|
1999-09-03 |
2002-05-14 |
Lilly Co Eli |
Método de utilização de inibidores de reabsorção de serotonina seletivo de rápido ataque para tratamento de disfunção sexual
|
US6491683B1
(en)
|
1999-09-07 |
2002-12-10 |
Alza Corporation |
Osmotic dosage form composed of an extruded polymer tube form
|
US6387403B1
(en)
|
1999-09-15 |
2002-05-14 |
Alza Corporation |
Dosage forms and methods for providing effective reboxetine therapy with once-a-day dosing
|
US6559188B1
(en)
|
1999-09-17 |
2003-05-06 |
Novartis Ag |
Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
|
AR028299A1
(es)
|
1999-09-17 |
2003-05-07 |
Novartis Ag |
Una composicion farmaceutica que comprende nateglinida, un proceso para su preparacion y el uso de dicha composicion para la preparacion de un medicamento para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con diabetes.
|
US6878749B2
(en)
*
|
1999-09-17 |
2005-04-12 |
Novartis Ag |
Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
|
US6638263B1
(en)
|
1999-10-12 |
2003-10-28 |
Durect Corporation |
Regulation of drug delivery through flow diversion
|
US6114346A
(en)
*
|
1999-10-22 |
2000-09-05 |
Schering Corporation |
Treating sleep disorders using desloratadine
|
US6331313B1
(en)
|
1999-10-22 |
2001-12-18 |
Oculex Pharmaceticals, Inc. |
Controlled-release biocompatible ocular drug delivery implant devices and methods
|
US10179130B2
(en)
|
1999-10-29 |
2019-01-15 |
Purdue Pharma L.P. |
Controlled release hydrocodone formulations
|
ES2374717T3
(es)
|
1999-10-29 |
2012-02-21 |
Euro-Celtique S.A. |
Formulaciones de hidrocodona de liberación controlada.
|
CA2393601A1
(en)
*
|
1999-12-09 |
2001-06-14 |
Alza Corporation |
Antiviral medication
|
US7182953B2
(en)
|
1999-12-15 |
2007-02-27 |
Celgene Corporation |
Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
|
SK287684B6
(sk)
*
|
1999-12-20 |
2011-06-06 |
Schering Corporation |
Pevná orálna farmaceutická dávková forma s predĺženým uvoľňovaním
|
AU2276801A
(en)
|
1999-12-20 |
2001-07-03 |
Schering Corporation |
Extended release oral dosage composition
|
US6491949B2
(en)
|
2000-01-14 |
2002-12-10 |
Osmotica Corp. |
Osmotic device within an osmotic device
|
US7700341B2
(en)
*
|
2000-02-03 |
2010-04-20 |
Dendreon Corporation |
Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
|
US6432446B2
(en)
|
2000-02-03 |
2002-08-13 |
Bridge Pharma, Inc. |
Non-arrhythmogenic metabolite of oxybutynin
|
US7405223B2
(en)
|
2000-02-03 |
2008-07-29 |
Schering Corporation |
Treating allergic and inflammatory conditions
|
CA2406930C
(en)
*
|
2000-02-04 |
2011-02-15 |
Seo Hong Yoo |
Preparation of aqueous clear solution dosage forms with bile acids
|
NZ520554A
(en)
|
2000-02-08 |
2005-08-26 |
Euro Celtique S |
Tamper-resistant oral opioid agonist formulations
|
PL357158A1
(en)
|
2000-02-08 |
2004-07-12 |
Euro-Celtique, S.A. |
Controlled-release compositions containing opioid agonist and antagonist
|
US6464688B1
(en)
|
2000-02-15 |
2002-10-15 |
Microsolutions, Inc. |
Osmotic pump delivery system with flexible drug compartment
|
US6471688B1
(en)
|
2000-02-15 |
2002-10-29 |
Microsolutions, Inc. |
Osmotic pump drug delivery systems and methods
|
US6616652B1
(en)
|
2000-02-15 |
2003-09-09 |
Microsolutions, Inc. |
Osmotic pump delivery system with pre-hydrated membrane(s) and/or primable catheter
|
BR0108452A
(pt)
|
2000-02-18 |
2003-04-01 |
Cv Therapeutics Inc |
Inibidores da oxidação parcial de ácido graxo no tratamento de insuficiência cardìaca congestiva
|
US20020012946A1
(en)
|
2000-02-23 |
2002-01-31 |
Luiz Belardinelli |
Method of identifying partial agonists of the A2A receptor
|
US6582441B1
(en)
|
2000-02-24 |
2003-06-24 |
Advanced Bionics Corporation |
Surgical insertion tool
|
US7074803B2
(en)
*
|
2001-03-02 |
2006-07-11 |
Durect Corporation |
Opioid formulations
|
US6569152B2
(en)
*
|
2000-03-21 |
2003-05-27 |
Farrington Pharmaceuticals, Llc |
Sustained release delivery systems for solutes
|
US20020022627A1
(en)
*
|
2000-03-31 |
2002-02-21 |
Dannenberg Andrew J. |
Inhibition of cyclooxygenase-2activity
|
DE60128910T2
(de)
|
2000-04-27 |
2008-02-28 |
Verion Inc. |
Nullte-ordnung-freisetzung und temperatur-kontrollierte mikrokapseln sowie herstellungsverfahren
|
US7259152B2
(en)
|
2000-06-07 |
2007-08-21 |
Alfa Wasserman, Inc. |
Methods and compositions using sulodexide for the treatment of diabetic nephropathy
|
US6726918B1
(en)
|
2000-07-05 |
2004-04-27 |
Oculex Pharmaceuticals, Inc. |
Methods for treating inflammation-mediated conditions of the eye
|
US7449454B2
(en)
*
|
2000-08-30 |
2008-11-11 |
Pharmacyclics, Inc. |
Metallotexaphyrin derivatives
|
US6638924B2
(en)
|
2000-08-30 |
2003-10-28 |
Pharmacyclics, Inc. |
Metallotexaphyrin derivatives
|
CA2423431A1
(en)
*
|
2000-10-06 |
2002-04-11 |
Durect Corporation |
Devices and methods for management of inflammation
|
JP2004512354A
(ja)
|
2000-10-30 |
2004-04-22 |
ユーロ−セルティーク,エス.エイ. |
ヒドロコドン放出制御製剤
|
US6866866B1
(en)
*
|
2000-11-03 |
2005-03-15 |
Andrx Labs, Llc |
Controlled release metformin compositions
|
US20060034922A1
(en)
*
|
2000-11-03 |
2006-02-16 |
Andrx Labs, Llc |
Controlled release metformin compositions
|
MXPA03003994A
(es)
|
2000-11-03 |
2004-09-10 |
Andrx Labs Llc |
Composiciones de metformina de liberacion controlada.
|
US20070208087A1
(en)
|
2001-11-02 |
2007-09-06 |
Sanders Virginia J |
Compounds, compositions and methods for the treatment of inflammatory diseases
|
US6790459B1
(en)
*
|
2000-11-03 |
2004-09-14 |
Andrx Labs, Llc |
Methods for treating diabetes via administration of controlled release metformin
|
JP2004513900A
(ja)
*
|
2000-11-17 |
2004-05-13 |
ファーマサイクリクス,インコーポレイテッド |
テキサフィリン配位化合物およびその使用
|
US20030195706A1
(en)
*
|
2000-11-20 |
2003-10-16 |
Michael Korenberg |
Method for classifying genetic data
|
BR0115772A
(pt)
|
2000-11-29 |
2004-01-13 |
Oculex Pharm Inc |
Processos para a redução ou para a prevenção da rejeição ao transplante ocular e de implantes intraoculares para uso para o mesmo
|
CA2429945A1
(en)
|
2000-11-29 |
2002-06-06 |
Durect Corporation |
Devices and methods for controlled delivery from a drug delivery device
|
US7812169B2
(en)
*
|
2000-11-30 |
2010-10-12 |
The Children's Medical Center Corporation |
Method of synthesis of 4-amino-thalidomide enantiomers
|
EP1347748A2
(en)
|
2000-12-05 |
2003-10-01 |
MacGregor, Alexander |
Hydrostatic delivery system for controlled delivery of agent
|
RU2003120061A
(ru)
|
2000-12-07 |
2004-11-27 |
Си Ви Терапьютикс, Инк. (Us) |
Замещенные 1,3,5-триазины и пиримидины в качестве повышающих авса-1 соединений против заболевания коронарной артерии или атеросклероза
|
US20030167524A1
(en)
*
|
2000-12-19 |
2003-09-04 |
Rooijen Gijs Van |
Methods for the production of multimeric protein complexes, and related compositions
|
US20050143789A1
(en)
*
|
2001-01-30 |
2005-06-30 |
Whitehurst Todd K. |
Methods and systems for stimulating a peripheral nerve to treat chronic pain
|
US20060064140A1
(en)
*
|
2001-01-30 |
2006-03-23 |
Whitehurst Todd K |
Methods and systems for stimulating a trigeminal nerve to treat a psychiatric disorder
|
US7493172B2
(en)
*
|
2001-01-30 |
2009-02-17 |
Boston Scientific Neuromodulation Corp. |
Methods and systems for stimulating a nerve originating in an upper cervical spine area to treat a medical condition
|
IN190699B
(US20080293856A1-20081127-C00127.png)
|
2001-02-02 |
2003-08-16 |
Sun Pharmaceutical Ind Ltd |
|
EP1360169B2
(en)
*
|
2001-02-12 |
2017-05-24 |
Wyeth LLC |
Succinate salt of o-desmethyl-venlafaxine
|
WO2002072786A2
(en)
|
2001-03-13 |
2002-09-19 |
Corvas International, Inc. |
Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon
|
JP2004535166A
(ja)
|
2001-03-22 |
2004-11-25 |
デンドレオン・サンディエゴ・リミテッド・ライアビリティ・カンパニー |
セリンプロテアーゼcvsp14をコードする核酸分子、コードされるポリペプチドおよびそれに基づく方法
|
CA2442089A1
(en)
|
2001-03-27 |
2002-10-03 |
Dendreon San Diego Llc |
Nucleic acid molecules encoding a transmembran serine protease 9, the encoded polypeptides and methods based thereon
|
WO2002083631A1
(en)
*
|
2001-04-13 |
2002-10-24 |
Sepracor Inc. |
Methods of preparing didesmethylsibutramine and other sibutramine derivatives
|
US6632217B2
(en)
|
2001-04-19 |
2003-10-14 |
Microsolutions, Inc. |
Implantable osmotic pump
|
US6964966B2
(en)
*
|
2001-04-25 |
2005-11-15 |
Wockhardt Limited |
Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments
|
US6878713B2
(en)
|
2001-04-25 |
2005-04-12 |
Wockhardt Limited |
Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments
|
UA81224C2
(uk)
|
2001-05-02 |
2007-12-25 |
Euro Celtic S A |
Дозована форма оксикодону та її застосування
|
CN1525851A
(zh)
|
2001-05-11 |
2004-09-01 |
������ҩ������˾ |
抗滥用阿片样物质控释剂型
|
KR20040080940A
(ko)
|
2001-05-14 |
2004-09-20 |
덴드레온 코포레이션 |
트랜스막 세린 프로테아제 10을 암호화하는 핵산 분자,암호화된 폴리펩티드 및 이에 근거한 방법
|
US7186855B2
(en)
*
|
2001-06-11 |
2007-03-06 |
Xenoport, Inc. |
Prodrugs of GABA analogs, compositions and uses thereof
|
US8048917B2
(en)
|
2005-04-06 |
2011-11-01 |
Xenoport, Inc. |
Prodrugs of GABA analogs, compositions and uses thereof
|
US7232924B2
(en)
*
|
2001-06-11 |
2007-06-19 |
Xenoport, Inc. |
Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
|
EP1412324A4
(en)
*
|
2001-06-11 |
2004-09-29 |
Xenoport Inc |
AMINO ACID CONJUGATES THAT RESULT IN GABA ANALOGA LASTING SYSTEMIC CONCENTRATIONS
|
US6818787B2
(en)
*
|
2001-06-11 |
2004-11-16 |
Xenoport, Inc. |
Prodrugs of GABA analogs, compositions and uses thereof
|
ES2296956T5
(es)
*
|
2001-06-11 |
2011-07-12 |
Xenoport, Inc. |
Profármacos de análogos de gaba, composiciones y sus usos.
|
US20040180087A1
(en)
*
|
2001-06-21 |
2004-09-16 |
Boyong Li |
Stable controlled release pharmaceutical compositions containing pravastatin
|
AUPR602401A0
(en)
*
|
2001-06-29 |
2001-07-26 |
Smart Drug Systems Inc |
Sustained release delivery system
|
US7034059B2
(en)
*
|
2001-07-02 |
2006-04-25 |
Sepracor Inc. |
Methods of using norfluoxetine
|
US20040247696A1
(en)
*
|
2001-07-05 |
2004-12-09 |
Antelman Marvin S. |
Methods of using electron active compounds for managing conditions afflicting mammals
|
EP1404332A1
(en)
|
2001-07-06 |
2004-04-07 |
Penwest Pharmaceuticals Company |
Methods of making sustained release formulations of oxymorphone related applications
|
CN1268338C
(zh)
|
2001-07-06 |
2006-08-09 |
恩德制药公司 |
用作止痛剂的6-羟基羟吗啡酮的口服给药
|
US8329216B2
(en)
|
2001-07-06 |
2012-12-11 |
Endo Pharmaceuticals Inc. |
Oxymorphone controlled release formulations
|
US7713946B2
(en)
*
|
2002-07-11 |
2010-05-11 |
Cv Therapeutics, Inc. |
Partial and full agonists A1 adenosine receptors
|
US7157440B2
(en)
*
|
2001-07-13 |
2007-01-02 |
Cv Therapeutics, Inc. |
Partial and full agonists of A1 adenosine receptors
|
US20030068375A1
(en)
|
2001-08-06 |
2003-04-10 |
Curtis Wright |
Pharmaceutical formulation containing gelling agent
|
US20030044458A1
(en)
|
2001-08-06 |
2003-03-06 |
Curtis Wright |
Oral dosage form comprising a therapeutic agent and an adverse-effect agent
|
US20030157168A1
(en)
|
2001-08-06 |
2003-08-21 |
Christopher Breder |
Sequestered antagonist formulations
|
DE60232417D1
(de)
|
2001-08-06 |
2009-07-02 |
Euro Celtique Sa |
Opioid-agonist-formulierungen mit freisetzbarem und sequestriertem antagonist
|
EP1283025A1
(de)
*
|
2001-08-10 |
2003-02-12 |
Stöckert Instrumente GmbH |
Ballonokklusionsvorrichtung
|
US20030087963A1
(en)
|
2001-09-13 |
2003-05-08 |
Senanayake Chris H. |
Methods of preparing and using 2-hydroxy derivatives of sibutramine and its metabolites
|
CN1596100A
(zh)
*
|
2001-09-28 |
2005-03-16 |
麦克内尔-Ppc股份有限公司 |
可食用组合物及含可食用外壳的制剂
|
US8101209B2
(en)
|
2001-10-09 |
2012-01-24 |
Flamel Technologies |
Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
|
TWI312285B
(en)
|
2001-10-25 |
2009-07-21 |
Depomed Inc |
Methods of treatment using a gastric retained gabapentin dosage
|
US7612112B2
(en)
*
|
2001-10-25 |
2009-11-03 |
Depomed, Inc. |
Methods of treatment using a gastric retained gabapentin dosage
|
US20070184104A1
(en)
*
|
2001-10-25 |
2007-08-09 |
Depomed, Inc. |
Gastric retentive gabapentin dosage forms and methods for using same
|
PL370207A1
(en)
|
2001-11-09 |
2005-05-16 |
Cv Therapeutics, Inc. |
A2b adenosine receptor antagonists
|
WO2003044179A2
(en)
*
|
2001-11-20 |
2003-05-30 |
Dendreon San Diego Llc |
Nucleic acid molecules encoding serine protease 17, the encoded polypeptides and methods based thereon
|
US7157493B2
(en)
*
|
2001-11-28 |
2007-01-02 |
Nashai Biotech, Llc |
Methods of making and using theaflavin, theaflavin-3-gallate, theaflavin-3′-gallate and theaflavin 3,3′-digallate and mixtures thereof
|
JP2005516001A
(ja)
|
2001-12-05 |
2005-06-02 |
ベイラー カレッジ オブ メディスン |
交感神経活動状態の調節による骨形成の制御のための方法及び組成物
|
US20030125714A1
(en)
*
|
2001-12-18 |
2003-07-03 |
Edgren David Emil |
Dosage form for time-varying patterns of drug delivery
|
EP1465592A2
(en)
*
|
2001-12-19 |
2004-10-13 |
Alza Corporation |
Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules
|
CA2471081A1
(en)
*
|
2001-12-19 |
2003-07-03 |
Alza Corporation |
Formulation & dosage form for the controlled delivery of therapeutic agents
|
US20030181416A1
(en)
*
|
2002-01-10 |
2003-09-25 |
Comper Wayne D. |
Antimicrobial charged polymers that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions and method of use thereof
|
US20040009953A1
(en)
*
|
2002-01-10 |
2004-01-15 |
Comper Wayne D. |
Antimicrobial charged polymers that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions and method of use thereof
|
BR0307332A
(pt)
|
2002-02-01 |
2004-12-07 |
Pfizer Prod Inc |
Formas de dosagem farmacêuticas de liberação controlada de um inibidor da proteìna de transferência do éster de colesterol
|
US20030161882A1
(en)
*
|
2002-02-01 |
2003-08-28 |
Waterman Kenneth C. |
Osmotic delivery system
|
PT1472225E
(pt)
|
2002-02-01 |
2010-07-30 |
Euro Celtique Sa |
2-piperazina-piridinas uteis para tratar a dor
|
US20030175346A1
(en)
*
|
2002-02-01 |
2003-09-18 |
Anne Billotte |
Osmotic delivery system
|
US8133501B2
(en)
|
2002-02-08 |
2012-03-13 |
Boston Scientific Scimed, Inc. |
Implantable or insertable medical devices for controlled drug delivery
|
US8685427B2
(en)
|
2002-07-31 |
2014-04-01 |
Boston Scientific Scimed, Inc. |
Controlled drug delivery
|
US7078526B2
(en)
*
|
2002-05-31 |
2006-07-18 |
Transform Pharmaceuticals, Inc. |
CIS-itraconazole crystalline forms and related processes, pharmaceutical compositions and methods
|
US7446107B2
(en)
*
|
2002-02-15 |
2008-11-04 |
Transform Pharmaceuticals, Inc. |
Crystalline forms of conazoles and methods of making and using the same
|
US7790905B2
(en)
|
2002-02-15 |
2010-09-07 |
Mcneil-Ppc, Inc. |
Pharmaceutical propylene glycol solvate compositions
|
US7927613B2
(en)
|
2002-02-15 |
2011-04-19 |
University Of South Florida |
Pharmaceutical co-crystal compositions
|
WO2004078161A1
(en)
|
2003-02-28 |
2004-09-16 |
Transform Pharmaceuticals, Inc. |
Pharmaceutical co-crystal compositions of drugs such as carbamazeptine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
|
AU2002316231A1
(en)
*
|
2002-02-19 |
2003-09-29 |
Xenoport, Inc. |
Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
|
US7144871B2
(en)
*
|
2002-02-19 |
2006-12-05 |
Cv Therapeutics, Inc. |
Partial and full agonists of A1 adenosine receptors
|
CA2477923C
(en)
|
2002-03-01 |
2021-02-23 |
University Of South Florida |
Multiple-component solid phases containing at least one active pharmaceutical ingredient
|
CN1638743B
(zh)
*
|
2002-03-11 |
2012-11-07 |
爱尔康公司 |
可植入药物的释放系统
|
ATE486842T1
(de)
|
2002-03-12 |
2010-11-15 |
Merck Sharp & Dohme |
Substituierte amide
|
US7893101B2
(en)
|
2002-03-20 |
2011-02-22 |
Celgene Corporation |
Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
|
US6962940B2
(en)
|
2002-03-20 |
2005-11-08 |
Celgene Corporation |
(+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
|
AU2003224794A1
(en)
*
|
2002-03-29 |
2003-10-13 |
Alza Corporation |
Volume efficient controlled release dosage form
|
US20080109040A1
(en)
*
|
2002-04-04 |
2008-05-08 |
Luiz Belardinelli |
Method of treating arrhythmias
|
US20030220344A1
(en)
|
2002-04-04 |
2003-11-27 |
Luiz Belardinelli |
Method of treating arrhythmias
|
KR20040098050A
(ko)
|
2002-04-05 |
2004-11-18 |
유로-셀띠끄 소시에떼 아노님 |
옥시코돈 및 날록손을 포함하는 약제학적 제제
|
WO2003090723A1
(en)
*
|
2002-04-23 |
2003-11-06 |
Bristol-Myers Squibb Company |
Modified-release vasopeptidase inhibitor formulation, combinations and method
|
RU2004134594A
(ru)
*
|
2002-04-29 |
2005-06-27 |
Алза Корпорейшн (Us) |
Способы и лекарственные формы для контролируемой доставки оксикодона
|
US20050106249A1
(en)
*
|
2002-04-29 |
2005-05-19 |
Stephen Hwang |
Once-a-day, oral, controlled-release, oxycodone dosage forms
|
US20060116663A1
(en)
*
|
2002-05-01 |
2006-06-01 |
Joshi Ashok V |
Electro-osmotic fluid delivery device and method
|
US7470267B2
(en)
*
|
2002-05-01 |
2008-12-30 |
Microlin, Llc |
Fluid delivery device having an electrochemical pump with an anionic exchange membrane and associated method
|
US7896867B2
(en)
*
|
2002-05-01 |
2011-03-01 |
Microlin, Llc |
Fluid delivery device having an electrochemical pump with an ion-exchange membrane and associated method
|
US7458965B2
(en)
*
|
2002-05-01 |
2008-12-02 |
Microlin, Llc |
Fluid delivery device having an electrochemical pump with an ion-exchange membrane and associated method
|
US7205413B2
(en)
*
|
2002-05-03 |
2007-04-17 |
Transform Pharmaceuticals, Inc. |
Solvates and polymorphs of ritonavir and methods of making and using the same
|
US7323479B2
(en)
*
|
2002-05-17 |
2008-01-29 |
Celgene Corporation |
Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
|
EP1556033A4
(en)
|
2002-05-17 |
2006-05-31 |
Celgene Corp |
METHODS AND COMPOSITIONS USING CYTOKINE INHIBITOR SELECTIVE MEDICAMENTS FOR THE TREATMENT AND MANAGEMENT OF CANCERS AND OTHER DISEASES
|
US7968569B2
(en)
|
2002-05-17 |
2011-06-28 |
Celgene Corporation |
Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
US7393862B2
(en)
|
2002-05-17 |
2008-07-01 |
Celgene Corporation |
Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
|
USRE48890E1
(en)
|
2002-05-17 |
2022-01-11 |
Celgene Corporation |
Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation
|
WO2003099338A2
(en)
*
|
2002-05-17 |
2003-12-04 |
Xenoport, Inc. |
Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
|
DE60331537D1
(de)
|
2002-05-17 |
2010-04-15 |
Celgene Corp |
Kombinationen zur behandlung von multiplem myelom
|
KR101030943B1
(ko)
|
2002-05-21 |
2011-04-28 |
씨브이 쎄러퓨틱스, 인코포레이티드 |
당뇨병 치료를 위한 라놀라진 등의 부분적 지방산 산화저해제 투여
|
US8822473B2
(en)
*
|
2002-05-21 |
2014-09-02 |
Gilead Sciences, Inc. |
Method of treating diabetes
|
WO2003099214A2
(en)
*
|
2002-05-23 |
2003-12-04 |
Andrx Corporation |
Biguanide formulations
|
US20040001801A1
(en)
*
|
2002-05-23 |
2004-01-01 |
Corvas International, Inc. |
Conjugates activated by cell surface proteases and therapeutic uses thereof
|
US7151961B1
(en)
*
|
2002-05-24 |
2006-12-19 |
Advanced Bionics Corporation |
Treatment of movement disorders by brain stimulation
|
US8829198B2
(en)
|
2007-10-31 |
2014-09-09 |
Proteotech Inc |
Compounds, compositions and methods for the treatment of beta-amyloid diseases and synucleinopathies
|
US20070059356A1
(en)
*
|
2002-05-31 |
2007-03-15 |
Almarsson Oern |
Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
|
US6995168B2
(en)
*
|
2002-05-31 |
2006-02-07 |
Euro-Celtique S.A. |
Triazaspiro compounds useful for treating or preventing pain
|
SI2527315T1
(sl)
*
|
2002-05-31 |
2014-06-30 |
Proteotech Inc., |
Spojine, sestavki in metode za zdravljenje amiloidnih bolezni in sinukleinopatij, kot so Alzheimerjeva bolezen, diabetes tipa 2 in Parkinsonova bolezen
|
IL165361A0
(en)
*
|
2002-05-31 |
2006-01-15 |
Alza Corp |
Dosage forms and compositions for osmotic deliveryof variable dosages of oxycodone
|
US6900203B2
(en)
|
2002-06-19 |
2005-05-31 |
Polium Technologies, Inc. |
Optically active fluorinated vasoconstrictors, methods for making them, and anesthetic formulations comprising them
|
MXPA05000232A
(es)
|
2002-06-21 |
2005-06-17 |
Transform Pharmaceuticals Inc |
Composiciones farmaceuticas con disolucion mejorada.
|
AR039744A1
(es)
*
|
2002-06-26 |
2005-03-09 |
Alza Corp |
Metodos y formas de dosificacion para aumentar la solubilidad de las composiciones de farmacos para la administracion controlada
|
IL166023A0
(en)
*
|
2002-06-28 |
2006-01-15 |
Alza Corp |
Oral dosage from comprising a liquid active agent formulation and controlling release thereof by an expandable osmotic composition
|
TWI326214B
(en)
|
2002-07-17 |
2010-06-21 |
Avanir Pharmaceuticals Inc |
Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
|
US7888389B2
(en)
|
2002-07-23 |
2011-02-15 |
The Regents Of The University Of Michigan |
Tetrapropylammonium tetrathiomolybdate and related compounds for anti-angiogenic therapies
|
US7189865B2
(en)
*
|
2002-07-23 |
2007-03-13 |
Attenuon, Llc |
Thiomolybdate analogues and uses thereof
|
ATE548354T1
(de)
|
2002-07-24 |
2012-03-15 |
Ptc Therapeutics Inc |
Ureido-substituierte benzoesäureverbindungen und ihre verwendung für die nonsense-suppression und behandlung von erkrankungen
|
US20050226926A1
(en)
|
2002-07-25 |
2005-10-13 |
Pfizer Inc |
Sustained-release tablet composition of pramipexole
|
US8679533B2
(en)
*
|
2002-07-25 |
2014-03-25 |
Pharmacia Corporation |
Pramipexole once-daily dosage form
|
US8470801B2
(en)
|
2002-07-29 |
2013-06-25 |
Gilead Sciences, Inc. |
Myocardial perfusion imaging methods and compositions
|
US20050232995A1
(en)
|
2002-07-29 |
2005-10-20 |
Yam Nyomi V |
Methods and dosage forms for controlled delivery of paliperidone and risperidone
|
JP2005538190A
(ja)
*
|
2002-07-29 |
2005-12-15 |
シーブイ・セラピューティクス・インコーポレイテッド |
心筋潅流イメージング
|
US20050020915A1
(en)
*
|
2002-07-29 |
2005-01-27 |
Cv Therapeutics, Inc. |
Myocardial perfusion imaging methods and compositions
|
CA2494233A1
(en)
*
|
2002-07-29 |
2004-02-05 |
Alza Corporation |
Formulations and dosage forms for controlled delivery of topiramate
|
US7254449B2
(en)
*
|
2002-07-31 |
2007-08-07 |
Advanced Bionics Corp |
Systems and methods for providing power to one or more implantable devices
|
US8920826B2
(en)
|
2002-07-31 |
2014-12-30 |
Boston Scientific Scimed, Inc. |
Medical imaging reference devices
|
EP1894562B1
(en)
|
2002-08-15 |
2010-12-15 |
Euro-Celtique S.A. |
Pharmaceutical compositions comprising an opioid antagonist
|
US20040132806A1
(en)
|
2002-09-03 |
2004-07-08 |
Jackie Butler |
Pravastatin pharmaceutical formulations and methods of their use
|
US20060009739A1
(en)
*
|
2002-09-06 |
2006-01-12 |
Durect Corporation |
Implantable flow regulator with failsafe mode and reserve drug supply
|
CA2497867A1
(en)
|
2002-09-06 |
2004-03-18 |
Durect Corporation |
Delivery of modulators of glutamate-mediated neurotransmission to the inner ear
|
US20050048119A1
(en)
*
|
2002-09-20 |
2005-03-03 |
Avinash Nangia |
Controlled release composition with semi-permeable membrane and poloxamer flux enhancer
|
PT1551372T
(pt)
*
|
2002-09-20 |
2018-07-23 |
Alpharma Pharmaceuticals Llc |
Subunidade de sequestração e composições e métodos relacionados
|
US20050051922A1
(en)
*
|
2002-09-20 |
2005-03-10 |
Avinash Nangia |
Pharmaceutical composition with sodium lauryl sulfate as an extra-granular absorption/compression enhancer and the process to make the same
|
US9060941B2
(en)
*
|
2002-09-20 |
2015-06-23 |
Actavis, Inc. |
Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
|
KR20120034211A
(ko)
|
2002-09-20 |
2012-04-10 |
안드렉스 랩스 엘엘씨 |
약제학적 정제
|
US7959946B2
(en)
|
2002-09-20 |
2011-06-14 |
Watson Pharmaceuticals, Inc. |
Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
|
US7785627B2
(en)
*
|
2002-09-20 |
2010-08-31 |
Watson Pharmaceuticals, Inc. |
Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
|
EP1543010B1
(en)
|
2002-09-25 |
2007-04-25 |
Euro-Celtique S.A. |
N-substituted hydromorphones and the use thereof
|
US20060135463A1
(en)
*
|
2002-09-27 |
2006-06-22 |
Wood Christopher B |
Methods and compositions for the treatment of lupus using clofarabine
|
GB0222522D0
(en)
|
2002-09-27 |
2002-11-06 |
Controlled Therapeutics Sct |
Water-swellable polymers
|
AU2003276988B2
(en)
*
|
2002-09-27 |
2009-11-05 |
Bioenvision, Inc. |
Methods and compositions for the treatment of autoimmune disorders using clofarabine
|
US20040167212A1
(en)
*
|
2002-10-07 |
2004-08-26 |
Bednarski Mark D. |
X-nitro compounds, pharmaceutical compositions thereof and uses thereof
|
EP1790648A1
(en)
*
|
2002-10-11 |
2007-05-30 |
Proteotech, Inc. |
Use of procyanidin B2 for the preparation of a medicament for the treatment of amyloid and synuclein diseases
|
EP1900369A1
(en)
|
2002-10-15 |
2008-03-19 |
Celgene Corporation |
Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes
|
US8404717B2
(en)
*
|
2002-10-15 |
2013-03-26 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes using lenalidomide
|
US11116782B2
(en)
|
2002-10-15 |
2021-09-14 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
|
US8404716B2
(en)
|
2002-10-15 |
2013-03-26 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
|
US7189740B2
(en)
*
|
2002-10-15 |
2007-03-13 |
Celgene Corporation |
Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
|
CA2501936A1
(en)
*
|
2002-10-15 |
2004-04-29 |
Celgene Corporation |
Selective cytokine inhibitory drugs for treating myelodysplastic syndrome
|
US20050203142A1
(en)
*
|
2002-10-24 |
2005-09-15 |
Zeldis Jerome B. |
Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
|
US20040087558A1
(en)
|
2002-10-24 |
2004-05-06 |
Zeldis Jerome B. |
Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
|
CA2504038A1
(en)
*
|
2002-10-31 |
2004-05-21 |
Alza Corporation |
Dosage form providing ascending release of liquid formulation
|
UY28057A1
(es)
*
|
2002-10-31 |
2003-12-31 |
Alza Corp |
Formulacion y forma de dosificacion que provee mayor biodisponibilidad de los farmacos hidrófobos
|
US7776907B2
(en)
*
|
2002-10-31 |
2010-08-17 |
Celgene Corporation |
Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
|
US7265096B2
(en)
*
|
2002-11-04 |
2007-09-04 |
Xenoport, Inc. |
Gemcitabine prodrugs, pharmaceutical compositions and uses thereof
|
CN1735412A
(zh)
|
2002-11-06 |
2006-02-15 |
细胞基因公司 |
利用选择性细胞因子抑制药物治疗和控制癌症和其它疾病的方法和组合物
|
US7563810B2
(en)
|
2002-11-06 |
2009-07-21 |
Celgene Corporation |
Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
|
MXPA05004777A
(es)
*
|
2002-11-06 |
2005-07-22 |
Celgene Corp |
Metodos de uso y composiciones que comprenden farmacos inhibidores selectivos de citocina para el tratamiento y el manejo de padecimientos mieloproliferativos.
|
US7202259B2
(en)
*
|
2002-11-18 |
2007-04-10 |
Euro-Celtique S.A. |
Therapeutic agents useful for treating pain
|
BR0316256A
(pt)
*
|
2002-11-18 |
2005-10-04 |
Celgene Corp |
Métodos de inibir a produção de tnf-alfa e a atividade de pde4, de tratar ou prevenir uma doença ou um distúrbio, de controlar os nìveis de camp em uma célula e de produzir um composto, composição farmacêutica e composto
|
AU2003294311B8
(en)
*
|
2002-11-18 |
2008-06-05 |
Celgene Corporation |
Method of using and compositions comprising (+)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
|
BR0316523A
(pt)
*
|
2002-11-25 |
2005-10-18 |
Attenuon Llc |
Composto, composição farmacêutica e método para tratar ou prevenir câncer em um paciente
|
US20040102476A1
(en)
*
|
2002-11-25 |
2004-05-27 |
Chan Tai Wah |
High concentration formulations of opioids and opioid derivatives
|
AU2003293423A1
(en)
|
2002-12-06 |
2004-06-30 |
Xenoport, Inc. |
Carbidopa prodrugs and uses thereof
|
US20040111071A1
(en)
*
|
2002-12-09 |
2004-06-10 |
Jeffrey Lewis Powers |
Portable device for dispensing hand treatments
|
US8286834B2
(en)
*
|
2002-12-09 |
2012-10-16 |
Jeffrey Lewis Powers |
Skin treatment dispenser and method of manufacture
|
US7060727B2
(en)
*
|
2002-12-11 |
2006-06-13 |
Xenoport, Inc. |
Prodrugs of fused GABA analogs, pharmaceutical compositions and uses thereof
|
AU2003297909A1
(en)
*
|
2002-12-11 |
2004-06-30 |
Xenoport, Inc. |
Orally administered dosage forms of fused gaba analog prodrugs having reduced toxicity
|
CN101797221B
(zh)
|
2002-12-13 |
2013-06-12 |
杜雷科特公司 |
包含高粘度液体载体材料的口服递药系统
|
EP2218779A1
(en)
|
2002-12-16 |
2010-08-18 |
Halozyme, Inc. |
Human chondroitinase glycoprotein (chasegp), process for preparing the same, and pharmaceutical compositions comprising thereof
|
WO2004054568A1
(en)
*
|
2002-12-17 |
2004-07-01 |
Abbott Gmbh & Co. Kg |
Formulation comprising fenofibric acid, a physiologically acceptable salt or derivative thereof
|
US20080051411A1
(en)
*
|
2002-12-17 |
2008-02-28 |
Cink Russell D |
Salts of Fenofibric Acid and Pharmaceutical Formulations Thereof
|
US7259186B2
(en)
*
|
2002-12-17 |
2007-08-21 |
Abbott Laboratories |
Salts of fenofibric acid and pharmaceutical formulations thereof
|
US20070077301A1
(en)
*
|
2002-12-23 |
2007-04-05 |
Meyer Glenn A |
Venlafaxine osmotic device formulation
|
US7582635B2
(en)
|
2002-12-24 |
2009-09-01 |
Purdue Pharma, L.P. |
Therapeutic agents useful for treating pain
|
EP2339328A3
(en)
|
2002-12-30 |
2011-07-13 |
Transform Pharmaceuticals, Inc. |
Pharmaceutical co-crystal compositions of celecoxib
|
US8183290B2
(en)
|
2002-12-30 |
2012-05-22 |
Mcneil-Ppc, Inc. |
Pharmaceutically acceptable propylene glycol solvate of naproxen
|
US20050048099A1
(en)
|
2003-01-09 |
2005-03-03 |
Allergan, Inc. |
Ocular implant made by a double extrusion process
|
KR20050095835A
(ko)
*
|
2003-01-14 |
2005-10-04 |
알자 코포레이션 |
조정된 점성층을 갖는 방법 및 제형
|
JP2006515891A
(ja)
|
2003-01-17 |
2006-06-08 |
シーブイ・セラピューティクス・インコーポレイテッド |
循環器疾患の処置に有効な置換ヘテロ環化合物
|
ZA200504940B
(en)
*
|
2003-01-28 |
2006-09-27 |
Xenoport Inc |
Amino acid derived prodrugs of propofol, compositions and uses thereof
|
ATE401866T1
(de)
*
|
2003-02-11 |
2008-08-15 |
Alza Corp |
Verfahren und dosierformen mit modifizierter schichtgeometrie
|
NZ540791A
(en)
|
2003-02-13 |
2009-09-25 |
Banyu Pharma Co Ltd |
Novel 2-pyridinecarboxamide derivatives
|
US7871607B2
(en)
|
2003-03-05 |
2011-01-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
|
US20060104968A1
(en)
|
2003-03-05 |
2006-05-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
|
ES2335005T5
(es)
|
2003-03-05 |
2013-04-17 |
Halozyme, Inc. |
Glicoproteína hialuronidasa soluble (shasegp), proceso para prepararla, usos y composiciones farmacéuticas que la comprenden
|
EP1608357A4
(en)
*
|
2003-03-31 |
2008-03-26 |
Xenoport Inc |
TREATMENT OR PREVENTION OF HITZEWALLUNGEN USING PRODRUGS OF GABA ANALOGUE
|
US20040214893A1
(en)
*
|
2003-04-11 |
2004-10-28 |
Matthew Peterson |
Gabapentin compositions
|
ES2770035T3
(es)
|
2003-04-11 |
2020-06-30 |
Ptc Therapeutics Inc |
Compuesto de ácido 1,2,4-oxadiazol benzoico y su uso para la supresión sin sentido y el tratamiento de enfermedades
|
TWI347201B
(en)
|
2003-04-21 |
2011-08-21 |
Euro Celtique Sa |
Pharmaceutical products,uses thereof and methods for preparing the same
|
US20070083240A1
(en)
*
|
2003-05-08 |
2007-04-12 |
Peterson David K L |
Methods and systems for applying stimulation and sensing one or more indicators of cardiac activity with an implantable stimulator
|
US20070172446A1
(en)
|
2003-05-16 |
2007-07-26 |
Intermune, Inc. |
Synthetic chemokine receptor ligands and methods of use thereof
|
US8029822B2
(en)
*
|
2003-05-22 |
2011-10-04 |
Osmotica Kereskedelmi és Seolgáltató KFT |
Rupturing controlled release device having a preformed passageway
|
WO2004105692A2
(en)
*
|
2003-05-23 |
2004-12-09 |
Bridge Pharma, Inc. |
Smooth muscle spasmolytic agents
|
JP2007502329A
(ja)
*
|
2003-05-23 |
2007-02-08 |
トランスフォーム・ファーマシューティカルズ・インコーポレイテッド |
セルトラリン組成物
|
ZA200509719B
(en)
*
|
2003-05-27 |
2007-03-28 |
Attenuon Llc |
Thiotungstate analogues and uses thereof
|
US8916598B2
(en)
|
2003-05-30 |
2014-12-23 |
Proteotech Inc |
Compounds, compositions, and methods for the treatment of β-amyloid diseases and synucleinopathies
|
US20100331380A1
(en)
*
|
2009-06-29 |
2010-12-30 |
Esposito Luke A |
Compounds, Compositions, and Methods for the Treatment of Beta-Amyloid Diseases and Synucleinopathies
|
US7438903B2
(en)
*
|
2003-06-06 |
2008-10-21 |
Nbty, Inc. |
Methods and compositions that enhance bioavailability of coenzyme-Q10
|
TWI287010B
(en)
*
|
2003-06-12 |
2007-09-21 |
Euro Celtique Sa |
Therapeutic agents useful for treating pain
|
AU2004249295A1
(en)
*
|
2003-06-20 |
2004-12-29 |
Viral Genomix, Inc. |
Compositions for and methods for treating HIV
|
US7145125B2
(en)
|
2003-06-23 |
2006-12-05 |
Advanced Optical Technologies, Llc |
Integrating chamber cone light using LED sources
|
US8802139B2
(en)
|
2003-06-26 |
2014-08-12 |
Intellipharmaceutics Corp. |
Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
|
ES2322707T3
(es)
*
|
2003-07-03 |
2009-06-25 |
Euro-Celtique S.A. |
Derivados de 2-piridina alquino utiles para tratar el dolor.
|
WO2005004882A1
(en)
*
|
2003-07-09 |
2005-01-20 |
Monash University |
Antiviral charged polymers that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions and methods of use thereof
|
WO2005009539A2
(en)
*
|
2003-07-23 |
2005-02-03 |
Synta Pharmaceuticals, Corp. |
Compounds for inflammation and immune-related uses
|
NZ544009A
(en)
*
|
2003-07-24 |
2009-07-31 |
Euro Celtique Sa |
Heteroaryl-tetrahydropiperidyl compounds useful for treating or preventing pain
|
US20050020692A1
(en)
*
|
2003-07-24 |
2005-01-27 |
Ciofalo Vincent B. |
Treatment of heaves
|
PL1867644T3
(pl)
|
2003-07-24 |
2009-10-30 |
Euro Celtique Sa |
Związki heteroarylo-tetrahydropiperydylowe przydatne w leczeniu lub zapobieganiu bólu
|
DK1648878T3
(da)
*
|
2003-07-24 |
2009-08-10 |
Euro Celtique Sa |
Piperidinforbindelser og farmaceutiske sammensætninger, som indeholder dem
|
WO2005011630A2
(en)
*
|
2003-07-31 |
2005-02-10 |
Alza Corporation |
Permeation-resistant osmotic engine and dosage form for controlled release of a liquid active agent formulation
|
US20090317476A1
(en)
*
|
2003-07-31 |
2009-12-24 |
Robinson Cynthia B |
Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
|
US20050026882A1
(en)
*
|
2003-07-31 |
2005-02-03 |
Robinson Cynthia B. |
Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
|
ES2340168T3
(es)
*
|
2003-08-01 |
2010-05-31 |
Euro-Celtique S.A. |
Agentes terapeuticos utiles para tratar el dolor.
|
US20050058707A1
(en)
*
|
2003-08-06 |
2005-03-17 |
Iran Reyes |
Uniform delivery of topiramate over prolonged period of time with enhanced dispersion formulation
|
GB0318824D0
(en)
*
|
2003-08-11 |
2003-09-10 |
Glaxo Group Ltd |
Novel composition
|
WO2005019163A2
(en)
*
|
2003-08-20 |
2005-03-03 |
Xenoport, Inc. |
Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
|
EP2354120A1
(en)
|
2003-08-20 |
2011-08-10 |
XenoPort, Inc. |
Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof
|
JP2007503389A
(ja)
*
|
2003-08-22 |
2007-02-22 |
アルザ・コーポレーシヨン |
長期間にわたるトピラメートの段階的送達
|
JP4874795B2
(ja)
*
|
2003-08-22 |
2012-02-15 |
ヴィスタ サイエンティフィック エルエルシー |
キャリヤ
|
GB0320020D0
(en)
|
2003-08-27 |
2003-10-01 |
Mw Encap Ltd |
Improved formulation for providing an enteric coating material
|
CA2564227A1
(en)
*
|
2003-09-02 |
2005-03-10 |
Alza Corporation |
Novel drug compositions and dosage forms of topiramate
|
WO2005020954A2
(en)
*
|
2003-09-03 |
2005-03-10 |
Agi Therapeutics Limited |
Proton pump inhibitor formulations, and methods of preparing and using such formulations
|
US7164023B2
(en)
*
|
2003-09-04 |
2007-01-16 |
Wockhardt Limited |
Benzoquinolizine-2-carboxylic acid arginine salt tetrahydrate
|
UA83504C2
(en)
|
2003-09-04 |
2008-07-25 |
Селджин Корпорейшн |
Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
US7230003B2
(en)
*
|
2003-09-09 |
2007-06-12 |
Xenoport, Inc. |
Aromatic prodrugs of propofol, compositions and uses thereof
|
KR20060119971A
(ko)
|
2003-09-11 |
2006-11-24 |
제노포트 인코포레이티드 |
Gaba 유사체의 전구약물을 이용한 요실금의 치료및/또는 예방
|
CN1871021B
(zh)
*
|
2003-09-17 |
2010-07-28 |
什诺波特有限公司 |
用gaba类似物的前药治疗或预防多动腿综合征
|
WO2005027853A2
(en)
*
|
2003-09-19 |
2005-03-31 |
University Of Louisville Research Foundation Inc |
Method for treating snoring and sleep apnea with leukotriene antagonists
|
EP1664041B1
(en)
*
|
2003-09-22 |
2008-07-02 |
Euro-Celtique S.A. |
Phenyl-carboxamide compounds useful for treating pain
|
PL1664016T3
(pl)
*
|
2003-09-22 |
2009-04-30 |
Euro Celtique Sa |
Środki terapeutyczne przydatne do leczenia bólu
|
EP2298303A1
(en)
|
2003-09-25 |
2011-03-23 |
Euro-Celtique S.A. |
Pharmaceutical combinations of hydrocodone and naltrexone
|
AU2004275816A1
(en)
*
|
2003-09-26 |
2005-04-07 |
Alza Corporation |
Controlled release formulations of opioid and nonopioid analgesics
|
KR20060092255A
(ko)
|
2003-09-26 |
2006-08-22 |
알자 코포레이션 |
고도의 약물적재를 제공하는 약물코팅제 및 그의 제조방법
|
CA2540045A1
(en)
*
|
2003-09-26 |
2005-04-07 |
Alza Corporation |
Dosage form for controlled release of an active agent formulation
|
JP2007524652A
(ja)
*
|
2003-09-26 |
2007-08-30 |
アルザ・コーポレーシヨン |
アルプラゾラムの制御送達のための浸透性投薬形態物
|
EP1667652B1
(en)
*
|
2003-09-26 |
2007-05-30 |
ALZA Corporation |
Improved controlled release dosage form including a banded engine
|
MXPA06003453A
(es)
|
2003-09-26 |
2006-08-31 |
Johnson & Johnson |
Barra de empuje oros para el suministro controlado de agentes activos.
|
MXPA06003452A
(es)
|
2003-09-26 |
2006-08-31 |
Johnson & Johnson |
Formulaciones de liberacion controlada que exhiben una velocidad de liberacion ascendente.
|
SI1677767T1
(sl)
|
2003-10-14 |
2011-11-30 |
Xenoport Inc |
Kristalinična oblika analoga gama-aminomaslene kisline
|
US7612096B2
(en)
*
|
2003-10-23 |
2009-11-03 |
Celgene Corporation |
Methods for treatment, modification and management of radiculopathy using 1-oxo-2-(2,6-dioxopiperidin-3yl)-4-aminoisoindoline
|
WO2005040758A2
(en)
*
|
2003-10-24 |
2005-05-06 |
Intermune, Inc. |
Use of pirfenidone in therapeutic regimens
|
US20050118246A1
(en)
*
|
2003-10-31 |
2005-06-02 |
Wong Patrick S. |
Dosage forms and layered deposition processes for fabricating dosage forms
|
EP1680083A1
(en)
*
|
2003-10-31 |
2006-07-19 |
ALZA Corporation |
Compositions and dosage forms for ehnanced absorption of iron
|
US20050113410A1
(en)
*
|
2003-11-03 |
2005-05-26 |
Mark Tawa |
Pharmaceutical salts of zafirlukast
|
US20050095288A1
(en)
*
|
2003-11-03 |
2005-05-05 |
Andrx Labs, Llc |
Decongestant and expectorant tablets
|
US8987322B2
(en)
*
|
2003-11-04 |
2015-03-24 |
Circ Pharma Research And Development Limited |
Pharmaceutical formulations for carrier-mediated transport statins and uses thereof
|
AU2004288714A1
(en)
|
2003-11-06 |
2005-05-26 |
Celgene Corporation |
Methods and compositions using thalidomide for the treatment and management of cancers and other diseases.
|
US20070224278A1
(en)
|
2003-11-12 |
2007-09-27 |
Lyons Robert T |
Low immunogenicity corticosteroid compositions
|
US20050101582A1
(en)
|
2003-11-12 |
2005-05-12 |
Allergan, Inc. |
Compositions and methods for treating a posterior segment of an eye
|
TW200528144A
(en)
*
|
2003-11-14 |
2005-09-01 |
Alza Corp |
Controlled release of topiramate in liquid dosage forms
|
US7470435B2
(en)
*
|
2003-11-17 |
2008-12-30 |
Andrx Pharmaceuticals, Llc |
Extended release venlafaxine formulation
|
KR20060109926A
(ko)
|
2003-11-19 |
2006-10-23 |
메타베이시스 테라퓨틱스, 인크. |
새로운 인-함유 갑상선 호르몬 모방약들
|
EP2065383A1
(en)
|
2003-11-19 |
2009-06-03 |
Signal Pharmaceuticals, Inc. |
Indazole compounds and methods of use thereof as protein kinase inhibitors
|
US8734850B2
(en)
*
|
2003-11-25 |
2014-05-27 |
Flamel Technologies |
Oral medicinal product with modified release of at least one active principle in multimicrocapsular form
|
WO2005051325A2
(en)
*
|
2003-11-25 |
2005-06-09 |
Sb Pharmco Puerto Rico Inc. |
Carvedilol compositions methods of treatment and delivery
|
CN1886427B
(zh)
|
2003-11-28 |
2012-05-23 |
伊士曼化工公司 |
纤维素共聚体和氧化方法
|
US20050129764A1
(en)
*
|
2003-12-11 |
2005-06-16 |
Vergez Juan A. |
Osmotic device containing licofelone
|
DK1691811T3
(da)
|
2003-12-11 |
2014-10-20 |
Sunovion Pharmaceuticals Inc |
Kombination af et sedativ og en neurotransmittermodulator og fremgangsmåder til forbedring af søvnkvaliteten og behandling af depression
|
US7769461B2
(en)
*
|
2003-12-19 |
2010-08-03 |
Boston Scientific Neuromodulation Corporation |
Skull-mounted electrical stimulation system and method for treating patients
|
AU2004308973A1
(en)
*
|
2003-12-23 |
2005-07-14 |
Alza Corporation |
Methods and dosage forms for increasing solubility of drug compositions for controlled delivery
|
TW200522944A
(en)
|
2003-12-23 |
2005-07-16 |
Lilly Co Eli |
CB1 modulator compounds
|
CA2550699A1
(en)
*
|
2003-12-29 |
2005-07-21 |
Alza Corporation, Inc. |
Novel drug compositions and dosage forms of topiramate
|
EP1701706A2
(en)
*
|
2003-12-29 |
2006-09-20 |
Alza Corporation |
Novel drug compositions and dosage forms
|
US20050175696A1
(en)
*
|
2003-12-29 |
2005-08-11 |
David Edgren |
Drug granule coatings that impart smear resistance during mechanical compression
|
JP4707560B2
(ja)
*
|
2003-12-29 |
2011-06-22 |
Msd株式会社 |
新規2−ヘテロアリール置換ベンズイミダゾール誘導体
|
WO2005066130A1
(en)
*
|
2003-12-30 |
2005-07-21 |
Euro-Celtique S.A. |
Piperazines useful for treating pain
|
US8524736B2
(en)
|
2004-01-07 |
2013-09-03 |
Armetheon, Inc. |
Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
|
US8138204B2
(en)
*
|
2004-01-07 |
2012-03-20 |
Aryx Therapeutics, Inc. |
Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
|
DK2194053T3
(da)
|
2004-01-07 |
2013-07-01 |
Armetheon Inc |
Methoxypiperidinderivater til brug i behandling af gastrointestinale forstyrrelser og forstyrrelser i centralnervesystemet.
|
US7976520B2
(en)
*
|
2004-01-12 |
2011-07-12 |
Nulens Ltd. |
Eye wall anchored fixtures
|
JP2007518804A
(ja)
|
2004-01-20 |
2007-07-12 |
アラーガン、インコーポレイテッド |
トリアムシノロンアセトニドおよびヒアルロン酸を好ましく含有する眼局所治療用組成物
|
EP2292213A1
(en)
|
2004-02-06 |
2011-03-09 |
Cephalon, Inc. |
Compositions comprising a polymorphic form of armodafinil
|
EP1722758A1
(en)
*
|
2004-02-11 |
2006-11-22 |
Athpharma Limited |
Chronotherapeutic compositions and methods of their use
|
DK1720540T3
(da)
|
2004-02-18 |
2008-10-06 |
Gpc Biotech Ag |
Satraplatin til behandling af resistente tumorer eller tumorer, der er vanskelige at behandle
|
EP1729784A1
(en)
*
|
2004-02-23 |
2006-12-13 |
Attenuon, LLC |
Formulations of thiomolybdate or thiotungstate compounds and uses thereof
|
US20050196448A1
(en)
*
|
2004-03-05 |
2005-09-08 |
Hai Yong Huang |
Polymeric compositions and dosage forms comprising the same
|
US20050196446A1
(en)
*
|
2004-03-05 |
2005-09-08 |
Huang Hai Y. |
Polymeric compositions and dosage forms comprising the same
|
US20050196442A1
(en)
*
|
2004-03-05 |
2005-09-08 |
Huang Hai Y. |
Polymeric compositions and dosage forms comprising the same
|
US20050196447A1
(en)
*
|
2004-03-05 |
2005-09-08 |
Huang Hai Y. |
Polymeric compositions and dosage forms comprising the same
|
US7612071B2
(en)
|
2004-03-12 |
2009-11-03 |
Syntrix Biosystems, Inc. |
Compositions and methods employing aminopterin
|
US20060211752A1
(en)
*
|
2004-03-16 |
2006-09-21 |
Kohn Leonard D |
Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
|
US20050209295A1
(en)
*
|
2004-03-16 |
2005-09-22 |
Kohn Leonard D |
Methimazole derivatives and tautomeric cyclic thiones to inhibit cell adhesion
|
US7928132B2
(en)
*
|
2004-08-06 |
2011-04-19 |
Ohio University |
Methods for the amelioration of episodes of acute or chronic ulcerative colitis
|
US20100004304A1
(en)
*
|
2004-03-16 |
2010-01-07 |
Kohn Leonard D |
Methods and compositions for the treatment of malignant melanoma, breast, prostate, colon, papillary thyroid and pancreatic cancer
|
EP2505200A1
(en)
|
2004-03-22 |
2012-10-03 |
Celgene Corporation |
Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of scleroderma
|
WO2005092065A2
(en)
*
|
2004-03-25 |
2005-10-06 |
Transform Pharmaceuticals, Inc. |
Novel tricyclic compounds and related methods of treatment
|
TWI483944B
(zh)
*
|
2004-03-30 |
2015-05-11 |
Euro Celtique Sa |
含有小於25ppm14-羥可待因酮之羥可酮鹽酸鹽組成物、醫藥劑型、延遲釋出口服劑型及醫藥上可以接受的包裝
|
JP4869221B2
(ja)
*
|
2004-04-08 |
2012-02-08 |
ワイス・エルエルシー |
プロゲステロン受容体調節剤としてのチオアミド誘導体
|
EP1744749A4
(en)
*
|
2004-04-14 |
2009-04-22 |
Celgene Corp |
METHODS OF USE AND COMPOSITION COMPRISING IMMUNOMODULATOR COMPOUNDS FOR THE TREATMENT AND CARE OF MYELODYSPLASIC SYNDROMES
|
BRPI0418743A
(pt)
*
|
2004-04-14 |
2007-09-18 |
Celgene Corp |
métodos de tratamento, prevenção ou controle de uma sìndrome mielodisplásica, de redução ou evitação de um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de uma sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária única, e, kit
|
CA2563377A1
(en)
*
|
2004-04-23 |
2005-11-03 |
Celgene Corporation |
Methods of using and compositions comprising pde4 modulators for the treatment and management of pulmonary hypertension
|
BRPI0510260A
(pt)
*
|
2004-04-27 |
2007-10-23 |
Wyeth Corp |
método para purificar um composto, e, kit farmacêutico
|
US8673341B2
(en)
|
2004-04-30 |
2014-03-18 |
Allergan, Inc. |
Intraocular pressure reduction with intracameral bimatoprost implants
|
US8425929B2
(en)
|
2004-04-30 |
2013-04-23 |
Allergan, Inc. |
Sustained release intraocular implants and methods for preventing retinal dysfunction
|
US9498457B2
(en)
|
2004-04-30 |
2016-11-22 |
Allergan, Inc. |
Hypotensive prostamide-containing biodegradable intraocular implants and related implants
|
US7993634B2
(en)
|
2004-04-30 |
2011-08-09 |
Allergan, Inc. |
Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
|
US8147865B2
(en)
|
2004-04-30 |
2012-04-03 |
Allergan, Inc. |
Steroid-containing sustained release intraocular implants and related methods
|
US20050244469A1
(en)
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Extended therapeutic effect ocular implant treatments
|
US7771742B2
(en)
|
2004-04-30 |
2010-08-10 |
Allergan, Inc. |
Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
|
US20050244500A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Intravitreal implants in conjuction with photodynamic therapy to improve vision
|
US8119154B2
(en)
|
2004-04-30 |
2012-02-21 |
Allergan, Inc. |
Sustained release intraocular implants and related methods
|
US7799336B2
(en)
|
2004-04-30 |
2010-09-21 |
Allergan, Inc. |
Hypotensive lipid-containing biodegradable intraocular implants and related methods
|
US20050244465A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Drug delivery systems and methods for treatment of an eye
|
US20050244463A1
(en)
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Sustained release intraocular implants and methods for treating ocular vasculopathies
|
US7351739B2
(en)
*
|
2004-04-30 |
2008-04-01 |
Wellgen, Inc. |
Bioactive compounds and methods of uses thereof
|
BRPI0510485A
(pt)
|
2004-04-30 |
2007-11-13 |
Allergan Inc |
implantes inibidores de tirosina cinase intravìtreos biodegradáveis
|
US8455656B2
(en)
|
2004-04-30 |
2013-06-04 |
Allergan, Inc. |
Kinase inhibitors
|
US20050244458A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Sustained release intraocular implants and methods for treating ocular neuropathies
|
US20050244466A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Photodynamic therapy in conjunction with intraocular implants
|
US8722097B2
(en)
|
2004-04-30 |
2014-05-13 |
Allergan, Inc. |
Oil-in-water method for making polymeric implants containing a hypotensive lipid
|
US20060185357A1
(en)
*
|
2004-05-07 |
2006-08-24 |
Kovacevich Ian D |
Independently drawing and tensioning lines with bi-directional rotary device having two spools
|
US7803366B2
(en)
*
|
2004-05-07 |
2010-09-28 |
Nbty, Inc. |
Methods and compositions that enhance bioavailability of coenzyme-Q10
|
AU2005245896A1
(en)
*
|
2004-05-14 |
2005-12-01 |
Receptor Biologix, Inc. |
Cell surface receptor isoforms and methods of identifying and using the same
|
RU2006145872A
(ru)
*
|
2004-05-25 |
2008-06-27 |
Метаболекс, Инк. (Us) |
Замещенные триазолы в качестве модуляторов ppar и способы их получения
|
WO2005115384A2
(en)
*
|
2004-05-25 |
2005-12-08 |
Metabolex, Inc. |
Bicyclic, substituted triazoles as modulators of ppar and methods of their preparation
|
JP2008501024A
(ja)
|
2004-05-28 |
2008-01-17 |
トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド |
混合コクリスタルおよびそれを含んでなる製薬学的組成物
|
US20060009425A1
(en)
*
|
2004-05-28 |
2006-01-12 |
Leticia Delgado-Herrera |
Oral formulations of paricalcitol
|
US20050267555A1
(en)
*
|
2004-05-28 |
2005-12-01 |
Marnfeldt Goran N |
Engagement tool for implantable medical devices
|
AU2005249508A1
(en)
*
|
2004-05-28 |
2005-12-15 |
Human Biomolecular Research Institute |
Synthesis of metabolically stable analgesics, pain medications and other agents
|
US20080138282A1
(en)
*
|
2004-06-03 |
2008-06-12 |
The Trustees Of Columbia University In The City Of New York |
Radiolabeled Arylsulfonyl Compounds and Uses Thereof
|
US7323585B2
(en)
*
|
2004-06-04 |
2008-01-29 |
Xenoport, Inc. |
Levodopa prodrugs, and compositions and uses thereof
|
ZA200610042B
(en)
*
|
2004-06-04 |
2008-06-25 |
Xenoport Inc |
Levodopa prodrugs, and compositions and uses thereof
|
EP1604667A1
(en)
|
2004-06-08 |
2005-12-14 |
Euro-Celtique S.A. |
Opioids for the treatment of the restless leg syndrome
|
EP1604666A1
(en)
|
2004-06-08 |
2005-12-14 |
Euro-Celtique S.A. |
Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
|
ES2653568T3
(es)
|
2004-06-12 |
2018-02-07 |
Collegium Pharmaceutical, Inc. |
Formulaciones de fármacos para la prevención del abuso
|
US20050276848A1
(en)
*
|
2004-06-15 |
2005-12-15 |
Nilobon Podhipleux |
Sustained release neutralized divalproex sodium
|
US7713550B2
(en)
*
|
2004-06-15 |
2010-05-11 |
Andrx Corporation |
Controlled release sodium valproate formulation
|
WO2006007448A2
(en)
*
|
2004-06-17 |
2006-01-19 |
Transform Pharmaceuticals, Inc. |
Pharmaceutical co-crystal compositions and related methods of use
|
EP1771435A4
(en)
*
|
2004-06-19 |
2008-02-13 |
Human Biomolecular Res Inst |
MODULATORS OF NEUROTRANSMITTERS OF THE CENTRAL NERVOUS SYSTEM
|
US20050287185A1
(en)
*
|
2004-06-23 |
2005-12-29 |
David Wong |
Extended release oxybutynin formulation
|
WO2006007351A2
(en)
*
|
2004-06-28 |
2006-01-19 |
Alza Corporation |
Squeeze controlled oral dosage form
|
WO2006007323A2
(en)
*
|
2004-06-28 |
2006-01-19 |
Alza Corporation |
Dosage forms for low solubility and/or low dissolution rate free acid pharmaceutical agents
|
US20050287212A1
(en)
*
|
2004-06-28 |
2005-12-29 |
Liang-Chang Dong |
Oral delivery system comprising a drug/polymer complex
|
US8394409B2
(en)
|
2004-07-01 |
2013-03-12 |
Intellipharmaceutics Corp. |
Controlled extended drug release technology
|
US20080027513A1
(en)
*
|
2004-07-09 |
2008-01-31 |
Advanced Bionics Corporation |
Systems And Methods For Using A Butterfly Coil To Communicate With Or Transfer Power To An Implantable Medical Device
|
WO2006017352A1
(en)
*
|
2004-07-12 |
2006-02-16 |
Xenoport, Inc. |
Amino acid derived prodrugs of propofol, compositions and uses thereof
|
US7241807B2
(en)
*
|
2004-07-12 |
2007-07-10 |
Xenoport, Inc. |
Prodrugs of propofol, compositions and uses thereof
|
US20060128676A1
(en)
*
|
2004-07-13 |
2006-06-15 |
Pharmacofore, Inc. |
Compositions of nicotinic agonists and therapeutic agents and methods for treating or preventing diseases or pain
|
WO2006012536A2
(en)
|
2004-07-22 |
2006-02-02 |
Ritter Andrew J |
Methods and compositions for treating lactose intolerance
|
GB0417401D0
(en)
|
2004-08-05 |
2004-09-08 |
Controlled Therapeutics Sct |
Stabilised prostaglandin composition
|
JP2008516890A
(ja)
*
|
2004-08-06 |
2008-05-22 |
トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド |
新規なフェノフィブラート製剤および関連治療方法
|
US20090042979A1
(en)
*
|
2004-08-06 |
2009-02-12 |
Transform Pharmaceuticals Inc. |
Novel Statin Pharmaceutical Compositions and Related Methods of Treatment
|
WO2006017698A2
(en)
*
|
2004-08-06 |
2006-02-16 |
Transform Pharmaceuticals, Inc. |
Novel statin pharmaceutical compositions and related methods of treatment
|
CA2576386A1
(en)
*
|
2004-08-13 |
2006-02-16 |
Boehringer Ingelheim International Gmbh |
Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
|
ATE486588T1
(de)
*
|
2004-08-13 |
2010-11-15 |
Boehringer Ingelheim Int |
Tablettenformulierung mit verlängerter freisetzung mit pramipexol oder einem pharmazeutisch zulässigen salz davon, herstellungsverfahren und verwendung dafür
|
US8452407B2
(en)
*
|
2004-08-16 |
2013-05-28 |
Boston Scientific Neuromodulation Corporation |
Methods for treating gastrointestinal disorders
|
JP2008510000A
(ja)
*
|
2004-08-19 |
2008-04-03 |
アルザ・コーポレーシヨン |
制御放出性ナノ粒子有効薬剤配合物投与剤型品および方法
|
US10624858B2
(en)
|
2004-08-23 |
2020-04-21 |
Intellipharmaceutics Corp |
Controlled release composition using transition coating, and method of preparing same
|
EP2457580A1
(en)
|
2004-08-25 |
2012-05-30 |
The UAB Research Foundation |
Absorption enhancers for drug administration
|
US8268791B2
(en)
|
2004-08-25 |
2012-09-18 |
Aegis Therapeutics, Llc. |
Alkylglycoside compositions for drug administration
|
JP2008511651A
(ja)
*
|
2004-08-30 |
2008-04-17 |
セオ ホン ユー |
局所虚血モデルでの可溶化udcaの神経保護効果
|
US20120277839A1
(en)
|
2004-09-08 |
2012-11-01 |
Kramer Jeffery M |
Selective stimulation to modulate the sympathetic nervous system
|
US7337005B2
(en)
*
|
2004-09-08 |
2008-02-26 |
Spinal Modulations, Inc. |
Methods for stimulating a nerve root ganglion
|
US9205261B2
(en)
|
2004-09-08 |
2015-12-08 |
The Board Of Trustees Of The Leland Stanford Junior University |
Neurostimulation methods and systems
|
AU2005287137B2
(en)
|
2004-09-17 |
2012-03-22 |
Foldrx Pharmaceuticals, Inc. |
Compounds, compositions and methods of inhibiting a-synuclein toxicity
|
CA2580852A1
(en)
*
|
2004-09-21 |
2006-03-30 |
Synta Pharmaceutical Corp. |
Compounds for inflammation and immune-related uses
|
US8541026B2
(en)
*
|
2004-09-24 |
2013-09-24 |
Abbvie Inc. |
Sustained release formulations of opioid and nonopioid analgesics
|
KR20070084211A
(ko)
|
2004-10-15 |
2007-08-24 |
유서홍 |
약제학적 화합물의 독성을 감소시키기 위한 방법 및 조성물
|
WO2006044610A1
(en)
|
2004-10-15 |
2006-04-27 |
Cv Therapeutics, Inc |
Method of preventing and treating airway remodeling and pulmonary inflammation using a2b adenosine receptor antagonists
|
JP2008517063A
(ja)
*
|
2004-10-20 |
2008-05-22 |
シーブイ・セラピューティクス・インコーポレイテッド |
A2aアデノシンレセプターアゴニストの使用
|
WO2006046112A2
(en)
*
|
2004-10-25 |
2006-05-04 |
Ranbaxy Laboratories Limited |
Ketolide derivatives as antibacterial agents
|
JP2008518924A
(ja)
*
|
2004-10-28 |
2008-06-05 |
セルジーン・コーポレーション |
中枢神経系損傷の治療及び管理のためのpde4モジュレータを使用する方法及び組成物
|
KR101358078B1
(ko)
*
|
2004-11-01 |
2014-02-06 |
주식회사 유스팜인터내셔널 |
근위축성 측삭 경화증의 신경퇴행을 감소시키기 위한 방법및 조성물
|
BRPI0517232A
(pt)
|
2004-11-02 |
2008-10-07 |
Banyu Pharma Co Ltd |
composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, ativador da glicocinase, e, agentes terapêuticos e/ou profiláticos para diabetes e para obesidade
|
WO2006050471A2
(en)
*
|
2004-11-03 |
2006-05-11 |
Xenoport, Inc. |
Acyloxyalkyl carbamate prodrugs of sulfinic acids, methods of synthesis, and use
|
US7494985B2
(en)
*
|
2004-11-03 |
2009-02-24 |
Xenoport, Inc. |
Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use
|
BRPI0517227B8
(pt)
*
|
2004-11-04 |
2021-05-25 |
Xenoport Inc |
comprimido oral de liberação prolongada do ácido 1-{[alfa-isobutanoiloxietoxi)carbonil]amino metil}-1-cicloexano acético, e, uso do comprimido
|
US9358393B1
(en)
|
2004-11-09 |
2016-06-07 |
Andres M. Lozano |
Stimulation methods and systems for treating an auditory dysfunction
|
WO2006053184A2
(en)
*
|
2004-11-10 |
2006-05-18 |
The Trustees Of Columbia University In The City Of New York |
Methods for treating or preventing a vascular disease
|
MX2007005940A
(es)
|
2004-11-18 |
2007-06-19 |
Synta Pharmaceuticals Corp |
Compuestos de triazol que modulan la actividad hsp90.
|
WO2006054162A1
(en)
*
|
2004-11-19 |
2006-05-26 |
Ranbaxy Laboratories Limited |
Azabicyclic muscarinic receptor antagonists
|
AR053986A1
(es)
|
2004-12-03 |
2007-05-30 |
Osmotica Pharmaceutical Argent |
Dispositivo osmotico que contiene amantadina y una sal osmotica
|
US7483746B2
(en)
*
|
2004-12-06 |
2009-01-27 |
Boston Scientific Neuromodulation Corp. |
Stimulation of the stomach in response to sensed parameters to treat obesity
|
WO2006065793A2
(en)
|
2004-12-13 |
2006-06-22 |
Indevus Pharmaceuticals, Inc. |
TREATMENT OF INTERSTITIAL CYSTITIS USING (6aR,10aR)-Δ8-TETRAHYDROCANNABINOL-11-OIC ACIDS
|
WO2006065792A2
(en)
*
|
2004-12-13 |
2006-06-22 |
Indevus Pharmaceuticals, Inc. |
Treatment of interstitial cystitis using cannabinoid analogs
|
EP1831235B1
(en)
|
2004-12-16 |
2013-02-20 |
The Regents of The University of California |
Lung-targeted drugs
|
US7560544B2
(en)
|
2004-12-17 |
2009-07-14 |
Anadys Pharmaceuticals, Inc. |
3,5-Disubsitituted and 3,5,7-trisubstituted-3H-oxazolo and 3H-thiazolo[4,5-d]pyrimidin-2-one compounds and prodrugs thereof
|
US20060161217A1
(en)
*
|
2004-12-21 |
2006-07-20 |
Jaax Kristen N |
Methods and systems for treating obesity
|
US9095713B2
(en)
*
|
2004-12-21 |
2015-08-04 |
Allison M. Foster |
Methods and systems for treating autism by decreasing neural activity within the brain
|
US20070038264A1
(en)
*
|
2004-12-21 |
2007-02-15 |
Jaax Kristen N |
Methods and systems for treating autism
|
US9327069B2
(en)
|
2004-12-21 |
2016-05-03 |
Boston Scientific Neuromodulation Corporation |
Methods and systems for treating a medical condition by promoting neural remodeling within the brain
|
US8515541B1
(en)
|
2004-12-22 |
2013-08-20 |
Boston Scientific Neuromodulation Corporation |
Methods and systems for treating post-stroke disorders
|
US9352145B2
(en)
*
|
2004-12-22 |
2016-05-31 |
Boston Scientific Neuromodulation Corporation |
Methods and systems for treating a psychotic disorder
|
ATE432921T1
(de)
|
2004-12-23 |
2009-06-15 |
Gpc Biotech Ag |
Quadratsäurederivate mit antiproliferativer wirkung
|
CA2586410A1
(en)
*
|
2004-12-23 |
2006-07-06 |
Xenoport, Inc. |
Serine amino acid derived prodrugs of propofol, compositions, uses and crystalline forms thereof
|
WO2006073779A1
(en)
*
|
2004-12-30 |
2006-07-13 |
Transform Phamaceuticals, Inc. |
Novel omeprazole forms and related methods
|
MX2007008290A
(es)
|
2005-01-07 |
2008-02-15 |
Synta Pharmaceuticals Corp |
Compuestos para inflamacion y usos inmuno-relacionados.
|
AU2006208045B2
(en)
|
2005-01-25 |
2012-08-30 |
Synta Pharmaceuticals Corp. |
Compounds for inflammation and immune-related uses
|
ATE413864T1
(de)
*
|
2005-01-27 |
2008-11-15 |
Alza Corp |
Orale osmotische darreichungsform mit membran mit hoher flussdichte
|
JP5704789B2
(ja)
*
|
2005-01-28 |
2015-04-22 |
ユーロ−セルティーク エス.エイ. |
耐アルコール性剤形
|
JP2006224318A
(ja)
*
|
2005-02-15 |
2006-08-31 |
Brother Ind Ltd |
インクジェット記録装置
|
EP1690540A1
(en)
|
2005-02-15 |
2006-08-16 |
Neuro3D |
Composition comprising ocaperidone
|
US20060185665A1
(en)
*
|
2005-02-22 |
2006-08-24 |
Bachinski Thomas J |
Sauna fireplace
|
US20060194724A1
(en)
*
|
2005-02-25 |
2006-08-31 |
Whitehurst Todd K |
Methods and systems for nerve regeneration
|
EP1695700A1
(en)
*
|
2005-02-28 |
2006-08-30 |
Euro-Celtique S.A. |
Dosage form containing oxycodone and naloxone
|
EP1702558A1
(en)
|
2005-02-28 |
2006-09-20 |
Euro-Celtique S.A. |
Method and device for the assessment of bowel function
|
US7312217B2
(en)
|
2005-03-11 |
2007-12-25 |
Syntrix Biosystems, Inc. |
Aminopterin dosage forms and methods for inflammatory disorders
|
US7702385B2
(en)
*
|
2005-11-16 |
2010-04-20 |
Boston Scientific Neuromodulation Corporation |
Electrode contact configurations for an implantable stimulator
|
US7853321B2
(en)
|
2005-03-14 |
2010-12-14 |
Boston Scientific Neuromodulation Corporation |
Stimulation of a stimulation site within the neck or head
|
US8423155B1
(en)
|
2005-03-14 |
2013-04-16 |
Boston Scientific Neuromodulation Corporation |
Methods and systems for facilitating stimulation of one or more stimulation sites
|
US7848803B1
(en)
|
2005-03-14 |
2010-12-07 |
Boston Scientific Neuromodulation Corporation |
Methods and systems for facilitating stimulation of one or more stimulation sites
|
US20060206165A1
(en)
*
|
2005-03-14 |
2006-09-14 |
Jaax Kristen N |
Occipital nerve stimulation to treat headaches and other conditions
|
US8288438B2
(en)
|
2005-03-21 |
2012-10-16 |
Metabolex, Inc. |
Methods for avoiding edema in the treatment or prevention of PPARγ-responsive diseases, including cancer
|
WO2006130217A2
(en)
*
|
2005-04-01 |
2006-12-07 |
The Regents Of The University Of California |
Substituted phosphate esters of nucleoside phosphonates
|
CN101189249B
(zh)
|
2005-04-01 |
2013-04-17 |
加利福尼亚大学董事会 |
膦酰基-戊-2-烯-1-基核苷和类似物
|
US20080152714A1
(en)
*
|
2005-04-08 |
2008-06-26 |
Yi Gao |
Pharmaceutical Formulations
|
UA100966C2
(ru)
|
2005-04-08 |
2013-02-25 |
Эбботт Леборетриз |
Фармацевтическая композиция на основе 2-[4-(4-хлорбензоил)фенокси]-2-метилпропионовой кислоты и ее солей
|
MY145694A
(en)
|
2005-04-11 |
2012-03-30 |
Xenon Pharmaceuticals Inc |
Spiroheterocyclic compounds and their uses as therapeutic agents
|
MY144968A
(en)
|
2005-04-11 |
2011-11-30 |
Xenon Pharmaceuticals Inc |
Spiro-oxindole compounds and their uses as therapeutic agents
|
US20060229261A1
(en)
*
|
2005-04-12 |
2006-10-12 |
John Devane |
Acarbose methods and formulations for treating chronic constipation
|
EP1874782A1
(en)
*
|
2005-04-15 |
2008-01-09 |
Ranbaxy Laboratories Limited |
Oxazolidinone derivatives as antimicrobials
|
US20060233882A1
(en)
*
|
2005-04-15 |
2006-10-19 |
Sowden Harry S |
Osmotic dosage form
|
WO2006113568A2
(en)
*
|
2005-04-19 |
2006-10-26 |
Alza Corporation |
Controlled delivery dosage form of tramadol and gabapentin
|
AR053713A1
(es)
*
|
2005-04-20 |
2007-05-16 |
Xenon Pharmaceuticals Inc |
Compuestos heterociclicos y sus usos como agentes terapeuticos
|
WO2006119365A2
(en)
|
2005-05-02 |
2006-11-09 |
Cold Spring Harbor Laboratory |
Composition and methods for cancer diagnosis utilizing the mir 17-92 cluster
|
WO2006119510A2
(en)
*
|
2005-05-04 |
2006-11-09 |
Receptor Biologix, Inc. |
Isoforms of receptor for advanced glycation end products (rage) and methods of identifying and using same
|
US20070041944A1
(en)
*
|
2005-05-05 |
2007-02-22 |
The Trustees Of Columbia University In The City Of New York |
Treating tumors by ENH dislocation of ID proteins
|
US20060270707A1
(en)
*
|
2005-05-24 |
2006-11-30 |
Zeldis Jerome B |
Methods and compositions using 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione for the treatment or prevention of cutaneous lupus
|
NZ564326A
(en)
*
|
2005-06-16 |
2010-01-29 |
Cv Therapeutics Inc |
Prodrugs of A2B adenosine receptor antagonists
|
CN101253148B
(zh)
|
2005-06-20 |
2013-01-02 |
克塞诺波特公司 |
凝血酸的酰氧基烷基氨基甲酸酯前药,合成和使用的方法
|
US20100098640A1
(en)
*
|
2005-06-20 |
2010-04-22 |
Cohen Seth M |
Multidentate Pyrone-Derived Chelators for Medicinal Imaging and Chelation
|
US20070054868A1
(en)
*
|
2005-06-20 |
2007-03-08 |
The Trustees Of Columbia University In The City Of New York |
Synergistic polyphenol compounds, compositions thereof, and uses thereof
|
RU2408368C2
(ru)
|
2005-06-27 |
2011-01-10 |
Биовэйл Лэборэториз Интернэшнл С.Р.Л. |
Препараты соли бупропиона с модифицированным высвобождением
|
CA2613703A1
(en)
*
|
2005-06-28 |
2007-01-04 |
Cv Therapeutics, Inc. |
Abca1 elevating compounds
|
US20070003624A1
(en)
*
|
2005-06-29 |
2007-01-04 |
Shanbhag Anant R |
Semi-permeable compositions providing reduced drying time for osmotic dosage forms
|
US8348930B2
(en)
*
|
2005-07-01 |
2013-01-08 |
Microlin, Llc |
Fluid delivery device with a diffusion membrane and electrochemical pump
|
JP2009500420A
(ja)
*
|
2005-07-06 |
2009-01-08 |
セプラコア インコーポレーテッド |
エスゾピクロン及びo−デスメチルベンラファキシンの組み合わせ、並びに閉経期並びに気分、不安、及び認知障害の治療方法
|
US20070009573A1
(en)
*
|
2005-07-07 |
2007-01-11 |
L N K International |
Method of forming immediate release dosage form
|
TWI279234B
(en)
*
|
2005-07-12 |
2007-04-21 |
Anchen Pharmaceuticals Taiwan |
Method for controlling lag time of in-situ passageway formation in osmotic delivery system
|
US20070023291A1
(en)
*
|
2005-07-15 |
2007-02-01 |
Sai Bhavaraju |
Metal Trap
|
US20070025869A1
(en)
*
|
2005-07-15 |
2007-02-01 |
Gordon John H |
Fluid Delivery Device
|
US20070021734A1
(en)
*
|
2005-07-15 |
2007-01-25 |
Sai Bhavaraju |
Bioelectro-osmotic engine fluid delivery device
|
EP1907357A1
(en)
|
2005-07-22 |
2008-04-09 |
Amgen Inc. |
Aniline sulfonamide derivatives and their uses
|
EP1912622A2
(en)
*
|
2005-08-04 |
2008-04-23 |
Alza Corporation |
Osmotic dosage forms comprising semipermeable membranes with polymer blends providing improved properties
|
US7507842B2
(en)
*
|
2005-08-12 |
2009-03-24 |
Radiorx, Inc. |
Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof
|
US20070135380A1
(en)
|
2005-08-12 |
2007-06-14 |
Radiorx, Inc. |
O-nitro compounds, pharmaceutical compositions thereof and uses thereof
|
EP1928450A2
(en)
*
|
2005-08-26 |
2008-06-11 |
Xenoport, Inc. |
Treating premature ejaculation using gabapentin and pregabalin prodrugs
|
US20080058282A1
(en)
|
2005-08-30 |
2008-03-06 |
Fallon Joan M |
Use of lactulose in the treatment of autism
|
MX2008002795A
(es)
*
|
2005-08-30 |
2009-02-25 |
Nicholas Piramal India Ltd |
Composicion farmaceutica de metformina de liberacion extendida y proceso para producirla.
|
AU2006284601B2
(en)
|
2005-08-31 |
2012-12-20 |
Renexxion, Llc |
Synthetic methods and intermediates for stereoisomeric compounds useful for the treatment of gastrointestinal and central nervous system disorders
|
CA2822094C
(en)
|
2005-08-31 |
2015-10-27 |
Celgene Corporation |
Isoindole-imide compounds and compositions comprising and methods of using the same
|
US20080138295A1
(en)
*
|
2005-09-12 |
2008-06-12 |
Celgene Coporation |
Bechet's disease using cyclopropyl-N-carboxamide
|
US20070066512A1
(en)
|
2005-09-12 |
2007-03-22 |
Dominique Verhelle |
Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels
|
US8492428B2
(en)
*
|
2005-09-20 |
2013-07-23 |
Mayo Foundation For Medical Education And Research |
Small-molecule botulinum toxin inhibitors
|
US7684858B2
(en)
*
|
2005-09-21 |
2010-03-23 |
Boston Scientific Neuromodulation Corporation |
Methods and systems for placing an implanted stimulator for stimulating tissue
|
US20070072838A1
(en)
|
2005-09-26 |
2007-03-29 |
Pharmacyclics, Inc. |
High-purity texaphyrin metal complexes
|
US20070078119A1
(en)
*
|
2005-09-30 |
2007-04-05 |
Pharmacyclics, Inc. |
Storage system for texaphyrin pharmaceutical formulations
|
CA2623958C
(en)
|
2005-09-30 |
2013-05-28 |
Banyu Pharmaceutical Co., Ltd. |
2-heteroaryl-substituted indole derivative
|
US20070190137A1
(en)
*
|
2005-10-07 |
2007-08-16 |
Reyes Iran |
Osmotic dosage form with controlled release and fast release aspects
|
ES2358351T3
(es)
*
|
2005-10-13 |
2011-05-09 |
Cv Therapeutics, Inc. |
Agonistas del receptor de adenosina a1.
|
US20070092585A1
(en)
*
|
2005-10-14 |
2007-04-26 |
Skinner Michael K |
Cancer chemotherapy compositions comprising PI3K pathways modulators and triptolide
|
PL116330U1
(en)
*
|
2005-10-31 |
2007-04-02 |
Alza Corp |
Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
|
EP2298770A1
(en)
|
2005-11-03 |
2011-03-23 |
ChemBridge Corporation |
Heterocyclic compounds as TrkA modulators
|
CA2628031C
(en)
|
2005-11-10 |
2013-03-05 |
Circ Pharma Research And Development Limited |
Once-daily administration of central nervous system drugs
|
KR20080082629A
(ko)
*
|
2005-11-10 |
2008-09-11 |
리셉터 바이오로직스 인크 |
간세포 성장인자 인트론 융합 단백질
|
WO2007059010A2
(en)
|
2005-11-14 |
2007-05-24 |
Enterprise Partners Venture Capital |
Stem cell factor therapy for tissue injury
|
UA91250C2
(en)
|
2005-11-21 |
2010-07-12 |
Пердью Фарма Л.П. |
4-oxadiazolyl-piperidine compounds and use thereof
|
US7729758B2
(en)
|
2005-11-30 |
2010-06-01 |
Boston Scientific Neuromodulation Corporation |
Magnetically coupled microstimulators
|
DK1959948T3
(da)
*
|
2005-12-05 |
2012-08-20 |
Xenoport Inc |
Levodopa prodrug-mesylat, sammensætninger deraf og anvendelser deraf
|
US7982066B2
(en)
|
2005-12-09 |
2011-07-19 |
Novalife, Inc. |
High protein supplement
|
US10064828B1
(en)
|
2005-12-23 |
2018-09-04 |
Intellipharmaceutics Corp. |
Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
|
US8138361B2
(en)
*
|
2005-12-28 |
2012-03-20 |
The Trustees Of The University Of Pennsylvania |
C-10 carbamates of taxanes
|
US20090176882A1
(en)
|
2008-12-09 |
2009-07-09 |
Depomed, Inc. |
Gastric retentive gabapentin dosage forms and methods for using same
|
EP1981525B1
(en)
|
2005-12-30 |
2015-01-21 |
Zensun (Shanghai) Science and Technology Limited |
Extended release of neuregulin for improved cardiac function
|
US7610100B2
(en)
*
|
2005-12-30 |
2009-10-27 |
Boston Scientific Neuromodulation Corporation |
Methods and systems for treating osteoarthritis
|
US7835803B1
(en)
*
|
2006-01-17 |
2010-11-16 |
Boston Scientific Neuromodulation Corporation |
Lead assemblies with one or more switching networks
|
US8623871B2
(en)
|
2006-01-25 |
2014-01-07 |
Synta Pharmaceuticals Corp. |
Substituted biaryl compounds for inflammation and immune-related uses
|
EP1983980A4
(en)
*
|
2006-01-25 |
2010-05-05 |
Synta Pharmaceuticals Corp |
THIAZOL AND THIADIAZOL COMPOUNDS FOR USES IN RELATION TO INFLAMMATION AND IMMUNITY
|
EP1984337B1
(en)
|
2006-01-25 |
2014-04-30 |
Synta Pharmaceuticals Corp. |
Vinyl-phenyl derivatives for inflammation and immune-related uses
|
EP1813276A1
(en)
*
|
2006-01-27 |
2007-08-01 |
Euro-Celtique S.A. |
Tamper resistant dosage forms
|
WO2007089904A2
(en)
|
2006-01-31 |
2007-08-09 |
Synta Pharmaceuticals Corp. |
Pyridylphenyl compounds for inflammation and immune-related uses
|
WO2007092372A1
(en)
|
2006-02-03 |
2007-08-16 |
Cv Therapeutics, Inc. |
Process for preparing an a2a-adenosine receptor agonist and its polymorphs
|
EP1986639A4
(en)
*
|
2006-02-03 |
2010-04-28 |
Avanir Pharmaceuticals |
PHARMACEUTICAL COMPOSITIONS OF DEXTROMETHORPHANE AND CHINIDINE FOR THE TREATMENT OF DEPRESSION, FEAR STATES AND NEURODEEGENERATIVE DISEASES
|
US20090041844A1
(en)
*
|
2006-02-10 |
2009-02-12 |
Boehringer Ingelheim International Gmbh |
Modified Release Formulation
|
US20090098202A1
(en)
*
|
2006-02-10 |
2009-04-16 |
Boehringer Ingelheim International Gmbh |
Extended Release Formulation
|
US20070196487A1
(en)
*
|
2006-02-16 |
2007-08-23 |
Geerke Johan H |
Method and apparatus for drilling orifices in osmotic tablets incorporating near-infrared spectroscopy
|
US20070190141A1
(en)
*
|
2006-02-16 |
2007-08-16 |
Aaron Dely |
Extended release opiate composition
|
US7518017B2
(en)
|
2006-02-17 |
2009-04-14 |
Idexx Laboratories |
Fenicol compounds and methods synthesizing 2-trifluoroacetamido-3-substituted propiophenone compounds
|
US20070201024A1
(en)
*
|
2006-02-28 |
2007-08-30 |
Geerke Johan H |
Method and apparatus for semi-permeable membrane detection on osmotic tablets incorating near-infrared spectroscopy
|
WO2007106349A2
(en)
|
2006-03-10 |
2007-09-20 |
Neurogen Corporation |
Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues
|
WO2007106494A2
(en)
*
|
2006-03-13 |
2007-09-20 |
Encysive Pharmaceuticals, Inc. |
Methods and compositions for treatment of diastolic heart failure
|
PL2383271T3
(pl)
*
|
2006-03-13 |
2013-12-31 |
Kyorin Seiyaku Kk |
Aminochinolony jako inhibitory GSK-3
|
RU2008136315A
(ru)
*
|
2006-03-13 |
2010-04-20 |
Инсайсив Фармасьютикалз, Инк. (US) |
Композиции ситаксентана натрия
|
US8175710B2
(en)
*
|
2006-03-14 |
2012-05-08 |
Boston Scientific Neuromodulation Corporation |
Stimulator system with electrode array and the method of making the same
|
US20070219174A1
(en)
*
|
2006-03-15 |
2007-09-20 |
Pharmacyclics, Inc. |
Methods of treating cancer using hypofractionated radiation and texaphyrins
|
US20100273776A1
(en)
*
|
2006-03-29 |
2010-10-28 |
FOLDRx PHARMACEUTICALS, INC |
Inhibition of alpha-synuclein toxicity
|
WO2007112579A1
(en)
*
|
2006-04-03 |
2007-10-11 |
Isa Odidi |
Drug delivery composition
|
CN101453993A
(zh)
|
2006-04-03 |
2009-06-10 |
伊萨·奥迪迪 |
含有机溶胶涂层的受控释放递送物件
|
CN101432032A
(zh)
*
|
2006-04-28 |
2009-05-13 |
皇家飞利浦电子股份有限公司 |
具有至少一种可充电材料的渗透泵
|
US9011930B2
(en)
*
|
2006-05-01 |
2015-04-21 |
Zycal Bioceuticals Healthcare Company, Inc. |
Nutritional supplement and use thereof
|
US10960077B2
(en)
|
2006-05-12 |
2021-03-30 |
Intellipharmaceutics Corp. |
Abuse and alcohol resistant drug composition
|
US8604031B2
(en)
|
2006-05-18 |
2013-12-10 |
Mannkind Corporation |
Intracellular kinase inhibitors
|
US8058260B2
(en)
*
|
2006-05-22 |
2011-11-15 |
Xenoport, Inc. |
2′-C-methyl-ribofuranosyl cytidine prodrugs, pharmaceutical compositions and uses thereof
|
EP2402037B8
(en)
|
2006-05-26 |
2019-12-04 |
Signature Therapeutics, Inc. |
Controlled release of phenolic opioids
|
TW200808695A
(en)
*
|
2006-06-08 |
2008-02-16 |
Amgen Inc |
Benzamide derivatives and uses related thereto
|
EP2029540B1
(en)
*
|
2006-06-08 |
2010-08-04 |
Amgen Inc. |
Benzamide derivatives and uses related thereto
|
CA2655205A1
(en)
*
|
2006-06-12 |
2007-12-21 |
Receptor Biologix Inc. |
Pan-cell surface receptor- specific therapeutics
|
US8158156B2
(en)
|
2006-06-19 |
2012-04-17 |
Alpharma Pharmaceuticals, Llc |
Abuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist
|
US20070299089A1
(en)
*
|
2006-06-22 |
2007-12-27 |
Cv Therapeutics, Inc. |
Use of A2A Adenosine Receptor Agonists in the Treatment of Ischemia
|
US20080026061A1
(en)
*
|
2006-06-22 |
2008-01-31 |
Reichwein John F |
Crystalline N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4.5-(methylenedioxy)phenylacetyl]-thiophene-3-sulfonamide
|
EP2034834B1
(en)
|
2006-06-22 |
2011-01-26 |
Anadys Pharmaceuticals, Inc. |
Prodrugs of 5-amino-3-(3'-deoxy-beta-d-ribofuranosyl)-thiazolo[4,5-d]pyrimidin-2,7-dione
|
US7462611B2
(en)
|
2006-06-22 |
2008-12-09 |
Anadys Pharmaceuticals, Inc. |
Pyrro[1,2-b]pyridazinone compounds
|
US20080085915A1
(en)
*
|
2006-06-23 |
2008-04-10 |
Cyrus Becker |
Compounds and methods for the treatment of gastrointestinal and central nervous system disorders
|
US8802128B2
(en)
|
2006-06-23 |
2014-08-12 |
Allergan, Inc. |
Steroid-containing sustained release intraocular implants and related methods
|
US20070298073A1
(en)
*
|
2006-06-23 |
2007-12-27 |
Allergan, Inc. |
Steroid-containing sustained release intraocular implants and related methods
|
US8504163B1
(en)
|
2006-06-30 |
2013-08-06 |
Boston Scientific Neuromodulation Corporation |
Cranially mounted stimulation systems and methods
|
US8401654B1
(en)
|
2006-06-30 |
2013-03-19 |
Boston Scientific Neuromodulation Corporation |
Methods and systems for treating one or more effects of deafferentation
|
KR20150033726A
(ko)
*
|
2006-07-05 |
2015-04-01 |
카탈리스트 바이오사이언시즈, 인코포레이티드 |
프로테아제 스크리닝 방법 및 이에 의해 확인된 프로테아제
|
GB0613333D0
(en)
|
2006-07-05 |
2006-08-16 |
Controlled Therapeutics Sct |
Hydrophilic polyurethane compositions
|
GB0613638D0
(en)
|
2006-07-08 |
2006-08-16 |
Controlled Therapeutics Sct |
Polyurethane elastomers
|
AU2007272970C1
(en)
|
2006-07-11 |
2013-01-10 |
Roy C. Levitt |
Rhinosinusitis prevention and therapy with proinflammatory cytokine inhibitors
|
DE602007012881D1
(en)
|
2006-07-18 |
2011-04-14 |
Anadys Pharmaceuticals Inc |
Carbonat- und carbamat-prodrugs von thiazolo ä4,5-dü-pyrimidinen
|
AU2007275033A1
(en)
*
|
2006-07-21 |
2008-01-24 |
Lab International Srl |
Hydrophobic abuse deterrent delivery system
|
KR20090033417A
(ko)
|
2006-07-27 |
2009-04-03 |
씨브이 쎄러퓨틱스, 인코포레이티드 |
중독의 치료에서의 aldh-2 저해제
|
CL2007002218A1
(es)
|
2006-08-03 |
2008-03-14 |
Celgene Corp Soc Organizada Ba |
Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa.
|
CA2659037A1
(en)
*
|
2006-08-04 |
2008-03-13 |
Agi Therapeutics Research Limited |
Methods for treating at least one condition having mt1 receptor, 5ht2b receptor, and l-type calcium channel activity
|
US8063225B2
(en)
|
2006-08-14 |
2011-11-22 |
Chembridge Corporation |
Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
|
US9114133B2
(en)
|
2006-08-25 |
2015-08-25 |
U.S. Dept. Of Veterans Affairs |
Method of improving diastolic dysfunction
|
US8877780B2
(en)
|
2006-08-30 |
2014-11-04 |
Celgene Corporation |
5-substituted isoindoline compounds
|
CL2007002513A1
(es)
|
2006-08-30 |
2008-04-04 |
Celgene Corp Soc Organizada Ba |
Compuestos derivados de isoindolina sustituidos, compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento y prevencion de enfermedades tales como cancer, dolor, degeneracion macular, entre otras.
|
US20090081120A1
(en)
*
|
2006-09-01 |
2009-03-26 |
Cv Therapeutics, Inc. |
Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods
|
EP2056834B1
(en)
*
|
2006-09-01 |
2012-08-29 |
Gilead Sciences, Inc. |
Methods and compositions for increasing patient tolerability during myocardial imaging methods
|
US8604244B2
(en)
|
2010-07-02 |
2013-12-10 |
Reviva Pharmaceuticals, Inc. |
Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives
|
US7585996B2
(en)
*
|
2006-09-15 |
2009-09-08 |
Xenoport, Inc. |
Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
|
JP2010503709A
(ja)
|
2006-09-15 |
2010-02-04 |
レビバ ファーマシューティカルズ,インコーポレーテッド |
シクロアルキルメチルアミンの合成、使用方法および組成物
|
PL2066662T3
(pl)
|
2006-09-21 |
2013-05-31 |
Kyorin Seiyaku Kk |
Inhibitory hydrolaz serynowych
|
HUE035308T2
(en)
|
2006-09-26 |
2018-05-02 |
Celgene Corp |
5-substituted quinazoline derivatives as anticancer agents
|
US8779154B2
(en)
|
2006-09-26 |
2014-07-15 |
Qinglin Che |
Fused ring compounds for inflammation and immune-related uses
|
EP2066232A1
(en)
*
|
2006-09-29 |
2009-06-10 |
Cv Therapeutics, Inc. |
Methods for myocardial imaging in patients having a history of pulmonary disease
|
US7445528B1
(en)
|
2006-09-29 |
2008-11-04 |
Boston Scientific Neuromodulation Corporation |
Connector assemblies
|
US7893066B2
(en)
*
|
2006-10-05 |
2011-02-22 |
Gilead Palo Alto, Inc. |
Pyridol[2,3-B]pyrazinones for use as stearoyl CoA desaturase inhibitors
|
CA2665476A1
(en)
*
|
2006-10-05 |
2008-04-10 |
Cv Therapeutics, Inc. |
Bicyclic nitrogen-containing heterocyclic compounds for use as stearoyl coa desaturase inhibitors
|
AR063028A1
(es)
|
2006-10-06 |
2008-12-23 |
Banyu Pharma Co Ltd |
Derivados heterociclicos de piridin-2-carboxamida activadores de glucoquinasas, utiles para el tratamiento de diabetes y obesidad y composiciones farmaceuticas que los contienen.
|
ES2524556T3
(es)
|
2006-10-09 |
2014-12-10 |
Charleston Laboratories, Inc. |
Composiciones farmacéuticas
|
US20110294842A9
(en)
*
|
2006-10-12 |
2011-12-01 |
Xenon Pharmaceuticals Inc. |
Spiro (furo [3, 2-c] pyridine-3-3' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain
|
BRPI0719166A2
(pt)
*
|
2006-10-12 |
2014-06-03 |
Xenon Pharmaceuticals Inc |
Derivados de espiro-oxindol tricíclicos e seus usos como agentes terapêuticos
|
JP5460324B2
(ja)
*
|
2006-10-12 |
2014-04-02 |
ゼノン・ファーマシューティカルズ・インコーポレイテッド |
治療剤としてのスピロ−オキシインドール化合物の使用
|
EP1914234A1
(en)
*
|
2006-10-16 |
2008-04-23 |
GPC Biotech Inc. |
Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors
|
GB0620685D0
(en)
|
2006-10-18 |
2006-11-29 |
Controlled Therapeutics Sct |
Bioresorbable polymers
|
CA2666149A1
(en)
|
2006-10-19 |
2008-04-24 |
Auspex Pharmaceuticals, Inc. |
Substituted indoles
|
EP2617423A1
(en)
|
2006-10-19 |
2013-07-24 |
Genzyme Corporation |
Purine derivatives for the treatment of cystic diseases
|
US7347746B1
(en)
|
2006-10-27 |
2008-03-25 |
Boston Scientific Neuromodulation Corporation |
Receptacle connector assembly
|
US20100137421A1
(en)
*
|
2006-11-08 |
2010-06-03 |
Emmanuel Theodorakis |
Small molecule therapeutics, synthesis of analogues and derivatives and methods of use
|
US20080207641A1
(en)
|
2006-11-13 |
2008-08-28 |
Synta Pharmaceuticals Corp. |
Cyclohexenyl-aryl compounds for inflammation and immune-related uses
|
MX2009005478A
(es)
|
2006-11-27 |
2009-08-12 |
Lundbeck & Co As H |
Derivados de heteroarilamida.
|
CA2670788A1
(en)
|
2006-12-01 |
2008-06-12 |
Cv Therapeutics, Inc. |
A2a adenosine receptor antagonists
|
CA2668713C
(en)
|
2006-12-01 |
2015-09-08 |
Banyu Pharmaceutical Co., Ltd. |
Novel phenyl-isoxazol-3-ol derivative
|
US8969415B2
(en)
|
2006-12-01 |
2015-03-03 |
Allergan, Inc. |
Intraocular drug delivery systems
|
CN101573079A
(zh)
*
|
2006-12-06 |
2009-11-04 |
脊髓调制公司 |
硬组织锚固件和输送装置
|
US8983624B2
(en)
|
2006-12-06 |
2015-03-17 |
Spinal Modulation, Inc. |
Delivery devices, systems and methods for stimulating nerve tissue on multiple spinal levels
|
US9314618B2
(en)
|
2006-12-06 |
2016-04-19 |
Spinal Modulation, Inc. |
Implantable flexible circuit leads and methods of use
|
WO2008070808A2
(en)
*
|
2006-12-06 |
2008-06-12 |
Spinal Modulation, Inc. |
Expandable stimulation leads and methods of use
|
MX2009006080A
(es)
*
|
2006-12-08 |
2009-07-14 |
Xenoport Inc |
Uso de profarmacos de analogos de gaba para el tratamiento de enfermedades.
|
BRPI0720211A2
(pt)
|
2006-12-11 |
2013-12-24 |
Reviva Pharmaceuticals Inc |
Derivado de indanona, composição, e, uso de uma composição
|
PT2101777E
(pt)
|
2006-12-12 |
2015-09-18 |
Gilead Sciences Inc |
Composição para tratar uma hipertensão pulmonar
|
US20080147186A1
(en)
*
|
2006-12-14 |
2008-06-19 |
Joshi Ashok V |
Electrochemical Implant For Delivering Beneficial Agents
|
GB0624880D0
(en)
*
|
2006-12-14 |
2007-01-24 |
Johnson Matthey Plc |
Improved method for making analgesics
|
US7829592B2
(en)
*
|
2006-12-21 |
2010-11-09 |
Xenoport, Inc. |
Catechol protected levodopa diester prodrugs, compositions, and methods of use
|
US7709527B2
(en)
*
|
2006-12-21 |
2010-05-04 |
Xenoport, Inc. |
Levodopa dimethyl-substituted diester prodrugs compositions, and methods of use
|
MX2009006812A
(es)
*
|
2006-12-22 |
2009-07-02 |
Encysive Pharmaceuticals Inc |
Moduladores del receptor c3a y metodos de uso de los mismos.
|
US7932421B2
(en)
*
|
2006-12-26 |
2011-04-26 |
Amgen Inc. |
N-cyclohexyl benzamides and benzeneacetamides as inhibitors of 11-beta-hydroxysteroid dehydrogenases
|
US7638541B2
(en)
|
2006-12-28 |
2009-12-29 |
Metabolex Inc. |
5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
|
US20090011018A1
(en)
*
|
2006-12-28 |
2009-01-08 |
Astellas Pharma Inc., |
Sustained release formulation for tacrolimus
|
US20080267861A1
(en)
*
|
2007-01-03 |
2008-10-30 |
Cv Therapeutics, Inc. |
Myocardial Perfusion Imaging
|
WO2008089260A2
(en)
*
|
2007-01-16 |
2008-07-24 |
Victory Pharma, Inc. |
Combined administration of benzonatate and guaifenesin
|
NZ601683A
(en)
*
|
2007-01-16 |
2012-11-30 |
Shionogi & Co |
Heterocyclic-substituted piperidine compounds for modulating ORL-1 receptor function in a cell
|
CN101678203A
(zh)
*
|
2007-01-29 |
2010-03-24 |
脊髓调制公司 |
无缝合线引线保持构造
|
US7999107B2
(en)
|
2007-01-31 |
2011-08-16 |
Merck Sharp & Dohme Corp. |
Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators
|
MX2009008534A
(es)
|
2007-02-09 |
2009-11-23 |
Metabasis Therapeutics Inc |
Antagonistas novedosos del receptor de glucagon.
|
US8524749B2
(en)
*
|
2007-02-09 |
2013-09-03 |
Alza Corporation |
Controlled release compositions of tizanidine
|
EP2114863B1
(en)
|
2007-02-21 |
2016-10-05 |
Sepracor Inc. |
Solid forms comprising (-)-o-desmethylvenlafaxine and uses thereof
|
EP2144604B1
(en)
|
2007-02-28 |
2011-09-21 |
Conatus Pharmaceuticals, Inc. |
Methods for the treatment of chronic viral hepatitis C using RO 113-0830
|
AR065628A1
(es)
*
|
2007-03-07 |
2009-06-17 |
Xenon Pharmaceuticals Inc |
Compuestos triciclicos de utilidad en el tratamiento de trastornos por carencia de hierro en el organismo
|
PE20090167A1
(es)
*
|
2007-03-09 |
2009-02-11 |
Wyeth Corp |
Sintesis y caracterizacion de la forma iii polimorfica de 4-(2-(4,4-dimetil-2-oxooxazolidin-3-il)tiazol-4-il)benzonitrilo
|
CA2680414A1
(en)
*
|
2007-03-12 |
2008-09-18 |
Biolipox Ab |
Piperidinones useful in the treatment of inflammation
|
US20070172525A1
(en)
*
|
2007-03-15 |
2007-07-26 |
Ramesh Sesha |
Anti-diabetic combinations
|
WO2008140859A1
(en)
|
2007-03-15 |
2008-11-20 |
Auspex Pharmaceuticals, Inc. |
Deuterated venlafaxines and 0-desmetylvenlafaxines with serotoninergic and / or norepinephrinergic activity
|
US20080064701A1
(en)
*
|
2007-04-24 |
2008-03-13 |
Ramesh Sesha |
Anti-diabetic combinations
|
ES2393814T3
(es)
|
2007-04-04 |
2012-12-28 |
Sigmoid Pharma Limited |
Una composición farmacéutica oral
|
JP2010523653A
(ja)
*
|
2007-04-09 |
2010-07-15 |
ギリアード・パロ・アルト・インコーポレイテッド |
ステアロイルCoAデサチュラーゼのインヒビターとして使用するためのプテリジノン誘導体
|
US20090105283A1
(en)
*
|
2007-04-11 |
2009-04-23 |
Dmitry Koltun |
3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
|
US20080255161A1
(en)
*
|
2007-04-11 |
2008-10-16 |
Dmitry Koltun |
3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
|
WO2008132707A1
(en)
|
2007-04-26 |
2008-11-06 |
Sigmoid Pharma Limited |
Manufacture of multiple minicapsules
|
KR20090130422A
(ko)
*
|
2007-04-27 |
2009-12-23 |
퍼듀 퍼머 엘피 |
통증 치료에 유용한 치료제
|
PL2142529T3
(pl)
*
|
2007-04-27 |
2014-06-30 |
Purdue Pharma Lp |
Antagoniści trpv1 i ich zastosowania
|
US7892776B2
(en)
|
2007-05-04 |
2011-02-22 |
The Regents Of The University Of California |
Screening assay to identify modulators of protein kinase A
|
US8247420B2
(en)
*
|
2007-05-21 |
2012-08-21 |
Reviva Pharmaceuticals, Inc. |
Compositions, synthesis, and methods of using quinolinone based atypical antipsychotic agents
|
EP2019101A1
(en)
*
|
2007-07-26 |
2009-01-28 |
GPC Biotech AG |
Pyrazol[3,4-d]pyrimidin-4-one useful as Kinase Inhibitor
|
CN103936605B
(zh)
|
2007-05-31 |
2017-09-01 |
赛诺维信制药公司 |
苯基取代的环烷胺作为一元胺再摄取抑制剂
|
EP2166843A4
(en)
|
2007-06-01 |
2010-08-11 |
Univ Princeton |
TREATMENT OF VIRUS INFECTIONS BY MODULATION OF HOST CELL METABOLISMS
|
EP2068855A2
(en)
*
|
2007-06-05 |
2009-06-17 |
Xenon Pharmaceuticals Inc. |
Aromatic and heteroaromatic compounds useful in treating iron disorders
|
WO2009011988A2
(en)
*
|
2007-06-05 |
2009-01-22 |
Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University |
Cyclodepsipeptides with antineoplastic activity and methods of using to inhibit cancer and microbial growth
|
US7928111B2
(en)
*
|
2007-06-08 |
2011-04-19 |
Senomyx, Inc. |
Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
|
US20080306076A1
(en)
*
|
2007-06-08 |
2008-12-11 |
Senomyx, Inc. |
Modulation of chemosensory receptors and ligands associated therewith
|
US8633186B2
(en)
|
2007-06-08 |
2014-01-21 |
Senomyx Inc. |
Modulation of chemosensory receptors and ligands associated therewith
|
US7858666B2
(en)
|
2007-06-08 |
2010-12-28 |
Mannkind Corporation |
IRE-1α inhibitors
|
US9603848B2
(en)
*
|
2007-06-08 |
2017-03-28 |
Senomyx, Inc. |
Modulation of chemosensory receptors and ligands associated therewith
|
US20090012103A1
(en)
*
|
2007-07-05 |
2009-01-08 |
Matthew Abelman |
Substituted heterocyclic compounds
|
BRPI0814409A2
(pt)
*
|
2007-07-06 |
2014-10-14 |
Nuon Therapeutics Inc |
Tratamento de dor neuropática
|
BRPI0814542A2
(pt)
*
|
2007-07-12 |
2014-09-30 |
Tragara Pharmaceuticals Inc |
Métodos e composições para o tratamento de câncer, tumores e desordens relacionadas a tumores
|
WO2009012263A2
(en)
*
|
2007-07-18 |
2009-01-22 |
The Trustees Of Columbia University In The City Of New York |
Tissue-specific micrornas and compositions and uses thereof
|
KR20100033419A
(ko)
*
|
2007-07-19 |
2010-03-29 |
메타볼렉스, 인코포레이티드 |
당뇨병 및 대사 장애의 치료를 위한 rup3 또는 gpr119 수용체의 작용제로서 n-아자시클릭 치환된 피롤, 피라졸, 이미다졸, 트리아졸 및 테트라졸 유도체
|
JP5511664B2
(ja)
|
2007-08-01 |
2014-06-04 |
シンタ ファーマシューティカルズ コーポレーション |
炎症および免疫関連用途のための複素環−アリール化合物
|
TW200914440A
(en)
|
2007-08-01 |
2009-04-01 |
Synta Pharmaceuticals Corp |
Vinyl-aryl derivatives for inflammation and immune-related uses
|
US7893045B2
(en)
|
2007-08-07 |
2011-02-22 |
Celgene Corporation |
Methods for treating lymphomas in certain patient populations and screening patients for said therapy
|
DK2194783T3
(en)
|
2007-08-10 |
2017-10-02 |
Vm Discovery Inc |
COMPOSITIONS AND PROCEDURES FOR APOPTOS MODULATORS
|
CN106279283A
(zh)
|
2007-08-13 |
2017-01-04 |
症变治疗公司 |
新颖的葡糖激酶活化剂
|
WO2009027852A2
(en)
*
|
2007-08-28 |
2009-03-05 |
Agi Therapeutics, P.L.C. |
Methods and compositions for treating gastrointestinal conditions
|
KR20140139125A
(ko)
|
2007-08-31 |
2014-12-04 |
퍼듀 퍼머 엘피 |
치환-퀴녹살린-형 피페리딘 화합물 및 그의 용도
|
US20090082315A1
(en)
*
|
2007-09-05 |
2009-03-26 |
Raif Tawakol |
Compositions and Methods for Controlling Cholesterol Levels
|
AU2008299903B2
(en)
*
|
2007-09-11 |
2013-08-29 |
Kyorin Pharmaceutical Co., Ltd |
Cyanoaminoquinolones and tetrazoloaminoquinolones as GSK-3 inhibitors
|
US8476261B2
(en)
|
2007-09-12 |
2013-07-02 |
Kyorin Pharmaceutical Co., Ltd. |
Spirocyclic aminoquinolones as GSK-3 inhibitors
|
CZ300468B6
(cs)
*
|
2007-09-20 |
2009-05-27 |
Zentiva, A. S |
Léková forma obsahující tramadol s kontrolovaným uvolnováním po dobu 24 hodin a zpusob její prípravy
|
CN104211684A
(zh)
|
2007-09-26 |
2014-12-17 |
细胞基因公司 |
6-、7-或8-取代的喹唑啉酮衍生物、含有它的组合物及其使用方法
|
AR068540A1
(es)
*
|
2007-09-28 |
2009-11-18 |
Merck & Co Inc |
Metodos de produccion de un derivado de pirazol-3-il-benzamida.
|
US20090087484A1
(en)
*
|
2007-09-28 |
2009-04-02 |
Alza Corporation |
Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules
|
US20090264421A1
(en)
*
|
2007-10-05 |
2009-10-22 |
Bible Keith C |
Methods and Compositions for Treating Cancer
|
WO2009052184A2
(en)
*
|
2007-10-16 |
2009-04-23 |
Receptor Biologix, Inc. |
Compositions comprising optimized her1 and her3 multimers and methods of use thereof
|
US9550827B2
(en)
|
2007-10-19 |
2017-01-24 |
The Regents Of The University Of California |
Methods for ameliorating and preventing central nervous system inflammation
|
CA2705370C
(en)
|
2007-11-12 |
2015-10-13 |
Banyu Pharmaceutical Co., Ltd. |
Heteroaryloxy quinazoline derivatives
|
KR101607112B1
(ko)
|
2007-11-23 |
2016-03-29 |
그뤼넨탈 게엠베하 |
타펜타돌 조성물
|
AU2008347158B8
(en)
|
2007-12-06 |
2013-08-22 |
Durect Corporation |
Oral pharmaceutical dosage forms
|
US8623418B2
(en)
|
2007-12-17 |
2014-01-07 |
Alpharma Pharmaceuticals Llc |
Pharmaceutical composition
|
US20090162417A1
(en)
*
|
2007-12-21 |
2009-06-25 |
Cook Incorporated |
Drug eluting ocular conformer
|
AU2008341960A1
(en)
|
2007-12-25 |
2009-07-02 |
Banyu Pharmaceutical Co., Ltd. |
N-pyrazole-2-pyridinecarboxamide derivative
|
US8193182B2
(en)
|
2008-01-04 |
2012-06-05 |
Intellikine, Inc. |
Substituted isoquinolin-1(2H)-ones, and methods of use thereof
|
CA2905541C
(en)
|
2008-01-09 |
2020-02-11 |
Charleston Laboratories, Inc. |
Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
|
CN101983062A
(zh)
*
|
2008-02-07 |
2011-03-02 |
吉利德帕洛阿尔托股份有限公司 |
提高abca-1的化合物及其用途
|
JP2011511782A
(ja)
|
2008-02-12 |
2011-04-14 |
アボット・ラボラトリーズ |
長期放出性ヒドロコドンアセトアミノフェンならびにその関連方法および用途
|
US20090232796A1
(en)
*
|
2008-02-20 |
2009-09-17 |
Corral Laura G |
Method of treating cancer by administering an immunomodulatory compound in combination with a cd40 antibody or cd40 ligand
|
US20090214665A1
(en)
*
|
2008-02-26 |
2009-08-27 |
Lai Felix S |
Controlled Release Muscarinic Receptor Antagonist Formulation
|
WO2009111611A2
(en)
*
|
2008-03-05 |
2009-09-11 |
Proteotech Inc. |
Compounds, compositions and methods for the treatment of islet amyloid polypeptide (iapp) accumulation in diabetes
|
TWI395593B
(zh)
|
2008-03-06 |
2013-05-11 |
Halozyme Inc |
可活化的基質降解酵素之活體內暫時性控制
|
US8658163B2
(en)
|
2008-03-13 |
2014-02-25 |
Curemark Llc |
Compositions and use thereof for treating symptoms of preeclampsia
|
US8551524B2
(en)
*
|
2008-03-14 |
2013-10-08 |
Iycus, Llc |
Anti-diabetic combinations
|
SI2268623T1
(sl)
*
|
2008-03-17 |
2016-01-29 |
Ambit Biosciences Corporation |
Derivati kinazolina kot modulatorji raf-kinaze in postopki uporabe le-teh
|
US9249147B2
(en)
|
2008-03-19 |
2016-02-02 |
Chembridge Corporation |
Tyrosine kinase inhibitors
|
AU2009226153B2
(en)
|
2008-03-19 |
2014-02-20 |
Chembridge Corporation |
Novel tyrosine kinase inhibitors
|
EP2695616A1
(en)
|
2008-03-27 |
2014-02-12 |
Celgene Corporation |
Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
|
EP2687213B1
(en)
|
2008-03-27 |
2019-01-23 |
Celgene Corporation |
Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
|
MX2010010562A
(es)
*
|
2008-03-31 |
2010-12-07 |
Metabolex Inc |
Compuestos de oximetilen-arilo y uso de los mismos.
|
SG10201608068SA
(en)
|
2008-04-01 |
2016-11-29 |
Antipodean Pharmaceuticals Inc |
Compositions And Methods For Skin Care
|
US8088792B2
(en)
*
|
2008-04-04 |
2012-01-03 |
Gilead Sciences, Inc. |
Triazolopyridinone derivatives for use as stearoyl CoA desaturase inhibitors
|
CA2721229C
(en)
|
2008-04-14 |
2022-08-23 |
Halozyme, Inc. |
Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
|
US8084025B2
(en)
|
2008-04-18 |
2011-12-27 |
Curemark Llc |
Method for the treatment of the symptoms of drug and alcohol addiction
|
EP2112152A1
(en)
|
2008-04-22 |
2009-10-28 |
GPC Biotech AG |
Dihydropteridinones as Plk Inhibitors
|
EP2112150B1
(en)
|
2008-04-22 |
2013-10-16 |
Forma Therapeutics, Inc. |
Improved raf inhibitors
|
WO2009139880A1
(en)
*
|
2008-05-13 |
2009-11-19 |
Celgene Corporation |
Thioxoisoindoline compounds and compositions and methods of using the same
|
JP2011521915A
(ja)
*
|
2008-05-20 |
2011-07-28 |
セレニス セラピューティクス エス.エー. |
ナイアシン及びnsaid併用療法
|
US8207163B2
(en)
*
|
2008-05-27 |
2012-06-26 |
Reviva Pharmaceuticals, Inc. |
Compositions, synthesis, and methods of using piperazine based antipsychotic agents
|
JPWO2009147990A1
(ja)
|
2008-06-02 |
2011-10-27 |
Msd株式会社 |
新規イソオキサゾール誘導体
|
US8894602B2
(en)
|
2010-09-17 |
2014-11-25 |
Johnson & Johnson Vision Care, Inc. |
Punctal plugs with directional release
|
ES2732453T3
(es)
|
2008-07-01 |
2019-11-22 |
Curemark Llc |
Métodos y composiciones para el tratamiento de síntomas de trastornos neurológicos y de salud mental
|
RU2519947C2
(ru)
|
2008-07-02 |
2014-06-20 |
Айденикс Фармасьютикалз, Инк. |
Соединения и фармацевтические композиции для лечения вирусных инфекций
|
BRPI0911031B8
(pt)
|
2008-07-21 |
2021-05-25 |
Purdue Pharma Lp |
compostos de piperidina ligada do tipo quinoxalina substituídos e os usos destes
|
CA2724533C
(en)
*
|
2008-07-24 |
2014-07-29 |
Handa Pharmaceuticals, Llc |
Stabilized atypical antipsychotic formulation
|
EP2703404A1
(en)
|
2008-07-30 |
2014-03-05 |
Purdue Pharma L.P. |
Buprenorphine analogs
|
MY153622A
(en)
|
2008-07-31 |
2015-02-27 |
Senomyx Inc |
Processes and intermediates for making sweet taste enhancers
|
EP2328426B1
(en)
|
2008-07-31 |
2014-10-01 |
Senomyx, Inc. |
Compositions comrpising sweetness enhancers and methods of making them
|
PT2799428T
(pt)
|
2008-08-13 |
2017-02-17 |
Metabasis Therapeutics Inc |
Antagonistas de glicagina
|
WO2010027975A1
(en)
|
2008-09-04 |
2010-03-11 |
Anacor Pharmaceuticals, Inc. |
Boron-containing small molecules
|
US20100190752A1
(en)
|
2008-09-05 |
2010-07-29 |
Gruenenthal Gmbh |
Pharmaceutical Combination
|
EP2344145A1
(en)
*
|
2008-09-29 |
2011-07-20 |
Gilead Sciences, Inc. |
Combinations of a rate control agent and an a-2-alpha receptor antagonist for use in multidetector computed tomography methods
|
CA2739322A1
(en)
*
|
2008-10-01 |
2010-04-08 |
Synta Pharmaceuticals Corp. |
Compounds for inflammation and immune-related uses
|
WO2010039801A2
(en)
|
2008-10-02 |
2010-04-08 |
The J. David Gladstone Institutes |
Methods of treating hepatitis c virus infection
|
CN102216257B
(zh)
|
2008-10-08 |
2015-11-25 |
凯飞药业公司 |
Gaba偶联物及其使用方法
|
WO2010042834A1
(en)
|
2008-10-09 |
2010-04-15 |
Anadys Pharmaceuticals, Inc. |
A method of inhibiting hepatitis c virus by combination of a 5,6-dihydro-1h-pyridin-2-one and one or more additional antiviral compounds
|
DK2356109T3
(en)
|
2008-10-10 |
2017-03-13 |
Vm Discovery Inc |
COMPOSITIONS AND PROCEDURES FOR TREATING DISEASES IN CONNECTION WITH ALCOHOL CONSUMPTION, Pain and OTHER DISEASES
|
WO2010045374A1
(en)
*
|
2008-10-15 |
2010-04-22 |
Gilead Palo Alto, Inc. |
3-hydroquinazolin-4-one derivatives for use as stearoyl coa desaturase inhibitors
|
EP2350091B1
(en)
|
2008-10-17 |
2015-06-03 |
Xenon Pharmaceuticals Inc. |
Spiro-oxindole compounds and their use as therapeutic agents
|
DK2350090T3
(en)
*
|
2008-10-17 |
2015-09-07 |
Xenon Pharmaceuticals Inc |
Spiro-oxindole compounds and their use as therapeutic agents
|
US8399513B2
(en)
|
2008-10-20 |
2013-03-19 |
Xenoport, Inc. |
Levodopa prodrug mesylate hydrate
|
CA2740017A1
(en)
*
|
2008-10-20 |
2010-04-29 |
Xenoport, Inc. |
Methods of synthesizing a levodopa ester prodrug
|
NZ592603A
(en)
|
2008-10-21 |
2013-02-22 |
Metabolex Inc |
Aryl gpr120 receptor agonists and uses thereof
|
WO2010047982A1
(en)
|
2008-10-22 |
2010-04-29 |
Merck Sharp & Dohme Corp. |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
US8759362B2
(en)
*
|
2008-10-24 |
2014-06-24 |
Purdue Pharma L.P. |
Bicycloheteroaryl compounds and their use as TRPV1 ligands
|
US8546388B2
(en)
*
|
2008-10-24 |
2013-10-01 |
Purdue Pharma L.P. |
Heterocyclic TRPV1 receptor ligands
|
US8703962B2
(en)
*
|
2008-10-24 |
2014-04-22 |
Purdue Pharma L.P. |
Monocyclic compounds and their use as TRPV1 ligands
|
CA2740791C
(en)
|
2008-10-27 |
2017-08-01 |
Spinal Modulation, Inc. |
Selective stimulation systems and signal parameters for medical conditions
|
JP5603876B2
(ja)
|
2008-10-29 |
2014-10-08 |
セルジーン コーポレイション |
癌の治療に使用するためのイソインドリン化合物
|
WO2010074807A1
(en)
|
2008-10-30 |
2010-07-01 |
Gilead Palo Alto, Inc. |
3, 4-dihydroquinolin-2 ( 1h ) -one derivatives as sodium channel modulators
|
US8389500B2
(en)
|
2008-10-30 |
2013-03-05 |
Gilead Sciences, Inc. |
Fused heterocyclic compounds as ion channel modulators
|
NZ592437A
(en)
|
2008-10-30 |
2013-03-28 |
Gruenenthal Chemie |
A dosage form comprising tapentadol and an opioid antagonist
|
CA2741672A1
(en)
|
2008-10-31 |
2010-05-06 |
Merck Sharp & Dohme Corp. |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
US20100260844A1
(en)
|
2008-11-03 |
2010-10-14 |
Scicinski Jan J |
Oral pharmaceutical dosage forms
|
EP2352505B1
(en)
|
2008-11-04 |
2016-07-06 |
University Of Kentucky Research Foundation |
D-tagatose-based compositions and methods for preventing and treating atherosclerosis, metabolic syndrome, and symptoms thereof
|
US20110160222A1
(en)
*
|
2008-11-26 |
2011-06-30 |
Metabolex, Inc. |
Modulators of glucose homeostasis for the treatment of diabetes and metabolic disorders
|
BRPI0922224A2
(pt)
|
2008-12-08 |
2016-08-02 |
Vm Pharma Llc |
composições de inibidores de proteína tirosina quiinase receptora.
|
EA022752B1
(ru)
|
2008-12-09 |
2016-02-29 |
Галозим, Инк. |
Длинные растворимые полипептиды рн20 и их использование
|
AU2009330355B2
(en)
|
2008-12-16 |
2016-06-30 |
Sunovion Pharmaceuticals Inc. |
Triple reuptake inhibitors and methods of their use
|
EP2376633A1
(en)
|
2008-12-17 |
2011-10-19 |
AVI BioPharma, Inc. |
Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis
|
AR074760A1
(es)
*
|
2008-12-18 |
2011-02-09 |
Metabolex Inc |
Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
|
US9056857B2
(en)
|
2008-12-22 |
2015-06-16 |
Sloan-Kettering Institute For Cancer Research |
Methods for treating or preventing cancer and neurodegenerative diseases
|
US20110306605A1
(en)
|
2008-12-22 |
2011-12-15 |
Sloan-Kettering Institute For Cancer Research |
Coumarin-based compounds for the treatment of alzheimer's disease and cancer
|
US20110269788A1
(en)
|
2008-12-29 |
2011-11-03 |
Xenon Pharmaceuticals Inc. |
Spiro-oxindole-derivatives as sodium channel blockers
|
AU2009334790B2
(en)
|
2008-12-31 |
2016-09-08 |
Scynexis, Inc. |
Derivatives of cyclosporin A
|
GB2480772B
(en)
|
2009-01-06 |
2013-10-16 |
Curelon Llc |
Compositions and methods for the treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus
|
EP2373693A4
(en)
|
2009-01-06 |
2012-04-25 |
Curelon Llc |
COMPOSITIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF ORAL INFECTIONS BY E. COLI
|
WO2010088450A2
(en)
|
2009-01-30 |
2010-08-05 |
Celladon Corporation |
Methods for treating diseases associated with the modulation of serca
|
JP5674684B2
(ja)
|
2009-02-03 |
2015-02-25 |
マイクロビオン コーポレーション |
上皮組織、急性および慢性創傷、細菌性バイオフィルムならびに他の適応症のための消毒剤としてのビスマス−チオール
|
WO2010091268A1
(en)
|
2009-02-09 |
2010-08-12 |
Sepracor Inc. |
Pyrrolidine triple reuptake inhibitors
|
MY160002A
(en)
|
2009-02-10 |
2017-02-15 |
Celgene Corp |
Methods of using and compositions comprising pde4 modulators for treatment, prevention and management of tuberculosis
|
CA2752073A1
(en)
|
2009-02-11 |
2010-08-19 |
Sunovion Pharmaceuticals Inc. |
Histamine h3 inverse agonists and antagonists and methods of use thereof
|
EP2396312A1
(en)
|
2009-02-11 |
2011-12-21 |
Celgene Corporation |
Isotopologues of lenalidomide
|
US8568793B2
(en)
|
2009-02-11 |
2013-10-29 |
Hope Medical Enterprises, Inc. |
Sodium nitrite-containing pharmaceutical compositions
|
EP2396070A4
(en)
|
2009-02-12 |
2012-09-19 |
Incept Llc |
ACTIVE COMPOSITION WITH HYDROGEL PLUGS
|
AU2010216633A1
(en)
|
2009-02-23 |
2011-09-08 |
Msd K.K. |
Pyrimidin-4(3H)-one derivatives
|
CA2984935C
(en)
|
2009-02-24 |
2021-01-12 |
Ritter Pharmaceuticals, Inc. |
Prebiotic formulations and methods of use
|
CN102413830A
(zh)
|
2009-02-26 |
2012-04-11 |
雷维瓦药品公司 |
利用芳基哌嗪衍生物的组合物、合成及方法
|
EP3045043B1
(en)
|
2009-02-26 |
2020-04-29 |
Relmada Therapeutics, Inc. |
Extended release oral pharmaceutical compositions of 3-hydroxy-n-methylmorphinan and method of use
|
TWI476192B
(zh)
|
2009-02-27 |
2015-03-11 |
Ambit Biosciences Corp |
Jak激酶調節化合物及其使用方法
|
US8193372B2
(en)
|
2009-03-04 |
2012-06-05 |
Idenix Pharmaceuticals, Inc. |
Phosphothiophene and phosphothiazole HCV polymerase inhibitors
|
EP2403523A1
(en)
*
|
2009-03-06 |
2012-01-11 |
Halozyme, Inc. |
Temperature sensitive mutants of matrix metalloprotease 1 und uses thereof
|
EP2405915B1
(en)
|
2009-03-10 |
2018-10-24 |
Euro-Celtique S.A. |
Immediate release pharmaceutical compositions comprising oxycodone and naloxone
|
CN102421784B
(zh)
*
|
2009-03-11 |
2015-09-30 |
杏林制药株式会社 |
作为gsk-3抑制剂的7-环烷基氨基喹诺酮
|
WO2010105016A1
(en)
|
2009-03-11 |
2010-09-16 |
Ambit Biosciences Corp. |
Combination of an indazolylaminopyrrolotriazine and taxane for cancer treatment
|
US8362052B2
(en)
|
2009-03-11 |
2013-01-29 |
Msd K.K. |
Isoindolin-1-one derivative
|
EP2408449A4
(en)
|
2009-03-18 |
2012-08-08 |
Univ Leland Stanford Junior |
METHODS AND COMPOSITIONS FOR TREATING INFECTION WITH A FLAVIVIRIDAE FAMILY VIRUS
|
AU2010229985B2
(en)
|
2009-03-24 |
2015-09-17 |
Spinal Modulation, Inc. |
Pain management with stimulation subthreshold to paresthesia
|
CA2756067A1
(en)
|
2009-03-27 |
2010-09-30 |
Pathway Therapeutics, Inc. |
Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
|
WO2010110686A1
(en)
|
2009-03-27 |
2010-09-30 |
Pathway Therapeutics Limited |
Pyrimidinyl and 1,3,5 triazinyl benzimidazoles and their use in cancer therapy
|
US9056050B2
(en)
|
2009-04-13 |
2015-06-16 |
Curemark Llc |
Enzyme delivery systems and methods of preparation and use
|
AR076341A1
(es)
|
2009-04-20 |
2011-06-01 |
Elcelyx Therapeutics Inc |
Terapias basadas en ligados de receptores quimiosensoriales. metodo de tratamiento. composicion
|
US9901551B2
(en)
|
2009-04-20 |
2018-02-27 |
Ambra Bioscience Llc |
Chemosensory receptor ligand-based therapies
|
US8828953B2
(en)
*
|
2009-04-20 |
2014-09-09 |
NaZura BioHealth, Inc. |
Chemosensory receptor ligand-based therapies
|
HUE025647T2
(en)
|
2009-04-22 |
2016-04-28 |
Axikin Pharmaceuticals Inc |
Arylsulfonamide CCR3 antagonists
|
NZ595797A
(en)
|
2009-04-22 |
2014-03-28 |
Axikin Pharmaceuticals Inc |
2,5-disubstituted arylsulfonamide ccr3 antagonists
|
ES2664984T3
(es)
|
2009-04-22 |
2018-04-24 |
SMA Therapeutics, Inc. |
Arilsulfonamidas 2,5-disustituidas antagonistas de CCR3
|
US8809382B2
(en)
|
2009-05-04 |
2014-08-19 |
The Royal Institution For The Advancement Of Learning/Mcgill University |
5-oxo-ETE receptor antagonist compounds
|
JP2012526848A
(ja)
*
|
2009-05-14 |
2012-11-01 |
ギリアード サイエンシーズ, インコーポレイテッド |
Cns障害の治療のためのラノラジン
|
EP2429407B1
(en)
|
2009-05-15 |
2018-10-17 |
Spinal Modulation Inc. |
Systems and devices for neuromodulating spinal anatomy
|
DK2471518T3
(en)
|
2009-05-18 |
2017-12-04 |
Sigmoid Pharma Ltd |
COMPOSITION INCLUDING OIL DROPS
|
JP5645816B2
(ja)
|
2009-05-25 |
2014-12-24 |
国立大学法人東京工業大学 |
中枢神経細胞の増殖及び分化に係る中核因子を含む医薬組成物
|
CN102573811A
(zh)
|
2009-06-02 |
2012-07-11 |
陶氏环球技术有限责任公司 |
缓释剂型
|
RU2011153723A
(ru)
|
2009-06-10 |
2013-07-20 |
Суновион Фармасьютикалз Инк. |
Обратные агонисты и антагонисты н3 рецепторов гистамина и способы их применения
|
US9050276B2
(en)
|
2009-06-16 |
2015-06-09 |
The Trustees Of Columbia University In The City Of New York |
Autism-associated biomarkers and uses thereof
|
MX2011013080A
(es)
|
2009-06-16 |
2012-01-20 |
Pfizer |
Formas de dosis de apixaban.
|
AR077252A1
(es)
|
2009-06-29 |
2011-08-10 |
Xenon Pharmaceuticals Inc |
Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
|
WO2011003870A2
(en)
|
2009-07-06 |
2011-01-13 |
Creabilis S.A. |
Mini-pegylated corticosteroids, compositions including same, and methods of making and using same
|
WO2011005119A1
(en)
|
2009-07-07 |
2011-01-13 |
Pathway Therapeutics Limited |
Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
|
HUE035519T2
(en)
|
2009-07-08 |
2018-05-02 |
Hope Medical Entpr Inc D B A Hope Pharmaceuticals |
Sodium thiosulfate-containing pharmaceutical composition
|
WO2011006012A1
(en)
|
2009-07-08 |
2011-01-13 |
Charleston Laboratories Inc. |
Pharmaceutical compositions
|
TWI598347B
(zh)
|
2009-07-13 |
2017-09-11 |
基利科學股份有限公司 |
調節細胞凋亡信號之激酶的抑制劑
|
EP2467144A1
(en)
|
2009-07-24 |
2012-06-27 |
ViroLogik GmbH |
Combination of proteasome inhibitors and anti-hepatitis medication for treating hepatitis
|
RS56410B1
(sr)
|
2009-07-27 |
2018-01-31 |
Gilead Sciences Inc |
Fuzionisana heterociklična jedinjenja kao modulatori jonskih kanala
|
US8404728B2
(en)
|
2009-07-30 |
2013-03-26 |
Mayo Foundation For Medical Education And Research |
Small-molecule botulinum toxin inhibitors
|
US20130017188A1
(en)
|
2009-07-31 |
2013-01-17 |
The Brigham And Women's Hospital, Inc. |
Modulation of sgk1 expression in th17 cells to modulate th17-mediated immune responses
|
US9284307B2
(en)
|
2009-08-05 |
2016-03-15 |
Idenix Pharmaceuticals Llc |
Macrocyclic serine protease inhibitors
|
IN2012DN00781A
(US20080293856A1-20081127-C00127.png)
|
2009-08-12 |
2015-06-26 |
Sigmoid Pharma Ltd |
|
WO2011019752A2
(en)
|
2009-08-14 |
2011-02-17 |
Gilead Palo Alto, Inc. |
A1 adenosine receptor agonist polymorphs
|
MX2012001974A
(es)
|
2009-08-19 |
2012-04-11 |
Ambit Biosciences Corp |
Compuestos de biarilo y metodos de uso de los mismos.
|
WO2011028234A1
(en)
*
|
2009-09-04 |
2011-03-10 |
Xenoport, Inc. |
Uses of acyloxyalkyl carbamate prodrugs of tranexamic acid
|
MX2012002551A
(es)
|
2009-09-04 |
2012-09-07 |
United Paragon Associates Inc |
Compuestos para tratar desordenes o enfermedades asociados con la actividad del receptor de neuroquinina 2.
|
WO2011031816A2
(en)
|
2009-09-11 |
2011-03-17 |
Sepracor Inc. |
Histamine h3 inverse agonists and antagonists and methods of use thereof
|
JP5909185B2
(ja)
|
2009-10-01 |
2016-04-26 |
シマベイ セラピューティクス, インコーポレーテッド |
置換テトラゾール−1−イルフェノキシメチルチアゾール−2−イルピペリジニルピリミジン塩
|
WO2011042482A1
(en)
|
2009-10-06 |
2011-04-14 |
Green Molecular |
Polyphenols for use in the treatment of cancer
|
US8282970B2
(en)
*
|
2009-10-07 |
2012-10-09 |
Jiahgsu Dehe Bio-Tech Co., Ltd |
Theaflavin compositions, related processes and methods of use
|
US20110082198A1
(en)
*
|
2009-10-07 |
2011-04-07 |
Jiangsu Dehe Bio-Tech Co., Ltd. |
Theaflavin compositions, production, and methods to control physiological disorders in mammals
|
WO2011047173A2
(en)
*
|
2009-10-14 |
2011-04-21 |
Xenon Pharmaceuticals Inc. |
Pharmaceutical compositions for oral administration
|
WO2011047174A1
(en)
|
2009-10-14 |
2011-04-21 |
Xenon Pharmaceuticals Inc. |
Synthetic methods for spiro-oxindole compounds
|
KR20120093970A
(ko)
|
2009-10-19 |
2012-08-23 |
신타 파마슈티칼스 코프. |
에이취에스피90 억제 화합물을 이용한 조합 항암 요법
|
TW201120037A
(en)
|
2009-10-26 |
2011-06-16 |
Sunesis Pharmaceuticals Inc |
Compounds and methods for treatment of cancer
|
EP2325185A1
(en)
|
2009-10-28 |
2011-05-25 |
GPC Biotech AG |
Plk inhibitor
|
WO2011056985A2
(en)
|
2009-11-04 |
2011-05-12 |
Gilead Sciences, Inc. |
Substituted heterocyclic compounds
|
WO2011056764A1
(en)
|
2009-11-05 |
2011-05-12 |
Ambit Biosciences Corp. |
Isotopically enriched or fluorinated imidazo[2,1-b][1,3]benzothiazoles
|
US20120322882A1
(en)
|
2009-11-09 |
2012-12-20 |
Allergan, Inc. |
Compositions And Methods For Stimulating Hair Growth
|
WO2011056240A2
(en)
|
2009-11-09 |
2011-05-12 |
Xenoport, Inc. |
Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use
|
US20110117055A1
(en)
|
2009-11-19 |
2011-05-19 |
Macdonald James E |
Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds
|
WO2011063102A1
(en)
|
2009-11-19 |
2011-05-26 |
Celgene Corporation |
Apremilast for the treatment of sarcoidosis
|
WO2011064769A1
(en)
|
2009-11-24 |
2011-06-03 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Methods and pharmaceutical compositions for the treatment of hot flashes
|
WO2011069002A1
(en)
|
2009-12-02 |
2011-06-09 |
Alquest Therapeutics, Inc. |
Organoselenium compounds and uses thereof
|
MX367327B
(es)
|
2009-12-04 |
2019-08-15 |
Sunovion Pharmaceuticals Inc |
Formulaciones, sales y polimorfos de transnorsertralina y usos de los mismos.
|
BR122021013836B1
(pt)
|
2009-12-04 |
2022-05-24 |
Sunovion Pharmaceuticals, Inc. |
Composto e seu uso, composição farmacêutica
|
EP2509615A1
(en)
|
2009-12-09 |
2012-10-17 |
Scynexis, Inc. |
Novel cyclic peptides
|
US10668060B2
(en)
|
2009-12-10 |
2020-06-02 |
Collegium Pharmaceutical, Inc. |
Tamper-resistant pharmaceutical compositions of opioids and other drugs
|
MX2012006877A
(es)
|
2009-12-18 |
2012-08-31 |
Idenix Pharmaceuticals Inc |
Inhibidores de virus de hepatitis c de arileno o heteroarileno 5, 5 - fusionado.
|
TWI508726B
(zh)
|
2009-12-21 |
2015-11-21 |
Gilead Sciences Inc |
治療心房纖維性顫動之方法
|
WO2011079091A1
(en)
|
2009-12-22 |
2011-06-30 |
Celgene Corporation |
(methylsulfonyl) ethyl benzene isoindoline derivatives and their therapeutical uses
|
EP2515654A4
(en)
*
|
2009-12-23 |
2013-04-24 |
Map Pharmaceuticals Inc |
NEW ERGOLINANALOGA
|
AU2010339460A1
(en)
|
2009-12-30 |
2012-07-19 |
Scynexis Inc. |
Cyclosporine analogues
|
USRE49251E1
(en)
|
2010-01-04 |
2022-10-18 |
Mapi Pharma Ltd. |
Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
|
CN107661490B
(zh)
|
2010-01-04 |
2021-12-31 |
Mapi医药公司 |
包含格拉默或其药用盐的储药系统
|
WO2011084968A1
(en)
|
2010-01-05 |
2011-07-14 |
Celgene Corporation |
A combination of an immunomodulatory compound and an artemisinin or a derivative thereof for treating cancer
|
WO2011089166A1
(en)
|
2010-01-19 |
2011-07-28 |
Virologik Gmbh |
Semicarbazone proteasome inhibitors for treating hiv and hepatitis infection
|
WO2011091164A1
(en)
*
|
2010-01-22 |
2011-07-28 |
Xenoport, Inc. |
Oral dosage forms having a high loading of a tranexamic acid prodrug
|
WO2011094890A1
(en)
|
2010-02-02 |
2011-08-11 |
Argusina Inc. |
Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
|
EA027622B1
(ru)
|
2010-02-05 |
2017-08-31 |
ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НоваМедика" |
Твердофазные формы макроциклических ингибиторов киназы
|
US8471041B2
(en)
*
|
2010-02-09 |
2013-06-25 |
Alliant Techsystems Inc. |
Methods of synthesizing and isolating N-(bromoacetyl)-3,3-dinitroazetidine and a composition including the same
|
ES2730763T3
(es)
|
2010-02-11 |
2019-11-12 |
Celgene Corp |
Derivados de arilmetoxi isoindolina y composiciones que los comprenden y métodos de uso de los mismos
|
AU2011218830B2
(en)
|
2010-02-25 |
2014-07-24 |
Merck Sharp & Dohme Corp. |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
US9504671B2
(en)
|
2010-02-26 |
2016-11-29 |
Xenon Pharmaceuticals Inc. |
Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
|
EP2542542B1
(en)
|
2010-03-02 |
2015-04-22 |
Axikin Pharmaceuticals, Inc. |
Isotopically enriched arylsulfonamide ccr3 antagonists
|
NZ602362A
(en)
|
2010-03-11 |
2014-11-28 |
Gilead Connecticut Inc |
Imidazopyridines syk inhibitors
|
WO2011112689A2
(en)
|
2010-03-11 |
2011-09-15 |
Ambit Biosciences Corp. |
Saltz of an indazolylpyrrolotriazine
|
MX2012010367A
(es)
*
|
2010-03-12 |
2012-11-23 |
Celgene Corp |
Metodos para el tratamiento de linfomas no hodgkin que usan lenalidomida y biomarcadores de genes y proteinas como un predictor.
|
MX336559B
(es)
|
2010-03-17 |
2016-01-25 |
Axikin Pharmaceuticals Inc |
Antagonistas de ccr3 de arilsulfonamida.
|
WO2011122524A1
(ja)
|
2010-03-29 |
2011-10-06 |
アステラス製薬株式会社 |
放出制御医薬組成物
|
CN103079558A
(zh)
|
2010-04-05 |
2013-05-01 |
满康德股份有限公司 |
IRE-1α抑制剂
|
MX341050B
(es)
|
2010-04-07 |
2016-08-05 |
Celgene Corp * |
Metodos para tratar infeccion viral respiratoria.
|
US8969327B2
(en)
|
2010-04-08 |
2015-03-03 |
Emory University |
Substituted androst-4-ene diones
|
WO2011133521A2
(en)
|
2010-04-19 |
2011-10-27 |
Synta Pharmaceuticals Corp. |
Cancer therapy using a combination of a hsp90 inhibitory compounds and a vegf inhibitor
|
WO2011133520A1
(en)
|
2010-04-19 |
2011-10-27 |
Synta Pharmaceuticals Corp. |
Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor
|
EP3202406A1
(en)
|
2010-04-28 |
2017-08-09 |
Ritter Pharmaceuticals, Inc. |
Prebiotic formulations and methods of use
|
WO2011140360A1
(en)
|
2010-05-05 |
2011-11-10 |
The Trustees Of Columbia University In The City Of New York |
Radiolabeled compounds and uses thereof
|
CN103079489B
(zh)
|
2010-05-10 |
2016-11-16 |
脊髓调制公司 |
用于减少迁移的方法、系统和装置
|
AU2011255438A1
(en)
|
2010-05-20 |
2013-01-10 |
Synta Pharmaceuticals Corp. |
Method of treating lung adenocarcinoma with Hsp90 inhibitory compounds
|
EP2575810A1
(en)
|
2010-05-24 |
2013-04-10 |
Synta Pharmaceuticals Corp. |
Cancer therapy using a combination of a hsp90 inhibitory compound and a topoisomerase ii inhibitor
|
EP2576540B1
(en)
|
2010-05-26 |
2019-09-04 |
Sunovion Pharmaceuticals Inc. |
Heteroaryl compounds and methods of use thereof
|
WO2011150201A2
(en)
|
2010-05-27 |
2011-12-01 |
Ambit Biosciences Corporation |
Azolyl amide compounds and methods of use thereof
|
WO2011150198A1
(en)
|
2010-05-27 |
2011-12-01 |
Ambit Biosciences Corporation |
Azolyl urea compounds and methods of use thereof
|
CN102918031A
(zh)
|
2010-05-28 |
2013-02-06 |
通用电气健康护理有限公司 |
放射标记的化合物及其方法
|
US20130178503A1
(en)
|
2010-06-01 |
2013-07-11 |
Biotheryx Inc. |
Methods of treating hematologic malignancies using 6-cyclohexyl-1-hydroxy-4-methyl-2(1h)-pyridone
|
EP2576513A1
(en)
|
2010-06-01 |
2013-04-10 |
Biotheryx Inc. |
Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating proliferative diseases
|
US8722731B2
(en)
|
2010-06-07 |
2014-05-13 |
Novomedix, Llc |
Furanyl compounds and the use thereof
|
US8299117B2
(en)
|
2010-06-16 |
2012-10-30 |
Metabolex Inc. |
GPR120 receptor agonists and uses thereof
|
CA2801182A1
(en)
|
2010-06-16 |
2011-12-22 |
Metabolex, Inc. |
Gpr120 receptor agonists and uses thereof
|
TW201215392A
(en)
|
2010-06-16 |
2012-04-16 |
Gilead Sciences Inc |
Use of ranolazine for treating pulmonary hypertension
|
CA2802541A1
(en)
|
2010-06-23 |
2011-12-29 |
Metabolex, Inc. |
Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
|
EA201291274A1
(ru)
|
2010-06-30 |
2013-12-30 |
Джилид Сайэнс, Инк. |
Применение антагонистов аденозиновых рецепторов aдля лечения легочной гипертензии
|
PT2588475E
(pt)
|
2010-07-02 |
2015-09-08 |
Gilead Sciences Inc |
Inibidores de cinase reguladora dos sinais da apoptose
|
BR112012033402A2
(pt)
|
2010-07-02 |
2017-01-24 |
Gilead Sciences Inc |
moduladores de canais de íons conforme os compostos heterocíclicos fundidos
|
WO2012003968A1
(en)
|
2010-07-06 |
2012-01-12 |
Grünenthal GmbH |
Novel gastro- retentive dosage forms comprising a gaba analog and an opioid
|
WO2012007159A2
(en)
|
2010-07-14 |
2012-01-19 |
Grünenthal GmbH |
Novel gastro-retentive dosage forms
|
NZ605860A
(en)
|
2010-07-19 |
2015-04-24 |
Summa Health System |
Use of vitamin c, and chromium-free vitamin k or 2-methyl-1,4-naphthalendione, and compositions thereof for treating a polycystic disease
|
WO2012019093A1
(en)
|
2010-08-05 |
2012-02-09 |
Human Biomolecular Research Institute |
Synthetic compounds and methods to decrease nicotine self-administration
|
CN106107406B
(zh)
|
2010-08-12 |
2020-06-09 |
弗门尼舍公司 |
提高甜味增强剂的稳定性的方法和包含稳定的甜味增强剂的组合物
|
ES2591355T3
(es)
|
2010-08-24 |
2016-11-28 |
Algiax Pharmaceuticals Gmbh |
Uso novedoso de leflunomida y malononitrilamidas
|
EP2611369A2
(en)
|
2010-08-30 |
2013-07-10 |
Sinusys Corporation |
Devices for dilating a paranasal sinus opening and for treating sinusitis
|
EP2611793A1
(en)
|
2010-09-01 |
2013-07-10 |
Ambit Biosciences Corporation |
2-cycloquinazoline derivatives and methods of use thereof
|
EP2663553B1
(en)
|
2010-09-01 |
2015-08-26 |
Ambit Biosciences Corporation |
Quinoline and isoquinoline derivatives for use as jak modulators
|
US20130225614A1
(en)
|
2010-09-01 |
2013-08-29 |
Ambit Biosciences Corporation |
4-azolylaminoquinazoline derivatives and methods of use thereof
|
EP2611809A1
(en)
|
2010-09-01 |
2013-07-10 |
Ambit Biosciences Corporation |
Azolopyridine and azolopyrimidine compounds and methods of use thereof
|
JP5933554B2
(ja)
|
2010-09-01 |
2016-06-15 |
アムビト ビオスシエンセス コルポラチオン |
光学活性のあるピラゾリルアミノキナゾリン及びその医薬組成物及び使用方法
|
CN103298805A
(zh)
|
2010-09-01 |
2013-09-11 |
埃姆比特生物科学公司 |
喹唑啉化合物及其使用方法
|
EP2611448A1
(en)
|
2010-09-01 |
2013-07-10 |
Ambit Biosciences Corporation |
7-cyclylquinazoline derivatives and methods of use thereof
|
US20120053176A1
(en)
|
2010-09-01 |
2012-03-01 |
Ambit Biosciences Corp. |
Adenosine a3 receptor modulating compounds and methods of use thereof
|
AU2011296046B2
(en)
|
2010-09-01 |
2015-05-14 |
Ambit Biosciences Corporation |
Hydrobromide salts of a pyrazolylaminoquinazoline
|
US20130317045A1
(en)
|
2010-09-01 |
2013-11-28 |
Ambit Biosciences Corporation |
Thienopyridine and thienopyrimidine compounds and methods of use thereof
|
US8821457B2
(en)
|
2010-09-08 |
2014-09-02 |
Johnson & Johnson Vision Care, Inc. |
Punctal plug containing drug formulation
|
CN103269701A
(zh)
|
2010-09-13 |
2013-08-28 |
辛塔医药品有限公司 |
用于治疗野生型egfr和/或kras患者的非小细胞肺癌的hsp90抑制剂
|
WO2012037155A2
(en)
|
2010-09-13 |
2012-03-22 |
Gtx, Inc. |
Tyrosine kinase inhibitors
|
CN107050456B
(zh)
|
2010-09-28 |
2022-08-12 |
加利福尼亚大学董事会 |
治疗代谢综合征相关疾病的gaba激动剂和治疗或预防i型糖尿病的gaba组合
|
EP2621487B1
(en)
|
2010-09-28 |
2017-05-03 |
Depomed, Inc. |
Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract
|
WO2012044641A1
(en)
|
2010-09-29 |
2012-04-05 |
Pathway Therapeutics Inc. |
1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
|
JP2013543512A
(ja)
|
2010-10-11 |
2013-12-05 |
アクシキン ファーマシューティカルズ インコーポレーテッド |
アリールスルホンアミドccr3アンタゴニストの塩
|
SI2637664T1
(sl)
|
2010-10-15 |
2017-07-31 |
Gilead Sciences, Inc. |
Sestavki in postopki zdravljenja pljučne hipertenzije
|
WO2012051567A2
(en)
|
2010-10-15 |
2012-04-19 |
The Trustees Of Columbia University In The City Of New York |
Obesity-related genes and their proteins and uses thereof
|
AU2011317152C1
(en)
|
2010-10-18 |
2016-02-25 |
Cerenis Therapeutics Holding Sa |
Compounds, compositions and methods useful for cholesterol mobilisation
|
AU2011317140A1
(en)
|
2010-10-19 |
2013-05-30 |
Elcelyx Therapeutics, Inc. |
Chemosensory receptor ligand-based therapies
|
LT2632451T
(lt)
|
2010-10-29 |
2018-02-12 |
Algiax Pharmaceuticals Gmbh |
Malononitrilamidų panaudojimas esant neuropatiniam skausmui
|
EP2638032A1
(en)
|
2010-11-09 |
2013-09-18 |
Synta Pharmaceuticals Corp. |
Tetrazolyl - tetrahydropyridine compounds for inflammation and immune - related uses
|
JP2013545749A
(ja)
|
2010-11-10 |
2013-12-26 |
インフィニティー ファーマシューティカルズ, インコーポレイテッド |
複素環化合物及びその使用
|
CA2817250A1
(en)
|
2010-11-18 |
2012-05-24 |
The General Hospital Corporation |
Novel compositions and uses of anti-hypertension agents for cancer therapy
|
GB201020032D0
(en)
|
2010-11-25 |
2011-01-12 |
Sigmoid Pharma Ltd |
Composition
|
BR112013014021A8
(pt)
|
2010-12-06 |
2017-10-03 |
Follica Inc |
Métodos para tratamento de calvície e promoção de crescimento de cabelos
|
US20140031325A1
(en)
|
2010-12-06 |
2014-01-30 |
Celgene Corporation |
Combination therapy with lenalidomide and a cdk inhibitor for treating multiple myeloma
|
EP2648708A2
(en)
|
2010-12-08 |
2013-10-16 |
Synta Pharmaceuticals Corp. |
Combination for breast cancer therapy with hsp90 inhibitory compounds
|
WO2012080050A1
(en)
|
2010-12-14 |
2012-06-21 |
F. Hoffmann-La Roche Ag |
Solid forms of a phenoxybenzenesulfonyl compound
|
US20120157938A1
(en)
|
2010-12-16 |
2012-06-21 |
Tokarski Jason M |
Punctal plug with drug core retention features
|
WO2012083017A2
(en)
|
2010-12-16 |
2012-06-21 |
Celgene Corporation |
Controlled release oral dosage forms of poorly soluble drugs and uses thereof
|
US9532977B2
(en)
|
2010-12-16 |
2017-01-03 |
Celgene Corporation |
Controlled release oral dosage forms of poorly soluble drugs and uses thereof
|
MY166034A
(en)
|
2010-12-22 |
2018-05-21 |
Purdue Pharma Lp |
Encased tamper resistant controlled release dosage forms
|
EP2654751B1
(en)
|
2010-12-22 |
2016-11-23 |
Purdue Pharma L.P. |
Phosphorus-substituted quinoxaline-type piperidine compounds and uses thereof
|
JP5638151B2
(ja)
|
2010-12-23 |
2014-12-10 |
パーデュー、ファーマ、リミテッド、パートナーシップ |
不正加工抵抗性の(tamperresistant)固形経口剤形
|
ES2834986T3
(es)
|
2011-01-07 |
2021-06-21 |
Anji Pharma Us Llc |
Terapias basadas en ligandos de receptores quimiosensoriales
|
MX347928B
(es)
|
2011-01-10 |
2017-05-19 |
Celgene Corp |
Derivados de fenetilsulfona isoindolina y su uso.
|
CA2824197C
(en)
|
2011-01-10 |
2020-02-25 |
Michael Martin |
Processes for preparing isoquinolinones and solid forms of isoquinolinones
|
ES2632979T3
(es)
|
2011-01-10 |
2017-09-18 |
Celgene Corporation |
Formas de dosificación oral de {2-[(1S)-1-(3-etoxi-4-metoxi-fenil)-2-metanosulfonil-etil]-3-oxo-2,3-dihidro-1H-isoindol-4-il}-amida de ácido ciclopropanocarboxílico
|
ES2627788T3
(es)
|
2011-01-11 |
2017-07-31 |
Sunovion Pharmaceuticals Inc. |
Compuestos heteroarilo y procedimientos de uso de los mismos
|
EP2663305A1
(en)
|
2011-01-11 |
2013-11-20 |
Synta Pharmaceuticals Corp. |
Combination therapy of hsp90 inhibitory compounds with proteasome inhibitors
|
US9045417B2
(en)
|
2011-01-14 |
2015-06-02 |
Celgene Corporation |
Isotopologues of isoindole derivatives
|
PL2665477T3
(pl)
|
2011-01-20 |
2016-05-31 |
Bionevia Pharmaceuticals Inc |
Kompozycje epalrestatu lub jego pochodnej o zmodyfikowanym uwalnianiu i sposoby ich stosowania
|
CN103338753A
(zh)
|
2011-01-31 |
2013-10-02 |
细胞基因公司 |
胞苷类似物的药物组合物及其使用方法
|
US9428565B2
(en)
|
2011-01-31 |
2016-08-30 |
The General Hospital Corporation |
Treatment and bioluminescent visualization using multimodal TRAIL molecules
|
WO2012106548A2
(en)
|
2011-02-02 |
2012-08-09 |
Spinal Modulation, Inc. |
Devices, systems and methods for the targeted treatment of movement disorders
|
AR085352A1
(es)
|
2011-02-10 |
2013-09-25 |
Idenix Pharmaceuticals Inc |
Inhibidores macrociclicos de serina proteasa, sus composiciones farmaceuticas y su uso para tratar infecciones por hcv
|
WO2012116061A1
(en)
|
2011-02-23 |
2012-08-30 |
Synta Pharmaceuticals Corp. |
Combination therapy of hsp90 inhibitory compounds with radiotherapy
|
JP2014507443A
(ja)
|
2011-02-24 |
2014-03-27 |
シンタ ファーマシューティカルズ コーポレーション |
Hsp90阻害化合物での前立腺癌治療
|
EP3243385B1
(en)
|
2011-02-25 |
2021-01-13 |
Merck Sharp & Dohme Corp. |
Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
|
WO2012116247A1
(en)
|
2011-02-25 |
2012-08-30 |
Synta Pharmaceuticals Corp. |
Hsp90 inhibitory compounds in treating jak/stat signaling-mediated cancers
|
US9795792B2
(en)
|
2011-02-25 |
2017-10-24 |
Medtronic, Inc. |
Emergency mode switching for non-pacing modes
|
US9387195B2
(en)
|
2011-03-07 |
2016-07-12 |
Celgene Corporation |
Methods for treating diseases using isoindoline compounds
|
BR112013023280A2
(pt)
|
2011-03-11 |
2017-09-19 |
Celgene Corp |
uso de 3-(5-amino-2-metil-4-oxoquinazolina-3(4h)-il)-piperidina-2,6-diona em tratamento de doenças inflamatórias e relacionadas ao sistema imune
|
DK2683708T3
(da)
|
2011-03-11 |
2018-01-29 |
Celgene Corp |
Faste former af 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidin-2,6-dion og farmaceutiske sammensætninger og anvendelser deraf
|
WO2012123353A1
(en)
|
2011-03-17 |
2012-09-20 |
Algiax Pharmaceuticals Gmbh |
Novel use of benzofuranylsulfonates
|
US20140038967A1
(en)
|
2011-03-17 |
2014-02-06 |
Algiax Pharmaceuticals Gmbh |
Novel use for imidazotriazinones
|
CA2830069C
(en)
|
2011-03-20 |
2019-11-12 |
The University Of British Columbia |
Therapeutic agent for emphysema and copd
|
EP2691388A1
(en)
|
2011-03-28 |
2014-02-05 |
MEI Pharma, Inc. |
(fused ring arylamino and heterocyclylamino) pyrimidynyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
|
US9056852B2
(en)
|
2011-03-28 |
2015-06-16 |
Mei Pharma, Inc. |
(Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
|
WO2012135175A1
(en)
|
2011-03-28 |
2012-10-04 |
Pathway Therapeutics Inc. |
(alpha-substituted cycloalkylamino and heterocyclylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
|
AU2012236655B2
(en)
|
2011-03-28 |
2016-09-22 |
Deuterx, Llc, |
2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds
|
CA2843324A1
(en)
|
2011-03-31 |
2012-11-15 |
Idenix Pharmaceuticals, Inc. |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
US20120252721A1
(en)
|
2011-03-31 |
2012-10-04 |
Idenix Pharmaceuticals, Inc. |
Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
|
WO2012158271A1
(en)
|
2011-04-06 |
2012-11-22 |
Anadys Pharmaceuticals, Inc. |
Bridged polycyclic compounds as antiviral agents
|
AR085942A1
(es)
|
2011-04-07 |
2013-11-06 |
Gilead Sciences Inc |
Uso de receptor de aadenosina para tratar la insuficiencia cardiaca y la arritmia en pacientes posinfarto de miocardio
|
WO2012145651A2
(en)
|
2011-04-21 |
2012-10-26 |
Curemark, Llc |
Compounds for the treatment of neuropsychiatric disorders
|
ES2601892T3
(es)
|
2011-04-21 |
2017-02-16 |
Mapi Pharma Limited |
Pentapolímero aleatorio para el tratamiento de enfermedades autoinmunes
|
US9272035B2
(en)
|
2011-04-28 |
2016-03-01 |
Celgene Corporation |
Methods and compositions using PDE4 inhibitors for the treatment and management of autoimmune and inflammatory diseases
|
JP6016892B2
(ja)
|
2011-04-29 |
2016-10-26 |
セルジーン コーポレイション |
セレブロンを予測因子として使用する癌及び炎症性疾患の治療方法
|
CA2834928C
(en)
|
2011-05-03 |
2017-10-17 |
Synta Pharmaceuticals Corp. |
Compounds for inflammation and immune-related uses
|
EP2704726B1
(en)
|
2011-05-04 |
2018-10-31 |
Trustees of Boston University |
Proton-motive force stimulation to potentiate aminoglycoside antibiotics against persistent bacteria
|
US9301874B2
(en)
|
2011-05-06 |
2016-04-05 |
Johnson & Johnson Vision Care, Inc. |
Punctal plugs for controlled release of therapeutic agents
|
JP5934787B2
(ja)
|
2011-05-10 |
2016-06-15 |
ギリアード サイエンシーズ, インコーポレイテッド |
イオンチャネルモジュレーターとしての縮合複素環式化合物
|
EP2714038A1
(en)
|
2011-05-24 |
2014-04-09 |
Synta Pharmaceuticals Corp. |
Combination therapy of hsp90 inhibitory compounds with mtor/pi3k inhibitors
|
SG195288A1
(en)
|
2011-06-07 |
2013-12-30 |
Anadys Pharmaceuticals Inc |
[1,2,4]thiadiazine 1,1-dioxide compounds for lowering serum uric acid
|
RU2011122942A
(ru)
|
2011-06-08 |
2012-12-20 |
Общество С Ограниченной Ответственностью "Асинэкс Медхим" |
Новые ингибиторы киназ
|
MY185061A
(en)
|
2011-06-22 |
2021-04-30 |
Shionogi & Co |
Trpv1 antagonists including dihydroxy substituent and uses thereof
|
US20140221427A1
(en)
|
2011-06-22 |
2014-08-07 |
Celgene Corporation |
Isotopologues of pomalidomide
|
MX2013015373A
(es)
|
2011-06-23 |
2014-02-11 |
Map Pharmaceuticals Inc |
Nuevos analogos de fluoroergolina.
|
WO2012175698A1
(en)
|
2011-06-23 |
2012-12-27 |
Université Libre de Bruxelles |
Therapeutic use of all-trans retinoic acid (atra) in patients suffering from alcoholic liver disease
|
WO2013003697A1
(en)
|
2011-06-30 |
2013-01-03 |
Trustees Of Boston University |
Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
|
NO3175985T3
(US20080293856A1-20081127-C00127.png)
|
2011-07-01 |
2018-04-28 |
|
|
TW201837023A
(zh)
|
2011-07-01 |
2018-10-16 |
美商基利科學股份有限公司 |
作為離子通道調節劑之稠合雜環化合物
|
TWI567061B
(zh)
|
2011-07-01 |
2017-01-21 |
吉李德科學股份有限公司 |
用於治療成癮之化合物
|
CA2840986A1
(en)
|
2011-07-07 |
2013-01-10 |
Synta Pharmaceuticals Corp. |
Treating cancer with hsp90 inhibitory compounds
|
DE102011051653A1
(de)
*
|
2011-07-07 |
2013-01-10 |
Lts Lohmann Therapie-Systeme Ag |
Quellfähige Manteltablette
|
US10702485B2
(en)
|
2011-07-09 |
2020-07-07 |
Syntrix Biosystems Inc. |
Compositions and methods for overcoming resistance to tramadol
|
CA2842190A1
(en)
|
2011-07-19 |
2013-01-24 |
Infinity Pharmaceuticals Inc. |
Heterocyclic compounds and uses thereof
|
CN103930422A
(zh)
|
2011-07-19 |
2014-07-16 |
无限药品股份有限公司 |
杂环化合物及其用途
|
GB201112987D0
(en)
|
2011-07-28 |
2011-09-14 |
Ge Healthcare Ltd |
Novel compound
|
US9394293B2
(en)
|
2011-08-10 |
2016-07-19 |
Purdue Pharma L.P. |
TRPV1 antagonists including dihydroxy substituent and uses thereof
|
WO2013022872A1
(en)
|
2011-08-10 |
2013-02-14 |
Celgene Corporation |
Gene methylation biomarkers and methods of use thereof
|
WO2013024040A2
(en)
|
2011-08-12 |
2013-02-21 |
B.S.R.C. Alexander Fleming |
Tnf superfamily trimerization inhibitors
|
WO2013028505A1
(en)
|
2011-08-19 |
2013-02-28 |
Synta Pharmaceuticals Corp. |
Combination cancer therapy of hsp90 inhibitor with antimetabolite
|
EP2959899B1
(en)
|
2011-08-23 |
2017-02-22 |
Cornerstone Therapeutics Inc. |
Use of zileuton for the treatment of nasal polyps in cystic fibrosis patients
|
US8664247B2
(en)
|
2011-08-26 |
2014-03-04 |
Radiorx, Inc. |
Acyclic organonitro compounds for use in treating cancer
|
AR091790A1
(es)
|
2011-08-29 |
2015-03-04 |
Infinity Pharmaceuticals Inc |
Derivados de isoquinolin-1-ona y sus usos
|
AR087700A1
(es)
|
2011-08-30 |
2014-04-09 |
Gilead Sciences Inc |
Inhibidores de aldh-2 en el tratamiento de adicciones
|
EP2751291B1
(en)
|
2011-09-01 |
2018-08-15 |
University of Southern California |
Methods for preparing high throughput peptidomimetics, orally bioavailable drugs and compositions containing same
|
EP2755983B1
(en)
|
2011-09-12 |
2017-03-15 |
Idenix Pharmaceuticals LLC. |
Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
|
AU2012308900A1
(en)
|
2011-09-12 |
2013-05-09 |
Idenix Pharmaceuticals, Inc. |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
WO2013040501A1
(en)
|
2011-09-16 |
2013-03-21 |
Pharmathene, Inc. |
Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and uses thereof
|
EP2758053A1
(en)
|
2011-09-21 |
2014-07-30 |
Gilead Sciences, Inc. |
Sodium channel blockers reduce glucagon secretion
|
AU2012312308B2
(en)
|
2011-09-23 |
2015-11-19 |
Celgene Corporation |
Romidepsin and 5-azacitidine for use in treating lymphoma
|
MX2014003591A
(es)
|
2011-09-26 |
2014-09-08 |
Celgene Corp |
Terapia de combinacion para canceres quimiorresistentes.
|
WO2013049332A1
(en)
|
2011-09-29 |
2013-04-04 |
Infinity Pharmaceuticals, Inc. |
Inhibitors of monoacylglycerol lipase and methods of their use
|
JP6019126B2
(ja)
|
2011-10-07 |
2016-11-02 |
エピセントアーレックス・インコーポレイテッドEpicentRx, Inc. |
有機ニトロチオエーテル化合物およびその医療用途
|
US20140308260A1
(en)
|
2011-10-07 |
2014-10-16 |
Radiorx, Inc. |
Methods and compositions comprising a nitrite-reductase promoter for treatment of medical disorders and preservation of blood products
|
EP2764406B1
(en)
|
2011-10-07 |
2018-03-14 |
Cedars-Sinai Medical Center |
Compositions and methods for tumor imaging and targeting by a class of organic heptamethine cyanine dyes that possess dual nuclear and near-infrared properties
|
US20140271657A1
(en)
|
2011-10-12 |
2014-09-18 |
Children's Medical Center Corporation |
Combinatorial compositions and methods of treating hemoglobinopathies
|
CA2851155C
(en)
|
2011-10-14 |
2021-02-23 |
Ambit Biosciences Corporation |
Heterocyclic compounds and methods of use thereof
|
US8507460B2
(en)
|
2011-10-14 |
2013-08-13 |
Idenix Pharmaceuticals, Inc. |
Substituted 3′,5′-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
|
ES2586213T3
(es)
|
2011-10-31 |
2016-10-13 |
Xenon Pharmaceuticals Inc. |
Compuestos de bencenosulfonamida y su uso como agentes terapéuticos
|
TWI615155B
(zh)
|
2011-11-01 |
2018-02-21 |
拜耳股份有限公司 |
滲透活性的陰道遞送系統
|
CA2853949A1
(en)
|
2011-11-01 |
2013-05-10 |
Celgene Corporation |
Methods for treating cancers using oral formulations of cytidine analogs
|
AU2012332424A1
(en)
|
2011-11-02 |
2014-06-05 |
Synta Pharmaceuticals Corp. |
Combination therapy of Hsp90 inhibitors with platinum-containing agents
|
CA2853799A1
(en)
|
2011-11-02 |
2013-05-10 |
Synta Pharmaceuticals Corp. |
Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
|
US9243037B2
(en)
|
2011-11-10 |
2016-01-26 |
Trustees Of Boston College |
Gramicidin a mutants that function as antibiotics with improved solubility and reduced toxicity
|
WO2013074594A1
(en)
|
2011-11-14 |
2013-05-23 |
Synta Pharmaceuticals Corp. |
Combination therapy of hsp90 inhibitors with braf inhibitors
|
AU2012324015A1
(en)
|
2011-12-01 |
2013-06-20 |
Purdue Pharma L.P. |
Azetidine-substituted quinoxaline-type piperidine compounds and uses thererof
|
US20130143867A1
(en)
|
2011-12-02 |
2013-06-06 |
Sychroneuron Inc. |
Acamprosate formulations, methods of using the same, and combinations comprising the same
|
WO2013085902A1
(en)
|
2011-12-05 |
2013-06-13 |
The University Of Texas M.D. |
Combination therapy methods for treating an inflammatory breast cancer
|
AU2012347785B2
(en)
|
2011-12-06 |
2017-03-16 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and compositions for treating viral diseases
|
EP2788358B1
(en)
|
2011-12-08 |
2018-08-29 |
Purdue Pharma LP |
Quaternized buprenorphine analogs
|
SG11201403434YA
(en)
|
2011-12-19 |
2014-09-26 |
Map Pharmaceuticals Inc |
Novel iso-ergoline derivatives
|
SG10201506202RA
(en)
|
2011-12-21 |
2015-09-29 |
Map Pharmaceuticals Inc |
Novel neuromodulatory compounds
|
WO2013101954A1
(en)
|
2011-12-28 |
2013-07-04 |
Allergan, Inc. |
3-phenyl-5-ureidoisothiazole-4-carboximide and 3-amino-5-phenylisothiazole derivatives as kinase inhibitors
|
EP2797896A1
(en)
|
2011-12-28 |
2014-11-05 |
Allergan, Inc. |
Benzimidazole derivatives as selective blockers of persistent sodium current
|
WO2013101911A2
(en)
|
2011-12-28 |
2013-07-04 |
Allergan, Inc. |
Benzimidazole derivatives as selective blockers of persistent sodium current
|
DK3130347T3
(da)
|
2011-12-30 |
2019-10-14 |
Halozyme Inc |
PH20-polypeptidvarianter, formuleringer og anvendelser deraf
|
KR20140110014A
(ko)
|
2011-12-30 |
2014-09-16 |
레비바 파마슈티칼스, 아이엔씨. |
페닐시클로알킬메틸아민 유도체의 조성물, 합성, 및 사용 방법
|
RU2674153C2
(ru)
|
2012-01-05 |
2018-12-05 |
Бостон Медикал Сентер Корпорэйшн |
Slit-robo сигналинг для диагностики и лечения заболевания почек
|
KR102231554B1
(ko)
|
2012-01-06 |
2021-03-23 |
앤지 파마 유에스 엘엘씨 |
대사 장애를 치료하는 조성물 및 방법
|
BR112014016808B1
(pt)
|
2012-01-06 |
2022-01-11 |
Anji Pharma (Us) Llc |
Uso de um composto de biguanida para a fabricação de um medicamento para baixar os níveis de glicose no sangue e para o tratamento de um distúrbio do metabolismo de glicose
|
WO2013112932A1
(en)
|
2012-01-27 |
2013-08-01 |
Gilead Sciences, Inc. |
Combination therapies using late sodium ion channel blockers and potassium ion channel blockers
|
CA3132120C
(en)
|
2012-02-08 |
2023-10-24 |
Sunovion Pharmaceuticals Inc. |
Heteroaryl compounds and methods of use thereof
|
WO2013126394A1
(en)
|
2012-02-21 |
2013-08-29 |
Celgene Corporation |
Solid forms of 3-(4-nitro-1-oxoisoindolin-2-yl)piperidine-2,6-dione
|
WO2013130468A1
(en)
|
2012-02-29 |
2013-09-06 |
SinuSys Corporation |
Devices and methods for dilating a paranasal sinus opening and for treating sinusitis
|
RU2630601C2
(ru)
|
2012-02-29 |
2017-09-11 |
Джонсон Энд Джонсон Вижн Кэа, Инк. |
Пробка для слезной точки с подключенной к источнику питания матрицей из удерживающих ячеек
|
WO2013130600A1
(en)
|
2012-02-29 |
2013-09-06 |
Ambit Biosciences Corporation |
Solid forms comprising optically active pyrazolylaminoquinazoline, compositions thereof, and uses therewith
|
WO2013133708A1
(en)
|
2012-03-07 |
2013-09-12 |
Stichting Vu-Vumc |
Compositions and methods for diagnosing and treating intellectual disability syndrome, autism and autism related disorders
|
RU2014141674A
(ru)
|
2012-03-16 |
2016-05-10 |
Аксикин Фармасьютикалз, Инк. |
3,5-диаминопиразоловые ингибиторы киназы
|
ES2779698T3
(es)
|
2012-03-19 |
2020-08-18 |
Brigham & Womens Hospital Inc |
Factor 11 de diferenciación del crecimiento (GDF) para el tratamiento de afecciones cardiovasculares relacionadas con la edad
|
US10039777B2
(en)
|
2012-03-20 |
2018-08-07 |
Neuro-Lm Sas |
Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
|
US20140350087A9
(en)
|
2012-03-22 |
2014-11-27 |
Halozyme, Inc. |
Oncovector Nucleic Acid Molecules and Methods of Use
|
EP2830616A1
(en)
|
2012-03-27 |
2015-02-04 |
Incuron LLC |
Curaxins for use in treating breast cancer and method for identifying patients likely to respond
|
AU2013239663A1
(en)
|
2012-03-28 |
2014-10-09 |
Synta Pharmaceuticals Corp. |
Triazole derivatives as HSP90 inhibitors
|
CA2868323A1
(en)
|
2012-04-04 |
2013-10-10 |
Synta Pharmaceuticals Corp. |
Novel triazole compounds that modulate hsp90 activity
|
AU2013243873B2
(en)
|
2012-04-04 |
2016-08-25 |
Halozyme, Inc. |
Combination therapy with an anti - hyaluronan agent and a tumor - targeted taxane
|
US8940742B2
(en)
|
2012-04-10 |
2015-01-27 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
WO2013156232A1
(en)
|
2012-04-16 |
2013-10-24 |
Algiax Pharmaceuticals Gmbh |
Use of benzofuranylsulfonates in neuropathic pain
|
WO2013156231A1
(en)
|
2012-04-16 |
2013-10-24 |
Algiax Pharmaceuticals Gmbh |
Use of imidazotriazinones in neuropathic pain
|
CN104302280A
(zh)
|
2012-04-17 |
2015-01-21 |
普渡制药公司 |
用于治疗阿片样物质所致不良药效学响应的系统和方法
|
WO2013158928A2
(en)
|
2012-04-18 |
2013-10-24 |
Elcelyx Therapeutics, Inc. |
Chemosensory receptor ligand-based therapies
|
ES2656292T3
(es)
|
2012-05-01 |
2018-02-26 |
Translatum Medicus Inc. |
Métodos de tratamiento y diagnóstico de enfermedades oculares que causan ceguera
|
EP2849751A1
(en)
|
2012-05-10 |
2015-03-25 |
Synta Pharmaceuticals Corp. |
Treating cancer with hsp90 inhibitory compounds
|
WO2013167963A1
(en)
|
2012-05-11 |
2013-11-14 |
Purdue Pharma L.P. |
Benzomorphan compounds as opioid receptors modulators
|
US9074972B2
(en)
|
2012-05-16 |
2015-07-07 |
Dionex Corporation |
Surrogate addition device and a method of analyte concentration
|
US9109001B2
(en)
|
2012-05-22 |
2015-08-18 |
Idenix Pharmaceuticals, Inc. |
3′,5′-cyclic phosphoramidate prodrugs for HCV infection
|
WO2013177195A1
(en)
|
2012-05-22 |
2013-11-28 |
Idenix Pharmaceuticals, Inc. |
3',5'-cyclic phosphate prodrugs for hcv infection
|
MX355708B
(es)
|
2012-05-22 |
2018-04-27 |
Idenix Pharmaceuticals Llc |
Compuestos de d-aminoacidos para enfermedades del higado.
|
US10350278B2
(en)
|
2012-05-30 |
2019-07-16 |
Curemark, Llc |
Methods of treating Celiac disease
|
EP3406598B1
(en)
|
2012-06-14 |
2020-01-29 |
Mayo Foundation for Medical Education and Research |
Pyrazole derivatives as inhibitors of stat3
|
US9789193B2
(en)
|
2012-06-15 |
2017-10-17 |
The Brigham And Women's Hospital, Inc. |
Compositions for treating cancer and methods for making the same
|
US9012640B2
(en)
|
2012-06-22 |
2015-04-21 |
Map Pharmaceuticals, Inc. |
Cabergoline derivatives
|
EP2867671B1
(en)
|
2012-06-29 |
2018-10-24 |
Celgene Corporation |
Methods for determining drug efficacy using cereblon-associated proteins
|
GB201212010D0
(en)
|
2012-07-05 |
2012-08-22 |
Sigmoid Pharma Ltd |
Formulations
|
AU2013290100A1
(en)
|
2012-07-11 |
2015-01-29 |
Elcelyx Therapeutics, Inc. |
Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
|
SG11201407988UA
(en)
|
2012-07-16 |
2015-01-29 |
Rhodes Technologies |
Process for improved opioid synthesis
|
WO2014014427A1
(en)
|
2012-07-16 |
2014-01-23 |
Mahmut Bilgic |
Modified release pharmaceutical tablet formulations
|
AR091779A1
(es)
|
2012-07-16 |
2015-02-25 |
Rhodes Technologies |
Procedimiento para la sintesis mejorada de opioides
|
US9085561B2
(en)
|
2012-07-30 |
2015-07-21 |
Purdue Pharma L.P. |
Cyclic urea- or lactam-substituted quinoxaline-type piperidines as ORL-1 modulators
|
EP3698809A1
(en)
|
2012-07-31 |
2020-08-26 |
The Brigham & Women's Hospital, Inc. |
Modulation of the immune response using agents binding tim-3 and ceacam-1
|
KR20150041040A
(ko)
|
2012-08-06 |
2015-04-15 |
세노믹스, 인코포레이티드 |
단맛 향미 개질제
|
KR102146848B1
(ko)
|
2012-08-09 |
2020-08-21 |
셀진 코포레이션 |
3-(4-((4-모르포리노메틸)벤질)옥시)-1-옥소이소인돌린-2-일)피페리딘-2,6-디온을 이용한 암의 치료방법
|
EP3741372A1
(en)
|
2012-08-09 |
2020-11-25 |
Celgene Corporation |
(s)-3-[4-(4-morphlin-4-ylmethylbenzyloxy)-1- oxo-1,3-dihydro-isoindo-2-yl]piperidine-2,6-dione for use in the treatment of immune-related and inflammatory diseases
|
CA2878954C
(en)
|
2012-08-09 |
2020-12-08 |
Benjamin M. Cohen |
Salts and solid forms of (s)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and compositions comprising and methods of using the same
|
US9587281B2
(en)
|
2012-08-14 |
2017-03-07 |
Celgene Corporation |
Cereblon isoforms and their use as biomarkers for therapeutic treatment
|
US8841340B2
(en)
|
2012-08-17 |
2014-09-23 |
Gilead Sciences, Inc. |
Solid forms of an antiviral compound
|
WO2014030053A1
(en)
|
2012-08-20 |
2014-02-27 |
Rhodes Technologies |
Systems and methods for increasing stability of dronabinol compositions
|
WO2014031465A1
(en)
|
2012-08-22 |
2014-02-27 |
Merck Sharp & Dohme Corp. |
Novel azabenzimidazole tetrahydropyran derivatives
|
US9315514B2
(en)
|
2012-08-27 |
2016-04-19 |
Rhodes Technologies |
1,3-dioxanomorphides and 1,3-dioxanocodides
|
WO2014035474A1
(en)
|
2012-08-30 |
2014-03-06 |
The General Hospital Corporation |
Compositions and methods for treating cancer
|
CA2922849A1
(en)
|
2012-08-31 |
2014-03-06 |
Ixchel Pharma, Llc |
Agents useful for treating obesity, diabetes and related disorders
|
WO2014039748A1
(en)
|
2012-09-07 |
2014-03-13 |
Axikin Pharmaceuticals, Inc. |
Isotopically enriched arylsulfonamide ccr3 antagonists
|
EA201590535A1
(ru)
|
2012-09-10 |
2015-07-30 |
Селджин Корпорейшн |
Способы лечения локально прогрессирующего запущенного рака молочной железы
|
WO2014055647A1
(en)
|
2012-10-03 |
2014-04-10 |
Mei Pharma, Inc. |
(sulfinyl and sulfonyl benzimidazolyl) pyrimidines and triazines, pharmaceutical compositions thereof, and their use for treating proliferative diseases
|
CA2887578A1
(en)
|
2012-10-08 |
2014-04-17 |
Idenix Pharamaceuticals, Inc. |
2'-chloro nucleoside analogs for hcv infection
|
EP3679950A1
(en)
|
2012-10-12 |
2020-07-15 |
The Brigham and Women's Hospital, Inc. |
Enhancement of the immune response
|
WO2014062856A1
(en)
|
2012-10-16 |
2014-04-24 |
Halozyme, Inc. |
Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
|
EP2909223B1
(en)
|
2012-10-19 |
2017-03-22 |
Idenix Pharmaceuticals LLC |
Dinucleotide compounds for hcv infection
|
US10723754B2
(en)
|
2012-10-22 |
2020-07-28 |
Idenix Pharmaceuticals Llc |
2′,4′-bridged nucleosides for HCV infection
|
AU2013337717B2
(en)
|
2012-11-01 |
2018-10-25 |
Infinity Pharmaceuticals, Inc. |
Treatment of cancers using PI3 kinase isoform modulators
|
US20150272924A1
(en)
|
2012-11-08 |
2015-10-01 |
Summa Health System |
Vitamin c, vitamin k, a polyphenol, and combinations thereof for wound healing
|
EP2916869A1
(en)
|
2012-11-09 |
2015-09-16 |
Celgene Corporation |
Methods for the treatment of bone loss
|
EP2917182B1
(en)
|
2012-11-09 |
2018-01-03 |
Purdue Pharma LP |
Benzomorphan analogs and the use thereof
|
US20160151321A1
(en)
|
2012-11-13 |
2016-06-02 |
Dinesh C. Patel |
Methods for the treatment of sialorrhea
|
US20140140951A1
(en)
|
2012-11-14 |
2014-05-22 |
Idenix Pharmaceuticals, Inc. |
D-Alanine Ester of Rp-Nucleoside Analog
|
EP2938624A1
(en)
|
2012-11-14 |
2015-11-04 |
IDENIX Pharmaceuticals, Inc. |
D-alanine ester of sp-nucleoside analog
|
JP6302480B2
(ja)
|
2012-11-29 |
2018-03-28 |
サノビオン ファーマシューティカルズ インクSunovion Pharmaceuticals Inc. |
中枢神経系疾患の治療に有用なトリアゾロ−ピラジン誘導体
|
WO2014085633A1
(en)
|
2012-11-30 |
2014-06-05 |
Novomedix, Llc |
Substituted biaryl sulfonamides and the use thereof
|
WO2014087226A1
(en)
|
2012-12-07 |
2014-06-12 |
Purdue Pharma L.P. |
Buprenorphine analogs as opiod receptor modulators
|
TW201427658A
(zh)
|
2012-12-10 |
2014-07-16 |
Merck Sharp & Dohme |
藉由投予升糖素受體拮抗劑及膽固醇吸收抑制劑治療糖尿病之方法
|
CA2894971C
(en)
|
2012-12-14 |
2018-06-26 |
Purdue Pharma L.P. |
Nitrogen containing morphinan derivatives and the use thereof
|
ES2631197T3
(es)
|
2012-12-14 |
2017-08-29 |
Purdue Pharma Lp |
Análogos de piridonamorfinano y actividad biológica sobre los receptores opiodes
|
US8987287B2
(en)
|
2012-12-14 |
2015-03-24 |
Purdue Pharma L.P. |
Spirocyclic morphinans and their use
|
EP2935304A1
(en)
|
2012-12-19 |
2015-10-28 |
IDENIX Pharmaceuticals, Inc. |
4'-fluoro nucleosides for the treatment of hcv
|
BR112015014964A2
(pt)
|
2012-12-21 |
2017-07-11 |
Map Pharmaceuticals Inc |
novos derivados de metisergida
|
NZ708870A
(en)
|
2012-12-21 |
2016-09-30 |
Gilead Calistoga Llc |
Isoquinolinone or quinazolinone phosphatidylinositol 3-kinase inhibitors
|
CA2895782C
(en)
|
2012-12-21 |
2017-08-22 |
Gilead Calistoga Llc |
Substituted pyrimidine aminoalkyl-quinazolones as phosphatidylinositol 3-kinase inhibitors
|
UY35212A
(es)
|
2012-12-21 |
2014-06-30 |
Gilead Sciences Inc |
Inhibidores de la quinasa que regula la señal de la apoptosis
|
US9090618B2
(en)
|
2012-12-27 |
2015-07-28 |
Purdue Pharma L.P. |
Substituted benzimidazole-type piperidine compounds and uses thereof
|
WO2014102590A1
(en)
|
2012-12-27 |
2014-07-03 |
Purdue Pharma L.P. |
Substituted piperidin-4-amino-type compounds and uses thereof
|
WO2014102589A1
(en)
|
2012-12-27 |
2014-07-03 |
Purdue Pharma L.P. |
Quinazolin-4(3h)-one-type piperidine compounds and uses thereof
|
US9963458B2
(en)
|
2012-12-27 |
2018-05-08 |
Purdue Pharma L.P. |
Indole and indoline-type piperidine compounds and uses thereof
|
WO2014102592A2
(en)
|
2012-12-27 |
2014-07-03 |
Purdue Pharma L.P. |
Oxime/substituted quinoxaline-type piperidine compounds and uses thereof
|
EP2941430B1
(en)
|
2012-12-28 |
2017-04-26 |
Purdue Pharma LP |
7,8-cyclicmorphinan analogs
|
EP2941431B1
(en)
|
2012-12-28 |
2017-10-25 |
Purdue Pharma L.P. |
Substituted morphinans and the use thereof
|
JP6359560B2
(ja)
|
2012-12-31 |
2018-07-18 |
サノビオン ファーマシューティカルズ インクSunovion Pharmaceuticals Inc. |
複素環式化合物及びその使用方法
|
AU2014203942B2
(en)
|
2013-01-05 |
2019-01-03 |
Anji Pharmaceuticals Inc. |
Delayed-release composition comprising biguanide
|
US20150196625A9
(en)
|
2013-01-07 |
2015-07-16 |
Rudolph D. Paladini |
Metal Sensitive Mutants of Matrix Metalloproteases and uses thereof
|
US9617607B2
(en)
|
2013-01-08 |
2017-04-11 |
Enzo Biochem, Inc. |
Diagnosis and treatment of viral diseases
|
WO2014110127A1
(en)
|
2013-01-08 |
2014-07-17 |
Enzo Biochem, Inc. |
Diagnosis and treatment of viral diseases
|
SG11201505352RA
(en)
|
2013-01-09 |
2015-08-28 |
Edgemont Pharmaceuticals Llc |
Controlled release formulations of lorazepam
|
US8999393B1
(en)
|
2013-01-09 |
2015-04-07 |
Edgemont Pharmaceuticals Llc |
Sustained release formulations of lorazepam
|
WO2014110305A1
(en)
|
2013-01-11 |
2014-07-17 |
Mayo Foundation For Medical Education And Research |
Vitamins c and k for treating polycystic diseases
|
US9540340B2
(en)
|
2013-01-14 |
2017-01-10 |
Deuterx, Llc |
3-(5-substituted-4-oxoquinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same
|
WO2014116573A1
(en)
|
2013-01-22 |
2014-07-31 |
Celgene Corporation |
Processes for the preparation of isotopologues of 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof
|
EP2950799B1
(en)
|
2013-01-30 |
2019-12-04 |
Pharmorx Therapeutics, Inc. |
Treatments for depression and other diseases with a low dose agent
|
EP2951160B1
(en)
|
2013-01-31 |
2019-04-24 |
Purdue Pharma LP |
Benzomorphan analogs and the use thereof
|
US9149533B2
(en)
|
2013-02-05 |
2015-10-06 |
Purdue Pharma L.P. |
Tamper resistant pharmaceutical formulations
|
EP2956096A1
(en)
|
2013-02-15 |
2015-12-23 |
Allergan, Inc. |
Sustained drug delivery implant
|
JO3155B1
(ar)
|
2013-02-19 |
2017-09-20 |
Senomyx Inc |
معدِّل نكهة حلوة
|
US20150366890A1
(en)
|
2013-02-25 |
2015-12-24 |
Trustees Of Boston University |
Compositions and methods for treating fungal infections
|
WO2014134419A1
(en)
|
2013-03-01 |
2014-09-04 |
Gilead Sciences, Inc. |
Use of ikach blockers for the treatment of cardiac diseases
|
US9309275B2
(en)
|
2013-03-04 |
2016-04-12 |
Idenix Pharmaceuticals Llc |
3′-deoxy nucleosides for the treatment of HCV
|
US9339541B2
(en)
|
2013-03-04 |
2016-05-17 |
Merck Sharp & Dohme Corp. |
Thiophosphate nucleosides for the treatment of HCV
|
WO2014139388A1
(en)
|
2013-03-14 |
2014-09-18 |
Merck Sharp & Dohme Corp. |
Novel indole derivatives useful as anti-diabetic agents
|
WO2014151180A1
(en)
|
2013-03-14 |
2014-09-25 |
Celgene Corporation |
Treatment of psoriatic arthritis using apremilast
|
WO2014144658A1
(en)
|
2013-03-15 |
2014-09-18 |
The Regents Of The University Of California |
Dual reactivity potent kunitz inhibitor of fibrinolysis
|
US8969358B2
(en)
|
2013-03-15 |
2015-03-03 |
Purdue Pharma L.P. |
Buprenorphine analogs
|
EP3401320B1
(en)
|
2013-03-15 |
2020-05-13 |
The Regents of the University of California |
Acyclic nucleoside phosphonate diesters for use in treating human papilloma virus, cervical intraepithelial neoplasia, anal intraepithelial neoplasia, or vulvar intraepithelial neoplasia
|
US10751287B2
(en)
|
2013-03-15 |
2020-08-25 |
Purdue Pharma L.P. |
Tamper resistant pharmaceutical formulations
|
NZ629037A
(en)
|
2013-03-15 |
2017-04-28 |
Infinity Pharmaceuticals Inc |
Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
|
WO2014144975A1
(en)
|
2013-03-15 |
2014-09-18 |
Durect Corporation |
Compositions with a rheological modifier to reduce dissolution variability
|
JP6041823B2
(ja)
|
2013-03-16 |
2016-12-14 |
ファイザー・インク |
トファシチニブの経口持続放出剤形
|
TWI530499B
(zh)
|
2013-03-28 |
2016-04-21 |
吉李德科學股份有限公司 |
作為溴結構域(bromodomain)抑制劑之苯並咪唑酮衍生物類
|
WO2014165542A1
(en)
|
2013-04-01 |
2014-10-09 |
Idenix Pharmaceuticals, Inc. |
2',4'-fluoro nucleosides for the treatment of hcv
|
WO2014165482A1
(en)
|
2013-04-02 |
2014-10-09 |
Celgene Corporation |
Methods and compositions using 4-amino-2-(2,6-dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment and management of central nervous system cancers
|
EP2983694B1
(en)
|
2013-04-08 |
2022-06-22 |
President and Fellows of Harvard College |
Compositions for rejuvenating skeletal muscle stem cells
|
JP2016521279A
(ja)
|
2013-04-30 |
2016-07-21 |
アッヴィ・インコーポレイテッド |
アトラセンタンを使用して脂質プロファイルを改善するための方法
|
TWI527811B
(zh)
|
2013-05-09 |
2016-04-01 |
吉李德科學股份有限公司 |
作爲溴結構域抑制劑的苯並咪唑衍生物
|
US9687263B2
(en)
|
2013-05-30 |
2017-06-27 |
SinuSys Corporation |
Devices and methods for inserting a sinus dilator
|
RU2019134551A
(ru)
|
2013-05-30 |
2019-11-22 |
Инфинити Фармасьютикалз, Инк. |
Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы
|
CN105431144A
(zh)
|
2013-06-05 |
2016-03-23 |
思康脑侒股份有限公司 |
阿坎酸制剂、使用阿坎酸制剂的方法以及包含阿坎酸制剂的组合
|
EP3004130B1
(en)
|
2013-06-05 |
2019-08-07 |
Idenix Pharmaceuticals LLC. |
1',4'-thio nucleosides for the treatment of hcv
|
WO2014197835A2
(en)
|
2013-06-06 |
2014-12-11 |
The General Hospital Corporation |
Methods and compositions for the treatment of cancer
|
US20160220640A1
(en)
|
2013-06-11 |
2016-08-04 |
The Brigham And Women's Hospital, Inc. |
Methods and compositions for increasing neurogenesis and angiogenesis
|
PL3008053T3
(pl)
|
2013-06-14 |
2018-08-31 |
Gilead Calistoga Llc |
Inhibitory 3-kinazy fosfatydyloinozytolu
|
US10017531B2
(en)
|
2013-06-14 |
2018-07-10 |
Invictus Oncology Pvt. Ltd. |
Lipid-based platinum-N-heterocyclic carbene compounds and nanoparticles
|
EP2815749A1
(en)
|
2013-06-20 |
2014-12-24 |
IP Gesellschaft für Management mbH |
Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
|
US20160120861A1
(en)
|
2013-06-28 |
2016-05-05 |
Purdue Pharma L.P. |
Compositions and Methods for Treating an Arrhythmia with an Opioid Antagonist
|
TW201534726A
(zh)
|
2013-07-03 |
2015-09-16 |
Halozyme Inc |
熱穩定ph20玻尿酸酶變異體及其用途
|
WO2015009534A2
(en)
|
2013-07-16 |
2015-01-22 |
Allergan, Inc. |
Hcn inhibitors affecting ganglion cell function and visual function
|
NZ716267A
(en)
|
2013-07-23 |
2017-05-26 |
Euro Celtique Sa |
A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
|
US9376441B2
(en)
|
2013-07-31 |
2016-06-28 |
Gilead Sciences, Inc. |
Substituted pyrrolidines as SYK inhibitors
|
US20150037282A1
(en)
|
2013-08-01 |
2015-02-05 |
Idenix Pharmaceuticals, Inc. |
D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
|
BR112016002079A2
(pt)
|
2013-08-02 |
2017-09-05 |
Johnson Matthey Plc |
Processo para preparação de um aditivo ácido de oximorfona, solução aquosa de aditivo ácido de oximorfona, aditivo ácido de oximorfona sólido, e, alcaloide de oximorfona sólido
|
CA2924141C
(en)
|
2013-08-22 |
2022-06-07 |
The General Hospital Corporation |
5-amino 4-cyano substituted oxazole and thiazole derivatives as inhibitors of human 12/15-lipoxygenase
|
CA2922361C
(en)
|
2013-08-29 |
2022-07-12 |
Trustees Of Boston University |
Intermediate metabolism products to potentiate aminoglycoside antibiotics in bacterial infections
|
KR20160055170A
(ko)
|
2013-08-30 |
2016-05-17 |
암비트 바이오사이언시즈 코포레이션 |
바이아릴 아세트아미드 화합물 및 이의 사용 방법
|
NZ631142A
(en)
|
2013-09-18 |
2016-03-31 |
Axikin Pharmaceuticals Inc |
Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
|
EP3046924A1
(en)
|
2013-09-20 |
2016-07-27 |
IDENIX Pharmaceuticals, Inc. |
Hepatitis c virus inhibitors
|
ES2729642T3
(es)
|
2013-09-24 |
2019-11-05 |
Purdue Pharma Lp |
Tratamiento del dolor por quemaduras mediante moduladores de TRPV1
|
US9700549B2
(en)
|
2013-10-03 |
2017-07-11 |
David Wise |
Compositions and methods for treating pelvic pain and other conditions
|
MX2016004340A
(es)
|
2013-10-04 |
2016-08-08 |
Infinity Pharmaceuticals Inc |
Compuestos heterociclicos y usos de los mismos.
|
WO2015051241A1
(en)
|
2013-10-04 |
2015-04-09 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
WO2015061204A1
(en)
|
2013-10-21 |
2015-04-30 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
EP3060680B1
(en)
|
2013-10-21 |
2019-02-27 |
The General Hospital Corporation |
Methods relating to circulating tumor cell clusters and the treatment of cancer
|
WO2015061683A1
(en)
|
2013-10-25 |
2015-04-30 |
Idenix Pharmaceuticals, Inc. |
D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv
|
WO2015065876A1
(en)
|
2013-10-29 |
2015-05-07 |
Thomas Jefferson University |
Methods of prevention or treatment for pathologic thrombosis or inflammation
|
US20160271162A1
(en)
|
2013-11-01 |
2016-09-22 |
Idenix Pharmacueticals, Llc |
D-alanine phosphoramide pronucleotides of 2'-methyl 2'-fluro guanosine nucleoside compounds for the treatment of hcv
|
GB201319792D0
(en)
|
2013-11-08 |
2013-12-25 |
Sigmoid Pharma Ltd |
Formulations
|
AU2013406206B2
(en)
|
2013-11-26 |
2017-07-20 |
Gilead Sciences, Inc. |
Quinoline derivatives as bromodomain inhibitors
|
WO2015081073A2
(en)
|
2013-11-26 |
2015-06-04 |
The Brigham And Women's Hospital, Inc. |
Compositions and methods for modulating an immune response
|
WO2015081297A1
(en)
|
2013-11-27 |
2015-06-04 |
Idenix Pharmaceuticals, Inc. |
2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection
|
CN105934438A
(zh)
|
2013-11-27 |
2016-09-07 |
艾登尼克斯药业有限公司 |
用于治疗肝癌的核苷酸
|
PT3076976T
(pt)
|
2013-12-04 |
2020-12-07 |
Kronos Bio Inc |
Métodos para tratar cancros
|
WO2015089321A2
(en)
|
2013-12-11 |
2015-06-18 |
The General Hospital Corporation |
Use of mullerian inhibiting substance (mis) proteins for contraception and ovarian reserve preservation
|
EP3083654A1
(en)
|
2013-12-18 |
2016-10-26 |
Idenix Pharmaceuticals LLC |
4'-or nucleosides for the treatment of hcv
|
KR101918375B1
(ko)
|
2013-12-19 |
2018-11-13 |
길리애드 사이언시즈, 인코포레이티드 |
이온 채널 조정제로서의 융합된 헤테로시클릭 화합물
|
CN111729090A
(zh)
|
2013-12-20 |
2020-10-02 |
通用医疗公司 |
与循环肿瘤细胞相关的方法和测定法
|
US9682123B2
(en)
|
2013-12-20 |
2017-06-20 |
The Trustees Of Columbia University In The City Of New York |
Methods of treating metabolic disease
|
UY35898A
(es)
|
2013-12-23 |
2015-07-31 |
Gilead Sciences Inc |
?compuestos inhibidores de syk y composiciones que los comprenden?.
|
WO2015097546A1
(en)
|
2013-12-26 |
2015-07-02 |
Purdue Pharma L.P. |
Propellane-based compounds and their use as opioid receptor modulators
|
US9994571B2
(en)
|
2013-12-26 |
2018-06-12 |
Purdue Pharma L.P. |
10-substituted morphinan hydantoins
|
WO2015097548A1
(en)
|
2013-12-26 |
2015-07-02 |
Purdue Pharma L.P. |
7-beta-alkyl analogs of orvinols
|
WO2015097545A1
(en)
|
2013-12-26 |
2015-07-02 |
Purdue Pharma L.P. |
Opioid receptor modulating oxabicyclo[2.2.2]octane morphinans
|
US10550088B2
(en)
|
2013-12-27 |
2020-02-04 |
Purdue Pharma L.P. |
6-substituted and 7-substituted morphinan analogs and the use thereof
|
EP3089978B1
(en)
|
2013-12-30 |
2018-08-29 |
Purdue Pharma L.P. |
Pyridone-sulfone morphinan analogs as opioid receptor ligands
|
WO2015109037A1
(en)
|
2014-01-15 |
2015-07-23 |
Deuterx, Llc |
Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
|
MX2016009300A
(es)
|
2014-01-15 |
2017-04-13 |
Rhodes Tech |
Proceso para la sintesis mejorada de oxicodona.
|
MX2016009125A
(es)
|
2014-01-15 |
2017-02-02 |
Rhodes Tech |
Proceso para la sintesis mejorada de oximorfona.
|
EP3096749B1
(en)
|
2014-01-24 |
2019-05-15 |
Celgene Corporation |
Methods for the treatment of obesity using apremilast
|
CN109820853B
(zh)
|
2014-02-05 |
2022-05-10 |
Vm肿瘤药物有限责任公司 |
取代的杂环化合物在制备治疗癌症药物中的用途
|
WO2015134560A1
(en)
|
2014-03-05 |
2015-09-11 |
Idenix Pharmaceuticals, Inc. |
Solid forms of a flaviviridae virus inhibitor compound and salts thereof
|
EP3116507B1
(en)
|
2014-03-10 |
2021-05-26 |
Kadmon Corporation, LLC |
Compounds for oral treatment of brain tumors
|
EP3119744B1
(en)
|
2014-03-18 |
2019-03-06 |
Algiax Pharmaceuticals GmbH |
2-cyano-3-cyclopropyl-3-hydroxy-n-aryl-thioacrylamide derivatives
|
PT3119397T
(pt)
|
2014-03-19 |
2022-04-11 |
Infinity Pharmaceuticals Inc |
Compostos heterocíclicos para utilização no tratamento de distúrbios mediados por pi3k-gama
|
US11369588B2
(en)
|
2014-03-20 |
2022-06-28 |
The Trustees Of Princeton University |
NADPH production by the 10-formyl-THF pathway, and its use in the diagnosis and treatment of disease
|
KR102663309B1
(ko)
|
2014-03-20 |
2024-05-03 |
카펠라 테라퓨틱스, 인크. |
암 치료용의 erbb 티로신 키나제 억제제로서의 벤즈이미다졸 유도체
|
JP6568926B2
(ja)
|
2014-03-20 |
2019-08-28 |
カペラ セラピューティクス,インコーポレーテッド |
癌の治療のためのerbbチロシンキナーゼ阻害剤としてのベンゾイミダゾール誘導体
|
US20170107300A1
(en)
|
2014-03-21 |
2017-04-20 |
The Brigham And Women's Hospital, Inc. |
Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring
|
US9062063B1
(en)
|
2014-03-21 |
2015-06-23 |
Johnson Matthey Public Limited Company |
Forms of oxymorphone hydrochloride
|
US20150283149A1
(en)
|
2014-04-02 |
2015-10-08 |
Gilead Sciences, Inc. |
Methods of treating patients having implantable cardiac devices
|
CA2944401A1
(en)
|
2014-04-03 |
2015-10-08 |
Invictus Oncology Pvt. Ltd. |
Supramolecular combinatorial therapeutics
|
US20170216328A1
(en)
|
2014-04-04 |
2017-08-03 |
Ritter Pharmaceuticals, Inc. |
Methods and compositions for microbiome alteration
|
WO2015157559A2
(en)
|
2014-04-09 |
2015-10-15 |
Siteone Therapeutics, Inc. |
10',11'-modified saxitoxins for the treatment of pain
|
US10130618B2
(en)
|
2014-04-11 |
2018-11-20 |
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi |
Pharmaceutical combinations of dabigatran and proton pump inhibitors
|
WO2015155307A1
(en)
|
2014-04-11 |
2015-10-15 |
Sanovel Ilac Sanayi Ve Ticaret A.S. |
Pharmaceutical combinations of rivaroxaban and proton pump inhibitors
|
EP3131914B1
(en)
|
2014-04-16 |
2023-05-10 |
Idenix Pharmaceuticals LLC |
3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
|
EP3148567A4
(en)
|
2014-04-25 |
2018-01-10 |
The Brigham and Women's Hospital, Inc. |
Methods to manipulate alpha-fetoprotein (afp)
|
US20170045528A1
(en)
|
2014-04-25 |
2017-02-16 |
The Brigham And Women's Hospital, Inc. |
Compositions and methods for treating subjects with immune-mediated diseases
|
RU2677538C2
(ru)
|
2014-04-25 |
2019-01-17 |
Джонсон Энд Джонсон Вижн Кэа, Инк. |
Способ и офтальмологическое устройство с системой высвобождения активного агента
|
WO2015168079A1
(en)
|
2014-04-29 |
2015-11-05 |
Infinity Pharmaceuticals, Inc. |
Pyrimidine or pyridine derivatives useful as pi3k inhibitors
|
MX2016014731A
(es)
|
2014-05-12 |
2017-05-04 |
Conatus Pharmaceuticals Inc |
Tratamiento de las complicaciones de la enfermedad cronica del higado con enfermedades de caspasa.
|
WO2015175773A1
(en)
|
2014-05-15 |
2015-11-19 |
Celgene Corporation |
Use of pde4 inhibitors and combinations thereof for the treatment of cystic fibrosis
|
US20170087129A1
(en)
|
2014-05-16 |
2017-03-30 |
Celgene Corporation |
Compositions and methods for the treatment of atherosclerotic cardiovascular diseases with pde4 modulators
|
JP6817073B2
(ja)
|
2014-05-19 |
2021-01-20 |
ノースイースタン ユニバーシティ |
セロトニン受容体を標的にする化合物および方法
|
EP3145500A1
(en)
|
2014-05-23 |
2017-03-29 |
Sigmoid Pharma Limited |
Celecoxib formulations useful for treating colorectal cancer
|
JP2017516779A
(ja)
|
2014-05-28 |
2017-06-22 |
アイデニクス・ファーマシューティカルズ・エルエルシー |
癌治療のためのヌクレオシド誘導体
|
MX2016015569A
(es)
|
2014-06-02 |
2017-04-25 |
Children´S Medical Center Corp |
Metodos y composiciones para inmunomodulacion.
|
TW201613916A
(en)
|
2014-06-03 |
2016-04-16 |
Gilead Sciences Inc |
TANK-binding kinase inhibitor compounds
|
US10076504B2
(en)
|
2014-06-12 |
2018-09-18 |
Ligand Pharmaceuticals, Inc. |
Glucagon antagonists
|
WO2015191754A2
(en)
|
2014-06-13 |
2015-12-17 |
Gilead Sciences, Inc. |
Phosphatidylinositol 3-kinase inhibitors
|
EP3154960A1
(en)
|
2014-06-13 |
2017-04-19 |
Gilead Sciences, Inc. |
Phosphatidylinositol 3-kinase inhibitors
|
US20150359810A1
(en)
|
2014-06-17 |
2015-12-17 |
Celgene Corporation |
Methods for treating epstein-barr virus (ebv) associated cancers using oral formulations of 5-azacytidine
|
US9527815B2
(en)
|
2014-06-18 |
2016-12-27 |
Biotheryx, Inc. |
Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating inflammatory, neurodegenerative, or immune-mediated diseases
|
MA40240B1
(fr)
|
2014-06-19 |
2019-03-29 |
Ariad Pharma Inc |
Composés hétéroaryle d'inhibition de la kinase
|
US10300042B2
(en)
|
2014-06-23 |
2019-05-28 |
Celgene Corporation |
Apremilast for the treatment of a liver disease or a liver function abnormality
|
EP3160486B1
(en)
|
2014-06-27 |
2020-11-18 |
Celgene Corporation |
Compositions and methods for inducing conformational changes in cereblon other e3 ubiquitin ligases
|
US9499514B2
(en)
|
2014-07-11 |
2016-11-22 |
Celgene Corporation |
Antiproliferative compounds and methods of use thereof
|
KR20170029580A
(ko)
|
2014-07-14 |
2017-03-15 |
길리애드 사이언시즈, 인코포레이티드 |
암을 치료하기 위한 조합물
|
CA2910865C
(en)
|
2014-07-15 |
2016-11-29 |
Isa Odidi |
Compositions and methods for reducing overdose
|
AU2015296037B2
(en)
|
2014-08-01 |
2021-04-29 |
The Brigham And Women's Hospital, Inc. |
Methods and compositions relating to treatment of pulmonary arterial hypertension
|
US10092541B2
(en)
|
2014-08-15 |
2018-10-09 |
Celgene Corporation |
Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast
|
ES2940302T3
(es)
|
2014-08-22 |
2023-05-05 |
Celgene Corp |
Métodos para tratar el mieloma múltiple con compuestos inmunomoduladores en combinación con anticuerpos
|
HUE043847T2
(hu)
|
2014-08-28 |
2019-09-30 |
Halozyme Inc |
Hialuronán-lebontó enzimmel és egy immun checkpoint inhibitorral végzett kombinációs terápia
|
EP4043567B1
(en)
|
2014-08-29 |
2024-05-08 |
The Children's Medical Center Corporation |
Methods and compositions for the treatment of cancer
|
RU2723559C2
(ru)
|
2014-09-12 |
2020-06-16 |
Тобира Терапьютикс, Инк. |
Комбинированная терапия с применением препарата ценикривирок для лечения фиброза
|
CN117427077A
(zh)
|
2014-09-14 |
2024-01-23 |
阿瓦尼尔制药股份有限公司 |
用于治疗痴呆中的激越行为的包含右美沙芬化合物和奎尼丁的药物组合物
|
RS63250B1
(sr)
|
2014-09-15 |
2022-06-30 |
Univ California |
Nukleotidni analozi
|
WO2016044707A1
(en)
|
2014-09-18 |
2016-03-24 |
Cedars-Sinai Medical Center |
Compositions and methods for treating fibrosis
|
KR101949624B1
(ko)
|
2014-09-26 |
2019-02-18 |
길리애드 사이언시즈, 인코포레이티드 |
Tank-결합 키나제 억제제 화합물로서 유용한 아미노트리아진 유도체
|
US9708348B2
(en)
|
2014-10-03 |
2017-07-18 |
Infinity Pharmaceuticals, Inc. |
Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
|
US9353093B2
(en)
|
2014-10-07 |
2016-05-31 |
Allergan, Inc. |
Indole-1-carboxamides as kinase inhibitors
|
US9403803B2
(en)
|
2014-10-08 |
2016-08-02 |
Allergan, Inc. |
Indole-3-carboxamides as kinase inhibitors
|
US9359336B2
(en)
|
2014-10-09 |
2016-06-07 |
Allergan, Inc. |
Heterocycle-substituted pyridyl benzothiophenes as kinase inhibitors
|
US9296747B1
(en)
|
2014-10-10 |
2016-03-29 |
Allergan, Inc. |
Piperidylpyrimidine derivatives as modulators of protein kinase inhibitors and of vascular endothelial growth factor receptor 2
|
DK3207130T3
(da)
|
2014-10-14 |
2019-11-11 |
Halozyme Inc |
Sammensætninger af Adenosin Deaminase-2 (ADA2), varianter deraf og fremgangsmåder til anvendelse af samme
|
WO2016109002A2
(en)
|
2014-10-16 |
2016-07-07 |
Cleveland Biolabs, Inc. |
Methods and compositions for the treatment of radiation-related disorders
|
RS60737B1
(sr)
|
2014-10-21 |
2020-09-30 |
Ariad Pharma Inc |
Kristalni oblici 5-hloro-n4-[-2-(dimetilfosforil)fenil]-n2-{2-metoksi-4-[4-(4-metilpiperazin-1-il)piperidin-1-il]pirimidin-2,4-diamina
|
WO2016065264A1
(en)
|
2014-10-24 |
2016-04-28 |
Biogen Ma Inc. |
Diterpenoid derivatives and methods of use thereof
|
CA2936741C
(en)
|
2014-10-31 |
2018-11-06 |
Purdue Pharma |
Methods and compositions particularly for treatment of attention deficit disorder
|
EP3881829A1
(en)
|
2014-11-07 |
2021-09-22 |
Sublimity Therapeutics Limited |
Compositions comprising cyclosporin
|
TW201702218A
(zh)
|
2014-12-12 |
2017-01-16 |
美國杰克森實驗室 |
關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
|
MX2017007955A
(es)
|
2014-12-16 |
2018-02-19 |
Celgene Corp |
Formas solidas que comprenden (1e, 4e)-2-amino-n,n-dipropil-8-(4-( pirrolidina-1-carbonil)fenil)-3h-benzo[b]azepina-4-carboxamida, composiciones de las mismas y usos de las mismas.
|
US9676793B2
(en)
|
2014-12-23 |
2017-06-13 |
Hoffmann-Laroche Inc. |
Co-crystals of 5-amino-2-oxothiazolo[4,5-d]pyrimidin-3(2H)-yl-5-hydroxymethyl tetrahydrofuran-3-yl acetate and methods for preparing and using the same
|
MA41252A
(fr)
|
2014-12-23 |
2017-10-31 |
Gilead Sciences Inc |
Formes solides d'un inhibiteur d'ask 1
|
UA118312C2
(uk)
|
2014-12-23 |
2018-12-26 |
Ексікін Фармасутікалз, Інк. |
3,5-діамінопіразолові інгібітори кінази
|
CN107206007B
(zh)
|
2015-01-12 |
2021-08-10 |
雷维瓦药品公司 |
用于治疗肺高血压的方法
|
CN107249592A
(zh)
|
2015-01-12 |
2017-10-13 |
雷维瓦药品公司 |
用于治疗阿尔茨海默病的方法
|
WO2016115345A1
(en)
|
2015-01-14 |
2016-07-21 |
The Brigham And Women's Hospital, |
Treatment of cancer with anti-lap monoclonal antibodies
|
BR112017015487A2
(pt)
|
2015-01-20 |
2018-01-30 |
Xoc Pharmaceuticals Inc |
Composto; composição; método de tratamento e/ou prevenção de enxaqueca, als, doença de alzheimer, doença de parkinson, distúrbios extrapirimidais, depressão, náusea, êmese, síndrome das pernas inquietas, insônia, agressão, doença de huntington, doença cardiopulmonar, fibrogênese, hipertensão arterial pulmonar, ansiedade, dependências a drogas, distonia, parassonia ou hiperlactinemia em um indivíduo; métodos de agonização dos receptores d2, 5-ht1d, 5-ht1a e 5-ht2c, em um indivíduo; método de antagonização do receptor d3 em um indivíduo; métodos de agonização seletiva dos receptores 5 -ht1d, e 5-ht2c, método de fornecimento de atividade de antagonista funcional no receptor 5 -ht2b ou no receptor 5-ht7, ou em ambos, em um indivíduo; método de fornecimento de atividade de antagonista funcional nos receptores adrenérgicos em um indivíduo
|
JP2018502889A
(ja)
|
2015-01-20 |
2018-02-01 |
エックスオーシー ファーマシューティカルズ インコーポレイテッドXoc Pharmaceuticals, Inc |
イソエルゴリン化合物およびその使用
|
US9918979B2
(en)
|
2015-01-29 |
2018-03-20 |
Johnson Matthey Public Limited Company |
Process of preparing low ABUK oxymorphone hydrochloride
|
US9682033B2
(en)
|
2015-02-05 |
2017-06-20 |
Teva Pharmaceuticals International Gmbh |
Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound
|
EP3256161A1
(en)
|
2015-02-09 |
2017-12-20 |
Synta Pharmaceuticals Corp. |
Combination therapy of hsp90 inhibitors and pd-1 inhibitors for treating cancer
|
BR112017017729A2
(pt)
|
2015-02-20 |
2018-04-10 |
Osmotica Kereskedelmi Es Szolgaltato Kft |
forma de dosagem oral de liberação controlada de agonista de receptor gaba
|
US20180104251A1
(en)
|
2015-03-09 |
2018-04-19 |
Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College |
Compositions and methods for the treatment of glioblastoma
|
SG11201707350TA
(en)
|
2015-03-10 |
2017-10-30 |
Rhodes Tech |
Acetate salt of buprenorphine and methods for preparing buprenorphine
|
TW201642857A
(zh)
|
2015-04-06 |
2016-12-16 |
西建公司 |
以組合療法治療肝細胞癌
|
CN107708718B
(zh)
|
2015-04-22 |
2022-01-11 |
西达-赛奈医疗中心 |
用于治疗2型糖尿病的肠内递送的苦味寡肽
|
WO2016187426A1
(en)
|
2015-05-19 |
2016-11-24 |
Amorphex Therapeutics Llc |
A device that delivers a sustained low-dose of a myopia-suppressing drug
|
EP3303361A1
(en)
|
2015-05-27 |
2018-04-11 |
Idenix Pharmaceuticals LLC |
Nucleotides for the treatment of cancer
|
WO2016196664A1
(en)
|
2015-06-01 |
2016-12-08 |
Cedars-Sinai Medical Center |
Methods and use of compounds that bind to rela of nf-kb
|
WO2016202721A1
(en)
|
2015-06-16 |
2016-12-22 |
F. Hoffmann-La Roche Ag |
Salts of (s)-4-[(r)-6-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-3,6- dihydro-pyrimidin-4-ylmethyl]-morpholine-3-carboxylic acid, salt former and methods for preparing and using the same
|
JP6919099B2
(ja)
|
2015-06-23 |
2021-08-18 |
ニューロクライン バイオサイエンシーズ,インコーポレイテッド |
神経学的疾患または障害を処置するためのvmat2阻害剤
|
ES2970117T3
(es)
|
2015-06-26 |
2024-05-27 |
Celgene Corp |
Métodos para el tratamiento de sarcoma de Kaposi o linfoma inducido por KSHV usando compuestos inmunomoduladores, y usos de biomarcadores
|
CA2991164A1
(en)
|
2015-07-02 |
2017-01-05 |
Celgene Corporation |
Combination therapy for treatment of hematological cancers and solid tumors
|
WO2017007689A1
(en)
|
2015-07-06 |
2017-01-12 |
Gilead Sciences, Inc. |
Cot modulators and methods of use thereof
|
WO2017017631A2
(en)
|
2015-07-28 |
2017-02-02 |
Vyome Biosciences Pvt. Ltd. |
Antibacterial therapeutics and prophylactics
|
US10940204B2
(en)
|
2015-07-31 |
2021-03-09 |
Research Institute At Nationwide Children's Hospital |
Peptides and antibodies for the removal of biofilms
|
ES2901506T3
(es)
|
2015-08-17 |
2022-03-22 |
Kura Oncology Inc |
Métodos para tratar pacientes con cáncer con inhibidores de la farnesiltransferasa
|
WO2017035508A1
(en)
|
2015-08-27 |
2017-03-02 |
Collier R John |
Compositions and methods for treatment of pain
|
EP3347486A4
(en)
|
2015-09-09 |
2019-06-19 |
The Trustees of Columbia University in the City of New York |
REDUCTION OF ER-MAM-LOCALIZED APP-C99 AND METHOD FOR THE TREATMENT OF ALZHEIMER DISEASE
|
US10172842B2
(en)
|
2015-09-11 |
2019-01-08 |
PharmaDax Inc. |
Sustained release oral dosage form containing dalfampridine
|
ES2930848T3
(es)
|
2015-09-23 |
2022-12-22 |
Xwpharma Ltd |
Profármacos de ácido gamma-hidroxibutírico, composiciones y usos de los mismos
|
WO2017058828A1
(en)
|
2015-09-28 |
2017-04-06 |
Children's Hospital Los Angeles |
Methods for treating diseases mediated by erbb4-positive pro-inflammatory macrophages
|
CA3000708A1
(en)
|
2015-09-30 |
2017-04-06 |
Siteone Therapeutics, Inc. |
11,13-modified saxitoxins for the treatment of pain
|
WO2017059459A1
(en)
|
2015-10-01 |
2017-04-06 |
Elysium Therapeutics, Inc. |
Polysubunit opioid prodrugs resistant to overdose and abuse
|
US10335406B2
(en)
|
2015-10-01 |
2019-07-02 |
Elysium Therapeutics, Inc. |
Opioid compositions resistant to overdose and abuse
|
CN116063566A
(zh)
|
2015-10-01 |
2023-05-05 |
热生物制品有限公司 |
作为异源嵌合蛋白邻接i型和ii型胞外结构域的组合物和方法
|
US20190255107A1
(en)
|
2015-10-09 |
2019-08-22 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
WO2017066719A2
(en)
|
2015-10-14 |
2017-04-20 |
Research Institute At Nationwide Children's Hospital |
Hu specific interfering agents
|
EP3362458A1
(en)
|
2015-10-16 |
2018-08-22 |
Invictus Oncology Pvt. Ltd. |
Fluorescent anticancer platinum drugs
|
US10342778B1
(en)
|
2015-10-20 |
2019-07-09 |
Epicentrx, Inc. |
Treatment of brain metastases using organonitro compound combination therapy
|
US9987270B1
(en)
|
2015-10-29 |
2018-06-05 |
Epicentrix, Inc. |
Treatment of gliomas using organonitro compound combination therapy
|
EP3875459B1
(en)
|
2015-10-30 |
2023-12-13 |
Neurocrine Biosciences, Inc. |
Valbenazine dihydrochloride salts and polymorphs thereof
|
WO2017079566A1
(en)
|
2015-11-05 |
2017-05-11 |
Conatus Pharmaceuticals, Inc. |
Caspase inhibitors for use in the treatment of liver cancer
|
WO2017077382A1
(en)
|
2015-11-06 |
2017-05-11 |
Orionis Biosciences Nv |
Bi-functional chimeric proteins and uses thereof
|
WO2017083348A1
(en)
|
2015-11-11 |
2017-05-18 |
Celgene Corporation |
Controlled release oral dosage forms of poorly soluble drugs and uses thereof
|
US10112924B2
(en)
|
2015-12-02 |
2018-10-30 |
Astraea Therapeutics, Inc. |
Piperdinyl nociceptin receptor compounds
|
CR20180320A
(es)
|
2015-12-17 |
2018-08-21 |
Gilead Sciences Inc |
Compuestos inhibidores de la quinasa de union a tank
|
US10160757B2
(en)
|
2015-12-23 |
2018-12-25 |
Neuroscrine Biosciences, Inc. |
Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate)
|
US10830762B2
(en)
|
2015-12-28 |
2020-11-10 |
Celgene Corporation |
Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases
|
US20190022043A1
(en)
|
2015-12-31 |
2019-01-24 |
Conatus Pharmaceuticals Inc. |
Methods of using caspase inhibitors in treatment of liver disease
|
SG10202003099XA
(en)
|
2016-01-08 |
2020-05-28 |
Celgene Corp |
Antiproliferative compounds, and their pharmaceutical compositions and uses
|
KR20180095094A
(ko)
|
2016-01-08 |
2018-08-24 |
셀진 코포레이션 |
암을 치료하기 위한 방법 및 치료요법에 대한 임상 감수성의 예측변수로서 바이오마커의 용도
|
CA3010794A1
(en)
|
2016-01-08 |
2017-07-13 |
Celgene Corporation |
Solid forms of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide, and their pharmaceutical compositions and uses
|
DK3402480T3
(da)
|
2016-01-11 |
2021-06-28 |
Epicentrx Inc |
Sammensætninger og fremgangsmåder til intravenøs administration af 2-brom-1-(3,3-dinitroazetidin-1-yl)ethanon
|
WO2017134301A1
(en)
|
2016-02-05 |
2017-08-10 |
Orionis Biosciences Nv |
Clec9a binding agents
|
US9771366B2
(en)
|
2016-02-19 |
2017-09-26 |
Phoenix Molecular Design |
Substituted tetrahydropyrido[3′,2′:4,5]pyrrolo[1,2-a]pyrazine-2-carboxamides as RSK inhibitors
|
US20190119236A1
(en)
|
2016-02-23 |
2019-04-25 |
Portola Pharmaceuticals, Inc. |
Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9)
|
EP3423041A4
(en)
|
2016-03-04 |
2019-09-11 |
Charleston Laboratories, Inc. |
PHARMACEUTICAL COMPOSITIONS
|
WO2017152062A1
(en)
|
2016-03-04 |
2017-09-08 |
Gilead Sciences, Inc. |
Compositions and combinations of autotaxin inhibitors
|
EP3426278B1
(en)
|
2016-03-07 |
2024-01-03 |
Vib Vzw |
Cd20 binding single domain antibodies
|
WO2017161116A1
(en)
|
2016-03-17 |
2017-09-21 |
Infinity Pharmaceuticals, Inc. |
Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
|
WO2017168174A1
(en)
|
2016-04-02 |
2017-10-05 |
N4 Pharma Uk Limited |
New pharmaceutical forms of sildenafil
|
WO2017180589A1
(en)
|
2016-04-11 |
2017-10-19 |
Auspex Pharmaceuticals, Inc. |
Deuterated ketamine derivatives
|
US10047077B2
(en)
|
2016-04-13 |
2018-08-14 |
Skyline Antiinfectives, Inc. |
Deuterated O-sulfated beta-lactam hydroxamic acids and deuterated N-sulfated beta-lactams
|
US20190119758A1
(en)
|
2016-04-22 |
2019-04-25 |
Kura Oncology, Inc. |
Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors
|
MX2018013221A
(es)
|
2016-04-29 |
2019-06-24 |
Fgh Biotech Inc |
Compuestos de pirazol disustituidos para el tratamiento de enfermedades.
|
MA44859A
(fr)
|
2016-05-04 |
2019-03-13 |
Purdue Pharma Lp |
Pseudodimères d'oxazoline, compositions pharmaceutiques et utilisation correspondantes
|
CN109563141A
(zh)
|
2016-05-13 |
2019-04-02 |
奥里尼斯生物科学公司 |
对非细胞结构的治疗性靶向
|
JP7105200B2
(ja)
|
2016-05-13 |
2022-07-22 |
オリオニス バイオサイエンシズ ビーブイ |
標的突然変異体インターフェロン-ベータおよびその使用
|
TWI753910B
(zh)
|
2016-05-16 |
2022-02-01 |
美商拜歐斯瑞克斯公司 |
吡啶硫酮、其醫藥組合物及其治療增生性、炎性、神經退化性或免疫介導疾病之治療用途
|
RU2769827C2
(ru)
|
2016-05-20 |
2022-04-06 |
Ксенон Фармасьютикалз Инк. |
Соединения бензолсульфонамида и их применение в качестве терапевтических средств
|
US10919914B2
(en)
|
2016-06-08 |
2021-02-16 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
WO2017222575A1
(en)
|
2016-06-23 |
2017-12-28 |
Collegium Pharmaceutical, Inc. |
Process of making more stable abuse-deterrent oral formulations
|
US10059695B2
(en)
|
2016-06-30 |
2018-08-28 |
Gilead Sciences, Inc. |
Cot modulators and methods of use thereof
|
WO2018002673A1
(en)
|
2016-07-01 |
2018-01-04 |
N4 Pharma Uk Limited |
Novel formulations of angiotensin ii receptor antagonists
|
MX2019000721A
(es)
|
2016-07-18 |
2019-06-10 |
Pharmena S A |
1-metilnicotinamida para el tratamiento de enfermedades asociadas con la proteína c reactiva.
|
JOP20190008A1
(ar)
|
2016-07-26 |
2019-01-24 |
Purdue Pharma Lp |
علاج ومنع اضطرابات النوم
|
JP2019523279A
(ja)
|
2016-07-29 |
2019-08-22 |
サノビオン ファーマシューティカルズ インクSunovion Pharmaceuticals Inc. |
化合物および組成物ならびにそれらの使用
|
MX2019000980A
(es)
|
2016-07-29 |
2019-07-04 |
Sunovion Pharmaceuticals Inc |
Compuestos y composiciones y usos de los mismos.
|
CN109862896A
(zh)
|
2016-08-03 |
2019-06-07 |
西玛贝医药公司 |
用于治疗炎症性胃肠疾病或胃肠病症的氧亚甲基芳基化合物
|
WO2018049080A1
(en)
|
2016-09-07 |
2018-03-15 |
Fgh Biotech, Inc. |
Di-substituted pyrazole compounds for the treatment of diseases
|
US10736905B1
(en)
|
2016-09-09 |
2020-08-11 |
Shahin Fatholahi |
Nefopam dosage forms and methods of treatment
|
EP3512519A1
(en)
|
2016-09-14 |
2019-07-24 |
Gilead Sciences, Inc. |
Syk inhibitors
|
TW201822764A
(zh)
|
2016-09-14 |
2018-07-01 |
美商基利科學股份有限公司 |
Syk抑制劑
|
SG10202102845XA
(en)
|
2016-09-19 |
2021-05-28 |
Mei Pharma Inc |
Combination therapy
|
TW201825465A
(zh)
|
2016-09-23 |
2018-07-16 |
美商基利科學股份有限公司 |
磷脂醯肌醇3-激酶抑制劑
|
TW201813963A
(zh)
|
2016-09-23 |
2018-04-16 |
美商基利科學股份有限公司 |
磷脂醯肌醇3-激酶抑制劑
|
WO2018057808A1
(en)
|
2016-09-23 |
2018-03-29 |
Gilead Sciences, Inc. |
Benzimidazole derivatives and their use as phosphatidylinositol 3-kinase inhibitors
|
US20200016202A1
(en)
|
2016-10-07 |
2020-01-16 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
WO2018069312A1
(en)
|
2016-10-11 |
2018-04-19 |
Deutsches Zentrum Für Neurodegenerative Erkrankungen E. V. (Dzne) |
Treatment of synucleinopathies
|
WO2018071814A1
(en)
|
2016-10-14 |
2018-04-19 |
The Trustees Of Columbia University In The City Of New York |
Methods of treating alcohol abuse disorder
|
BR112019007453A2
(pt)
|
2016-10-14 |
2019-07-16 |
Epicentrx Inc |
organonitro de sulfoxialquila e compostos relacionados e composições farmacêuticas para uso em medicina
|
CN110072522A
(zh)
|
2016-10-21 |
2019-07-30 |
美国大仁医疗有限公司 |
提高癌细胞对顺铂的敏感性的物质和方法
|
JP7204643B2
(ja)
|
2016-10-24 |
2023-01-16 |
オリオニス バイオサイエンシズ ビーブイ |
標的変異インターフェロン-ガンマおよびその使用
|
PT3534885T
(pt)
|
2016-11-03 |
2021-04-13 |
Kura Oncology Inc |
Inibidores de farnesiltransferase para usar em métodos de tratamento do cancro
|
WO2018089427A1
(en)
|
2016-11-09 |
2018-05-17 |
Novomedix, Llc |
Nitrite salts of 1, 1-dimethylbiguanide, pharmaceutical compositions, and methods of use
|
US10106521B2
(en)
|
2016-11-09 |
2018-10-23 |
Phloronol, Inc. |
Eckol derivatives, methods of synthesis and uses thereof
|
JP7105797B2
(ja)
|
2016-11-28 |
2022-07-25 |
プラクシス プレシジョン メディシンズ, インコーポレイテッド |
化合物及びその使用方法
|
US11261188B2
(en)
|
2016-11-28 |
2022-03-01 |
Praxis Precision Medicines, Inc. |
Fused heteroaryl compounds, and methods thereof for treating diseases, disorders, and conditions relating to aberrant function of a sodium channel
|
AR110252A1
(es)
|
2016-11-30 |
2019-03-13 |
Gilead Sciences Inc |
Compuestos heterocíclicos fusionados como inhibidores de la quinasa cam
|
CN110191705A
(zh)
|
2016-12-01 |
2019-08-30 |
亚尼塔公司 |
治疗癌症的方法
|
TW201827051A
(zh)
|
2016-12-02 |
2018-08-01 |
美商神經性分泌生物科學公司 |
戊苯那嗪(valbenazine)於治療精神分裂症或情感性精神分裂症之用途
|
WO2018106738A1
(en)
|
2016-12-05 |
2018-06-14 |
Massachusetts Institute Of Technology |
Brush-arm star polymers, conjugates and particles, and uses thereof
|
WO2018106284A1
(en)
|
2016-12-09 |
2018-06-14 |
Xenon Pharmaceuticals Inc. |
Benzenesulfonamide compounds and their use as therapeutic agents
|
US10784877B2
(en)
|
2016-12-21 |
2020-09-22 |
Johnson & Johnson Vision Care, Inc. |
Extended period timer circuits for ophthalmic devices
|
WO2018115888A1
(en)
|
2016-12-21 |
2018-06-28 |
N4 Pharma Uk Limited |
Novel formulations of aprepitant
|
JP7514621B2
(ja)
|
2017-01-04 |
2024-07-11 |
リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル |
Dnabiiワクチンおよび強化された活性を有する抗体
|
CA3049114A1
(en)
|
2017-01-04 |
2018-07-12 |
Lauren O. Bakaletz |
Antibody fragments for the treatment of biofilm-related disorders
|
EA201991780A1
(ru)
|
2017-01-27 |
2021-10-26 |
Нейрокрин Байосайенсиз, Инк. |
Способы введения некоторых vmat2-ингибиторов
|
WO2018140671A1
(en)
|
2017-01-27 |
2018-08-02 |
Celgene Corporation |
3-(1-oxo-4-((4-((3-oxomorpholino) methyl)benzyl)oxy)isoindolin-2-yl)piperidine-2,6-dione and isotopologues thereof
|
US10906985B2
(en)
|
2017-02-06 |
2021-02-02 |
Orionis Biosciences, Inc. |
Targeted engineered interferon and uses thereof
|
US10889587B2
(en)
|
2017-02-06 |
2021-01-12 |
Spero Therapeutics, Inc. |
Tebipenem pivoxil crystalline forms, compositions including the same, methods of manufacture, and methods of use
|
JOP20180009A1
(ar)
|
2017-02-06 |
2019-01-30 |
Gilead Sciences Inc |
مركبات مثبط فيروس hiv
|
WO2018141964A1
(en)
|
2017-02-06 |
2018-08-09 |
Orionis Biosciences Nv |
Targeted chimeric proteins and uses thereof
|
WO2018146074A1
(en)
|
2017-02-07 |
2018-08-16 |
Vib Vzw |
Immune-cell targeted bispecific chimeric proteins and uses thereof
|
WO2018148745A1
(en)
|
2017-02-13 |
2018-08-16 |
Praxis Precision Medicines , Inc. |
Compounds and their methods of use
|
JP7146782B2
(ja)
|
2017-02-16 |
2022-10-04 |
サノビオン ファーマシューティカルズ インク |
統合失調症を処置する方法
|
US10137121B2
(en)
|
2017-02-21 |
2018-11-27 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
EP4119142A1
(en)
|
2017-02-21 |
2023-01-18 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
WO2018157163A1
(en)
|
2017-02-27 |
2018-08-30 |
Shattuck Labs, Inc. |
Vsig8-based chimeric proteins
|
WO2018164996A1
(en)
|
2017-03-06 |
2018-09-13 |
Neurocrine Biosciences, Inc. |
Dosing regimen for valbenazine
|
US20180258064A1
(en)
|
2017-03-07 |
2018-09-13 |
Celgene Corporation |
Solid forms of 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses
|
EP3595663A4
(en)
|
2017-03-17 |
2021-01-13 |
Elysium Therapeutics, Inc. |
MULTI-UNIT OPIOID MEDICINES RESISTANT TO OVERDOSE AND ABUSE
|
EP3601326A4
(en)
|
2017-03-20 |
2020-12-16 |
The Broad Institute, Inc. |
COMPOUNDS AND METHODS OF REGULATING INSULIN SECRETION
|
WO2018178973A1
(en)
|
2017-03-26 |
2018-10-04 |
Mapi Pharma Ltd. |
Glatiramer depot systems for treating progressive forms of multiple sclerosis
|
MX2019010060A
(es)
|
2017-03-27 |
2019-10-21 |
Univ California |
Composiciones y metodo para tratar cancer.
|
WO2018183781A1
(en)
|
2017-03-29 |
2018-10-04 |
Siteone Therapeutics, Inc. |
11,13-modified saxitoxins for the treatment of pain
|
WO2018183782A1
(en)
|
2017-03-29 |
2018-10-04 |
Siteone Therapeutics, Inc. |
11,13-modified saxitoxins for the treatment of pain
|
WO2018187480A1
(en)
|
2017-04-04 |
2018-10-11 |
Praxis Precision Medicines, Inc. |
Compounds and their methods of use
|
WO2018195471A1
(en)
|
2017-04-21 |
2018-10-25 |
Gilead Sciences, Inc. |
Syk inhibitors in combination with hypomethylating agents
|
US20200179352A1
(en)
|
2017-04-26 |
2020-06-11 |
Neurocrine Biosciences, Inc. |
Use of valbenazine for treating levodopa-induced dyskinesia
|
JOP20190219A1
(ar)
|
2017-05-09 |
2019-09-22 |
Cardix Therapeutics LLC |
تركيبات صيدلانية وطرق لعلاج أمراض القلب والأوعية الدموية
|
US10085999B1
(en)
|
2017-05-10 |
2018-10-02 |
Arixa Pharmaceuticals, Inc. |
Beta-lactamase inhibitors and uses thereof
|
KR102659322B1
(ko)
|
2017-05-19 |
2024-04-22 |
엔플렉션 테라퓨틱스, 인코포레이티드 |
피부병 치료를 위한 융합된 헤테로방향족-아닐린 화합물
|
WO2018213810A1
(en)
|
2017-05-19 |
2018-11-22 |
Nflection Therapeutics, Inc. |
Pyrrolopyridine-aniline compounds for treatment of dermal disorders
|
US20200155526A1
(en)
|
2017-05-31 |
2020-05-21 |
The Children's Medical Center Corporation |
Targeting lysine demethylases (kdms) as a therapeutic strategy for diffuse large b-cell lymphoma
|
WO2018223065A1
(en)
|
2017-06-01 |
2018-12-06 |
Xoc Pharmaceuticals, Inc. |
Ergoline derivatives for use in medicine
|
US11400136B2
(en)
|
2017-06-19 |
2022-08-02 |
President And Fellows Of Harvard College |
Methods and compositions for treating a microbial infection
|
WO2019005874A1
(en)
|
2017-06-26 |
2019-01-03 |
The Trustees Of Columbia University In The City Of New York |
CHOLINERGIC AGONISM FOR THE TREATMENT OF PANCREATIC CANCER
|
IL271777B2
(en)
|
2017-07-07 |
2024-09-01 |
Epicentrx Inc |
Preparations for intravenous administration of medical substances
|
WO2019014398A1
(en)
|
2017-07-11 |
2019-01-17 |
Actym Therapeutics, Inc. |
MODIFIED IMMUNOSTIMULATORY BACTERIAL STRAINS AND USES THEREOF
|
MX2020000523A
(es)
|
2017-08-02 |
2020-08-20 |
Sunovion Pharmaceuticals Inc |
Compuestos de isocromano y usos de los mismos.
|
MX2020001207A
(es)
|
2017-08-07 |
2020-03-20 |
Kura Oncology Inc |
Metodos de tratamiento del cancer con inhibidores de farnesiltransferasa.
|
US10806730B2
(en)
|
2017-08-07 |
2020-10-20 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
WO2019035951A1
(en)
|
2017-08-15 |
2019-02-21 |
Praxis Precision Medicines, Inc. |
COMPOUNDS AND THEIR METHODS OF USE
|
AR112412A1
(es)
|
2017-08-17 |
2019-10-23 |
Gilead Sciences Inc |
Formas de sal de colina de un inhibidor de la cápside del vih
|
TW202024061A
(zh)
|
2017-08-17 |
2020-07-01 |
美商基利科學股份有限公司 |
Hiv蛋白質膜抑制劑之固體形式
|
CN111051305A
(zh)
|
2017-08-22 |
2020-04-21 |
吉利德科学公司 |
治疗性杂环化合物
|
US11446311B2
(en)
|
2017-09-08 |
2022-09-20 |
Shahin Fatholahi |
Methods for treating pain associated with sickle cell disease
|
US10736874B1
(en)
|
2017-09-08 |
2020-08-11 |
Shahin Fatholahi |
Methods for treating pain associated with sickle cell disease
|
IL273300B2
(en)
|
2017-09-21 |
2024-06-01 |
Neurocrine Biosciences Inc |
High dose valbenazine formulation and related preparations, methods and kits
|
EP3691658A4
(en)
|
2017-10-04 |
2021-06-23 |
The Regents of The University of California |
IMMUNOMODULATOR OLIGOSACCHARIDES
|
US10993941B2
(en)
|
2017-10-10 |
2021-05-04 |
Neurocrine Biosciences, Inc. |
Methods for the administration of certain VMAT2 inhibitors
|
JP2021502959A
(ja)
|
2017-10-10 |
2021-02-04 |
ニューロクライン バイオサイエンシーズ,インコーポレイテッド |
特定のvmat2インヒビターを投与するための方法
|
JOP20180092A1
(ar)
|
2017-10-13 |
2019-04-13 |
Gilead Sciences Inc |
مثبطات hiv بروتياز
|
US20200340060A1
(en)
|
2017-11-13 |
2020-10-29 |
Gilead Sciences, Inc. |
Compositions and methods for identifying and treating liver diseases and monitoring treatment outcomes
|
WO2019097080A1
(en)
|
2017-11-20 |
2019-05-23 |
Kiakos Konstantinos |
3,5-diarylidenyl-n-substituted-piperid-4-one-derived inhibitors of stat3 pathway acitivty and uses therof
|
WO2019113269A1
(en)
|
2017-12-08 |
2019-06-13 |
Kura Oncology, Inc. |
Methods of treating cancer patients with farnesyltransferase inhibitors
|
CA3088630A1
(en)
|
2017-12-15 |
2019-06-20 |
Solarea Bio, Inc. |
Microbial compositions and methods for treating type 2 diabetes, obesity, and metabolic syndrome
|
US11708335B2
(en)
|
2017-12-18 |
2023-07-25 |
Sterngreene, Inc. |
Pyrimidine compounds useful as tyrosine kinase inhibitors
|
EP3749324A4
(en)
|
2017-12-28 |
2022-03-09 |
Reviva Pharmaceuticals Inc. |
METHODS OF TREATMENT OF LUNG FIBROSIS
|
US11510901B2
(en)
|
2018-01-08 |
2022-11-29 |
Epicentrx, Inc. |
Methods and compositions utilizing RRx-001 combination therapy for radioprotection
|
EP3737382A1
(en)
|
2018-01-10 |
2020-11-18 |
Cura Therapeutics, LLC |
Pharmaceutical compositions comprising phenylsulfonamides, and their therapeutic applications
|
TW201929847A
(zh)
|
2018-01-10 |
2019-08-01 |
美商克拉治療有限責任公司 |
包含二羧酸之醫藥組合物及其治療應用
|
JP7108041B2
(ja)
|
2018-01-24 |
2022-07-27 |
パーデュー、ファーマ、リミテッド、パートナーシップ |
睡眠障害の治療及び予防
|
CA3090406A1
(en)
|
2018-02-05 |
2019-08-08 |
Orionis Biosciences, Inc. |
Fibroblast binding agents and use thereof
|
AU2019217207A1
(en)
|
2018-02-12 |
2020-08-27 |
Diabetes-Free, Inc. |
Improved antagonistic anti-human CD40 monoclonal antibodies
|
US10836746B2
(en)
|
2018-02-15 |
2020-11-17 |
Gilead Sciences, Inc. |
Therapeutic compounds
|
CA3175384A1
(en)
|
2018-02-16 |
2019-08-22 |
Gilead Sciences, Inc. |
Methods and intermediates for preparing therapeutic compounds useful in the treatment of retroviridae viral infection
|
WO2019161236A1
(en)
|
2018-02-16 |
2019-08-22 |
Sunovion Pharmaceuticals Inc. |
Methods of treating social function disorders
|
MX2020008527A
(es)
|
2018-02-16 |
2020-09-18 |
Esperion Therapeutics Inc |
Formulaciones de liberacion sostenida de acido bempedoico.
|
CA3090807A1
(en)
|
2018-02-21 |
2019-08-29 |
AI Therapeutics, Inc. |
Combination therapy with apilimod and glutamatergic agents
|
JP7044416B2
(ja)
|
2018-02-28 |
2022-03-30 |
シャンハイ ダブリュディー ファーマシューティカル カンパニー,リミティド |
薬物組成物およびその製造方法と使用
|
US11613517B2
(en)
|
2018-03-02 |
2023-03-28 |
Oregon Health & Science University |
Amide prodrugs of small molecule nuclear receptor modulators
|
WO2019182683A1
(en)
|
2018-03-22 |
2019-09-26 |
The Children's Medical Center Corporation |
Methods and compositions relating to lung repair
|
WO2019222435A1
(en)
|
2018-05-16 |
2019-11-21 |
Halozyme, Inc. |
Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
|
JP7125791B2
(ja)
|
2018-05-23 |
2022-08-25 |
シャンハイ ダブリュディー ファーマシューティカル カンパニー,リミティド |
活性薬物成分の放出制御システムおよびその製造方法
|
US11911513B2
(en)
|
2018-05-23 |
2024-02-27 |
Shanghai Wd Pharmaceutical Co., Ltd |
Controlled-release system of active pharmaceutical ingredient and preparation method therefor
|
AU2019278814A1
(en)
|
2018-05-30 |
2020-12-17 |
Praxis Precision Medicines, Inc. |
Ion channel modulators
|
CN112262142B
(zh)
|
2018-06-13 |
2023-11-14 |
泽农医药公司 |
苯磺酰胺化合物及其作为治疗剂的用途
|
WO2019241555A1
(en)
|
2018-06-14 |
2019-12-19 |
Neurocrine Biosciences, Inc. |
Vmat2 inhibitor compounds, compositions, and methods relating thereto
|
WO2020006341A1
(en)
|
2018-06-29 |
2020-01-02 |
Conatus Pharmaceuticals, Inc. |
(s)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid derivatives and related compounds as caspase inhibitors for treating cardiovascular diseases
|
US11186579B2
(en)
|
2018-07-06 |
2021-11-30 |
Gilead Sciences, Inc. |
Therapeutic heterocyclic compounds
|
EP3818052A1
(en)
|
2018-07-06 |
2021-05-12 |
Gilead Sciences, Inc. |
Therapeutic heterocyclic compounds
|
JP7340591B2
(ja)
|
2018-07-11 |
2023-09-07 |
アクティム・セラピューティクス・インコーポレイテッド |
遺伝子操作された免疫刺激性細菌菌株およびその使用
|
US20210299233A1
(en)
|
2018-07-12 |
2021-09-30 |
The Children's Medical Center Corporation |
Method for treating cancer
|
CN112423750A
(zh)
|
2018-07-16 |
2021-02-26 |
吉利德科学公司 |
用于治疗hiv的衣壳抑制剂
|
US20200030260A1
(en)
|
2018-07-27 |
2020-01-30 |
Xenon Pharmaceuticals Inc. |
Method for treating epilepsy
|
TWI829205B
(zh)
|
2018-07-30 |
2024-01-11 |
美商基利科學股份有限公司 |
抗hiv化合物
|
EP3814344B1
(en)
|
2018-08-07 |
2024-07-24 |
Firmenich Incorporated |
5-substituted 4-amino-1h-benzo[c][1,2,6]thiadiazine 2,2-dioxides and formulations and uses thereof
|
JP2021528481A
(ja)
|
2018-08-15 |
2021-10-21 |
ニューロクライン バイオサイエンシーズ,インコーポレイテッド |
特定のvmat2阻害剤を投与するための方法
|
CN112912141A
(zh)
|
2018-08-27 |
2021-06-04 |
斯皮诺吉尼克斯公司 |
用于树突棘生成的肌成束蛋白结合化合物
|
WO2020046753A1
(en)
|
2018-08-27 |
2020-03-05 |
Oregon Health & Science University |
Parp inhibitors for treating cancer and asthma
|
US11242528B2
(en)
|
2018-08-28 |
2022-02-08 |
Actym Therapeutics, Inc. |
Engineered immunostimulatory bacterial strains and uses thereof
|
CN112839952A
(zh)
|
2018-08-29 |
2021-05-25 |
沙塔克实验室有限公司 |
包含基于pd-1的嵌合蛋白的组合疗法
|
EP3844158A1
(en)
|
2018-08-31 |
2021-07-07 |
Xenon Pharmaceuticals Inc. |
Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors
|
CR20210099A
(es)
|
2018-08-31 |
2021-06-24 |
Xenon Pharmaceuticals Inc |
Compuestos de sulfonamida sustituidos con heteroarilo y su uso como agentes terapèuticos
|
CA3111795A1
(en)
|
2018-09-05 |
2020-03-12 |
Solarea Bio, Inc. |
Methods and compositions for treating musculoskeletal diseases
|
US11980647B2
(en)
|
2018-09-05 |
2024-05-14 |
Solarea Bio, Inc. |
Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
|
EP3860975B1
(en)
|
2018-10-01 |
2023-10-18 |
Global Blood Therapeutics, Inc. |
Modulators of hemoglobin for the treatment of sickle cell disease
|
EP3860717A1
(en)
|
2018-10-03 |
2021-08-11 |
Gilead Sciences, Inc. |
Imidozopyrimidine derivatives
|
WO2020072835A1
(en)
|
2018-10-03 |
2020-04-09 |
Siteone Therapeutics, Inc. |
11,13-modified saxitoxins for the treatment of pain
|
SG11202103839UA
(en)
|
2018-10-31 |
2021-05-28 |
Gilead Sciences Inc |
Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
|
AU2019373221B2
(en)
|
2018-10-31 |
2022-05-26 |
Gilead Sciences, Inc. |
Substituted 6-azabenzimidazole compounds having HPK1 inhibitory activity
|
JP2022506463A
(ja)
|
2018-11-01 |
2022-01-17 |
クラ オンコロジー, インコーポレイテッド |
ファルネシルトランスフェラーゼ阻害剤でがんを治療する方法
|
US10570127B1
(en)
|
2018-11-05 |
2020-02-25 |
Renexxion, Llc |
Material and methods for the treatment of gastro-intestinal disorders
|
WO2020102454A1
(en)
|
2018-11-13 |
2020-05-22 |
Regents Of The University Of Minnesota |
Cd40 targeted peptides and uses thereof
|
US10722473B2
(en)
|
2018-11-19 |
2020-07-28 |
Purdue Pharma L.P. |
Methods and compositions particularly for treatment of attention deficit disorder
|
CR20210335A
(es)
|
2018-11-19 |
2021-09-14 |
Global Blood Therapeutics Inc |
Compuestos de 2-formil-3-hidroxifeniloximetilo capaces de modular la hemoglobina
|
US11572344B2
(en)
|
2018-11-20 |
2023-02-07 |
Nflection Therapeutics, Inc. |
Cyanoaryl-aniline compounds for treatment of dermal disorders
|
JP7393808B2
(ja)
|
2018-11-20 |
2023-12-07 |
エヌフレクション セラピューティクス インコーポレイテッド |
皮膚障害の処置のためのナフチリジノン-アニリン化合物
|
US20220087989A1
(en)
|
2018-11-20 |
2022-03-24 |
Nflection Therapeutics, Inc. |
Aryl-aniline and heteroaryl-aniline compounds for treatment of skin cancers
|
MA55148A
(fr)
|
2018-11-20 |
2021-09-29 |
Nflection Therapeutics Inc |
Composés d'aryl-aniline et d'hétéroaryl-aniline pour le traitement de marques de naissance
|
CN113454216A
(zh)
|
2018-11-29 |
2021-09-28 |
旗舰先锋创新V股份有限公司 |
调节rna的方法
|
US11827596B2
(en)
|
2018-12-12 |
2023-11-28 |
Autobahn Therapeutics, Inc. |
Thyromimetics
|
WO2020123850A1
(en)
|
2018-12-13 |
2020-06-18 |
Global Blood Therapeutics, Inc. |
Ferroportin inhibitors and methods of use
|
US20230078755A1
(en)
|
2018-12-19 |
2023-03-16 |
Shy Therapeutics, Llc |
Compounds that Interact with the RAS Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease
|
EP3897638A1
(en)
|
2018-12-21 |
2021-10-27 |
Kura Oncology, Inc. |
Therapies for squamous cell carcinomas
|
WO2020132700A1
(en)
|
2018-12-21 |
2020-06-25 |
Fgh Biotech Inc. |
Methods of using inhibitors of srebp in combination with niclosamide and analogs thereof
|
EP3921038A1
(en)
|
2019-02-06 |
2021-12-15 |
Dice Alpha, Inc. |
Il-17a modulators and uses thereof
|
WO2020163637A1
(en)
|
2019-02-06 |
2020-08-13 |
Oregon Health & Science University |
Bisphosphonate-linked compounds
|
EP3924352A4
(en)
|
2019-02-11 |
2022-11-16 |
Phoenix Molecular Designs |
CRYSTALLINE FORMS OF AN RSK INHIBITOR
|
JP2022521413A
(ja)
|
2019-02-22 |
2022-04-07 |
クロノス バイオ インコーポレイテッド |
Syk阻害剤としての縮合ピラジンの固体形態
|
WO2020176510A1
(en)
|
2019-02-25 |
2020-09-03 |
Gilead Sciences, Inc. |
Protein kinase c agonists
|
WO2020176505A1
(en)
|
2019-02-25 |
2020-09-03 |
Gilead Sciences, Inc. |
Protein kinase c agonists
|
WO2020176424A1
(en)
|
2019-02-25 |
2020-09-03 |
Chdi Foundation, Inc. |
Compounds for targeting mutant huntingtin protein and uses thereof
|
US12024709B2
(en)
|
2019-02-27 |
2024-07-02 |
Actym Therapeutics, Inc. |
Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
|
SG11202108459QA
(en)
|
2019-02-27 |
2021-09-29 |
Actym Therapeutics Inc |
Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
|
WO2020180663A1
(en)
|
2019-03-01 |
2020-09-10 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
EP3931180A1
(en)
|
2019-03-01 |
2022-01-05 |
Autobahn Therapeutics, Inc. |
Novel thyromimetics
|
AU2020231396A1
(en)
|
2019-03-07 |
2021-10-21 |
Nobo Medicine Inc. |
Caspase inhibitors and methods of use thereof
|
US11136304B2
(en)
|
2019-03-14 |
2021-10-05 |
Sunovion Pharmaceuticals Inc. |
Salts of a heterocyclic compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof
|
US20220143006A1
(en)
|
2019-03-15 |
2022-05-12 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
JP2022524887A
(ja)
|
2019-03-22 |
2022-05-10 |
ドイチェス クレブスフォルシュングスツェントルム |
ヒストンデアセチラーゼ10の新規の阻害剤
|
US11000488B2
(en)
|
2019-03-22 |
2021-05-11 |
Syntrix Biosystems Inc. |
Treating pain using desmetramadol
|
EP3712127A1
(en)
|
2019-03-22 |
2020-09-23 |
Deutsches Krebsforschungszentrum |
Novel inhibitors of histone deacetylase 10
|
KR20210144778A
(ko)
|
2019-03-29 |
2021-11-30 |
쿠라 온콜로지, 인크. |
파르네실트랜스퍼라제 억제제를 사용한 편평 세포 암종의 치료 방법
|
WO2020205387A1
(en)
|
2019-04-01 |
2020-10-08 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
WO2020205409A1
(en)
|
2019-04-03 |
2020-10-08 |
President And Fellows Of Harvard College |
Ionic liquids for drug delivery
|
TW202104210A
(zh)
|
2019-04-17 |
2021-02-01 |
美商基利科學股份有限公司 |
Hiv蛋白酶抑制劑
|
TWI751517B
(zh)
|
2019-04-17 |
2022-01-01 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
TWI751516B
(zh)
|
2019-04-17 |
2022-01-01 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
WO2020223583A1
(en)
|
2019-05-02 |
2020-11-05 |
Kura Oncology, Inc. |
Methods of treating acute myeloid leukemia with farnesyltransferase inhibitors
|
SG11202112158YA
(en)
|
2019-05-03 |
2021-12-30 |
Praxis Prec Medicines Inc |
Kcnt1 inhibitors and methods of use
|
WO2020237025A1
(en)
|
2019-05-23 |
2020-11-26 |
Gilead Sciences, Inc. |
Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
|
US11773099B2
(en)
|
2019-05-28 |
2023-10-03 |
Praxis Precision Medicines, Inc. |
Compounds and their methods of use
|
US11279700B2
(en)
|
2019-05-31 |
2022-03-22 |
Praxis Precision Medicines, Inc. |
Ion channel modulators
|
US11505554B2
(en)
|
2019-05-31 |
2022-11-22 |
Praxis Precision Medicines, Inc. |
Substituted pyridines as ion channel modulators
|
WO2020246503A1
(ja)
|
2019-06-03 |
2020-12-10 |
株式会社大分大学先端医学研究所 |
狂犬病治療のための環状アミド化合物およびその方法
|
TW202235416A
(zh)
|
2019-06-14 |
2022-09-16 |
美商基利科學股份有限公司 |
Cot 調節劑及其使用方法
|
EP3986163A2
(en)
|
2019-06-19 |
2022-04-27 |
Solarea Bio, Inc. |
Microbial compositions and methods for producing upgraded probiotic assemblages
|
KR20220032066A
(ko)
|
2019-07-08 |
2022-03-15 |
더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 |
생물막을 파괴하기 위한 항체 조성물
|
CA3146157A1
(en)
|
2019-07-11 |
2021-01-14 |
Cura Therapeutics, Llc |
Sulfone compounds and pharmaceutical compositions thereof, and their therapeutic applications for the treatment of neurodegenerative diseases
|
US20220274921A1
(en)
|
2019-07-11 |
2022-09-01 |
Cura Therapeutics, Llc |
Phenyl compounds and pharmaceutical compositions thereof, and their therapeutic applications
|
US20220241258A1
(en)
|
2019-07-11 |
2022-08-04 |
Praxis Precision Medicines, Inc. |
Formulations of t-type calcium channel modulators and methods of use thereof
|
EP4003314B1
(en)
|
2019-07-26 |
2024-07-10 |
Espervita Therapeutics, Inc. |
Functionalized long-chain hydrocarbon mono- and di-carboxylic acids useful for the prevention or treatment of disease
|
US10792262B1
(en)
|
2019-07-29 |
2020-10-06 |
Saol International Limited |
Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives
|
US11654124B2
(en)
|
2019-07-29 |
2023-05-23 |
Amneal Pharmaceuticals Llc |
Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives
|
US10940141B1
(en)
|
2019-08-23 |
2021-03-09 |
Neurocrine Biosciences, Inc. |
Methods for the administration of certain VMAT2 inhibitors
|
CN115551530A
(zh)
|
2019-08-27 |
2022-12-30 |
通尼克斯制药有限公司 |
经修饰的tff2多肽
|
AU2020348685A1
(en)
|
2019-09-16 |
2022-04-14 |
Dice Alpha, Inc. |
IL-17A modulators and uses thereof
|
EP4034532A1
(en)
|
2019-09-26 |
2022-08-03 |
Exelixis, Inc. |
Pyridone compounds and methods of use in the modulation of a protein kinase
|
US20230008367A1
(en)
|
2019-09-26 |
2023-01-12 |
Abionyx Pharma Sa |
Compounds useful for treating liver diseases
|
CA3151626A1
(en)
|
2019-10-01 |
2021-04-08 |
Molecular Skin Therapeutics, Inc. |
Benzoxazinone compounds as klk5/7 dual inhibitors
|
TW202128627A
(zh)
|
2019-10-10 |
2021-08-01 |
加拿大商再諾製藥公司 |
選擇性鉀通道調節劑之固態晶型
|
KR20220097442A
(ko)
|
2019-11-01 |
2022-07-07 |
기안알엑스 사이언스 인코포레이티드 |
글리콜레이트 산화효소 억제제로서의 헤테로사이클릭 카르복실레이트 화합물
|
AU2020382614A1
(en)
|
2019-11-12 |
2022-06-02 |
Actym Therapeutics, Inc. |
Immunostimulatory bacteria delivery platforms and their use for delivery of therapeutic products
|
MX2022005795A
(es)
|
2019-11-13 |
2022-06-08 |
Rapt Therapeutics Inc |
Formas cristalinas del antagonista del receptor de quimiocinas cc tipo 4 y usos de las mismas.
|
EP4061338A1
(en)
|
2019-11-22 |
2022-09-28 |
President And Fellows Of Harvard College |
Ionic liquids for drug delivery
|
EP4065116A1
(en)
|
2019-11-26 |
2022-10-05 |
Gilead Sciences, Inc. |
Capsid inhibitors for the prevention of hiv
|
CN115038442A
(zh)
|
2019-11-27 |
2022-09-09 |
普拉西斯精密医药公司 |
离子通道调节剂的调配物及制备和使用离子通道调节剂的方法
|
WO2021113212A1
(en)
|
2019-12-02 |
2021-06-10 |
Celgene Corporation |
Therapy for the treatment of cancer
|
US20230151003A1
(en)
|
2020-02-24 |
2023-05-18 |
Exelixis, Inc. |
Compounds and methods of use
|
JP7453399B2
(ja)
|
2020-02-24 |
2024-03-19 |
ギリアード サイエンシーズ, インコーポレイテッド |
Hiv感染症を治療するための四環式化合物及びその使用
|
MX2022010625A
(es)
|
2020-02-28 |
2022-10-27 |
Praxis Prec Medicines Inc |
Inhibidores de kcnt1 y metodos de uso.
|
US20230093147A1
(en)
|
2020-03-09 |
2023-03-23 |
President And Fellows Of Harvard College |
Methods and compositions relating to improved combination therapies
|
US11655237B2
(en)
|
2020-03-30 |
2023-05-23 |
Gilead Sciences, Inc. |
Solid forms of a Cot inhibitor compound
|
BR112022019423A2
(pt)
|
2020-03-31 |
2022-12-06 |
Global Blood Therapeutics Inc |
Moduladores de hemoglobina
|
EP4126876A1
(en)
|
2020-04-01 |
2023-02-08 |
Global Blood Therapeutics, Inc. |
Pyrrolidine-pyrazoles as pyruvate kinase activators
|
AU2021245924B2
(en)
|
2020-04-02 |
2024-02-29 |
Gilead Sciences, Inc. |
Process for preparing a Cot inhibitor compound
|
CA3181583A1
(en)
|
2020-04-28 |
2021-11-04 |
Global Blood Therapeutics, Inc. |
Methods of use for pyrimidines as ferroportin inhibitors
|
US20230159553A1
(en)
|
2020-04-28 |
2023-05-25 |
Global Blood Therapeutics, Inc |
Thieno pyrimidines as ferroportin inhibitors
|
EP4142787A1
(en)
|
2020-04-28 |
2023-03-08 |
President And Fellows Of Harvard College |
Methods and compositions relating to ionic liquid adjuvants
|
AU2021263818A1
(en)
|
2020-04-28 |
2022-11-03 |
Global Blood Therapeutics, Inc. |
Cycloalkyl pyrimidines as ferroportin inhibitors
|
WO2021226033A1
(en)
|
2020-05-07 |
2021-11-11 |
President And Fellows Of Harvard College |
Hyaluronic acid drug conjugates
|
US11529331B2
(en)
|
2020-05-29 |
2022-12-20 |
Boulder Bioscience Llc |
Methods for improved endovascular thrombectomy using 3,3′-diindolylmethane
|
US20230173095A1
(en)
|
2020-05-29 |
2023-06-08 |
President And Fellows Of Harvard College |
Living cells engineered with polyphenol-functionalized biologically active nanocomplexes
|
PT4153136T
(pt)
|
2020-06-10 |
2024-03-22 |
Auspex Pharmaceuticals Inc |
Formas de dosagem osmótica que compreendem deutetrabenazina e métodos de utilização da mesma
|
US20230227466A1
(en)
|
2020-06-18 |
2023-07-20 |
Shy Therapeutics, Llc |
Substituted thienopyrimidines that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
|
US20230102840A1
(en)
|
2020-06-23 |
2023-03-30 |
President And Fellows Of Harvard College |
Compositions and methods relating to combinatorial hyaluronic acid conjugates
|
WO2021262990A1
(en)
|
2020-06-25 |
2021-12-30 |
Gilead Sciences, Inc. |
Capsid inhibitors for the treatment of hiv
|
US11319313B2
(en)
|
2020-06-30 |
2022-05-03 |
Poxel Sa |
Crystalline forms of deuterium-enriched pioglitazone
|
WO2022006228A1
(en)
|
2020-06-30 |
2022-01-06 |
Prosetta Biosciences, Inc. |
Isoquinoline derivatives, methods of synthesis and uses thereof
|
WO2022008976A1
(en)
|
2020-07-10 |
2022-01-13 |
Institut Pasteur |
Use of gdf11 to diagnose and treat anxiety and depression
|
WO2022031735A1
(en)
|
2020-08-03 |
2022-02-10 |
Global Blood Therapeutics, Inc. |
Urea derivatives as pyruvate kinase activators
|
CA3191433A1
(en)
|
2020-08-12 |
2022-02-17 |
Actym Therapeutics, Inc. |
Immunostimulatory bacteria-based vaccines, therapeutics, and rna delivery platforms
|
IL300626A
(en)
|
2020-08-14 |
2023-04-01 |
Siteone Therapeutics Inc |
Ketone-free inhibitors of NAV1.7 for the treatment of pain
|
US11541009B2
(en)
|
2020-09-10 |
2023-01-03 |
Curemark, Llc |
Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
|
CN116390924A
(zh)
|
2020-09-30 |
2023-07-04 |
吉利德科学公司 |
桥连三环氨基甲酰基吡啶酮化合物及其用途
|
WO2022069701A1
(en)
|
2020-10-01 |
2022-04-07 |
Nogra Pharma Limited |
Methods of treating pulmonary fibrosis
|
TW202233173A
(zh)
|
2020-10-30 |
2022-09-01 |
愛爾蘭商Ds生物製藥有限公司 |
包括15-HETrE之醫藥組合物及其使用方法
|
US11773088B2
(en)
|
2020-11-02 |
2023-10-03 |
Praxis Precision Medicines, Inc. |
KCNT1 inhibitors and methods of use
|
WO2022140326A1
(en)
|
2020-12-22 |
2022-06-30 |
Gilead Sciences, Inc. |
Substituted indole compounds
|
EP4267560A1
(en)
|
2020-12-22 |
2023-11-01 |
Gilead Sciences, Inc. |
6-substituted indole compounds
|
US20240117033A1
(en)
|
2021-01-15 |
2024-04-11 |
President And Fellows Of Harvard College |
Methods and compositions relating to anti-mfsd2a antibodies
|
US11613546B2
(en)
|
2021-01-19 |
2023-03-28 |
Gilead Sciences, Inc. |
Substituted pyridotriazine compounds and uses thereof
|
US20240115607A1
(en)
|
2021-01-26 |
2024-04-11 |
Cytocares (Shanghai) Inc. |
Chimeric antigen receptor (car) constructs and nk cells expressing car constructs
|
EP4284377A1
(en)
|
2021-01-27 |
2023-12-06 |
Shy Therapeutics LLC |
Methods for the treatment of fibrotic disease
|
US20240309015A1
(en)
|
2021-01-27 |
2024-09-19 |
Shy Therapeutics, Llc |
Methods for the Treatment of Fibrotic Disease
|
WO2022170200A1
(en)
|
2021-02-08 |
2022-08-11 |
Global Blood Therapeutics, Inc. |
1-(2-sulfonyl-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4h)-yl]-ethanone derivatives as pyruvate kinase (pkr) and pkm2 activators for the treatment of sickle cell disease
|
WO2022173722A1
(en)
|
2021-02-09 |
2022-08-18 |
Gilead Sciences, Inc. |
Thienopyrrole compounds
|
CA3211063A1
(en)
|
2021-02-19 |
2022-08-25 |
Exelixis, Inc. |
Pyridone compounds and methods of use
|
WO2022187573A1
(en)
|
2021-03-05 |
2022-09-09 |
President And Fellows Of Harvard College |
Methods and compositions relating to cell membrane hybridization and camouflaging
|
WO2022189856A1
(en)
|
2021-03-08 |
2022-09-15 |
Abionyx Pharma Sa |
Compounds useful for treating liver diseases
|
CR20230472A
(es)
|
2021-03-10 |
2024-03-21 |
Dice Molecules Sv Inc |
Inhibidores de integrina alpha v beta 6 y alpha v beta 1 y sus usos
|
AU2022238403A1
(en)
|
2021-03-19 |
2023-09-21 |
Tiba Biotech Llc |
Artificial alphavirus-derived rna replicon expression systems
|
MX2023012110A
(es)
|
2021-04-16 |
2023-10-24 |
Gilead Sciences Inc |
Compuestos de tienopirrol.
|
WO2022226166A1
(en)
|
2021-04-22 |
2022-10-27 |
Protego Biopharma, Inc. |
Spirocyclic imidazolidinones and imidazolidinediones for treatment of light chain amyloidosis
|
MX2023012156A
(es)
|
2021-05-14 |
2023-10-26 |
Global Blood Therapeutics Inc |
Formas solidas de un modulador de hemoglobina.
|
WO2022251533A1
(en)
|
2021-05-27 |
2022-12-01 |
Protego Biopharma, Inc. |
Heteroaryl diamide ire1/xbp1s activators
|
TW202304435A
(zh)
|
2021-06-04 |
2023-02-01 |
美商基利科學股份有限公司 |
治療nash之方法
|
WO2022265880A1
(en)
|
2021-06-16 |
2022-12-22 |
President And Fellows Of Harvard College |
Improved methods and compositions for drug delivery relating to ionic liquids
|
WO2022266370A1
(en)
|
2021-06-17 |
2022-12-22 |
Aria Pharmaceuticals, Inc. |
Sparsentan for treating idiopathic pulmonary fibrosis
|
TW202311256A
(zh)
|
2021-06-18 |
2023-03-16 |
美商基利科學股份有限公司 |
用於治療fxr誘發之搔癢之il-31調節劑
|
WO2022271537A1
(en)
|
2021-06-25 |
2022-12-29 |
President And Fellows Of Harvard College |
Compositions and methods relating to injectable microemulsions
|
WO2023278843A2
(en)
|
2021-07-02 |
2023-01-05 |
Acer Therapeutics, Inc. |
Solid forms of osanetant
|
WO2023015240A1
(en)
|
2021-08-05 |
2023-02-09 |
Bristol-Myers Squibb Company |
Tricyclic fused pyrimidine compounds for use as her2 inhibitors
|
EP4396578A1
(en)
|
2021-09-01 |
2024-07-10 |
Flagship Pioneering Innovations VI, LLC |
Methods and compositions for promoting adipocyte beiging
|
WO2023034504A1
(en)
|
2021-09-01 |
2023-03-09 |
Flagship Pioneering Innovations Vi, Llc |
Methods and compositions for inducing fetal hemoglobin, modulating erythroid cell lineages, and perturbing megakaryocyte lineages
|
WO2023034507A1
(en)
|
2021-09-01 |
2023-03-09 |
Flagship Pioneering Innovations Vi, Llc |
In vivo and ex vivo methods of modulating t cell exhaustion/de-exhaustion
|
US20230144855A1
(en)
|
2021-09-01 |
2023-05-11 |
Flagship Pioneering Innovations Vi, Llc |
Methods and compositions for inducing fetal hemoglobin
|
WO2023034530A1
(en)
|
2021-09-02 |
2023-03-09 |
Teon Therapeutics, Inc. |
Methods of improving growth and function of immune cells
|
EP4399278A1
(en)
|
2021-09-09 |
2024-07-17 |
Flagship Pioneering Innovations VI, LLC |
Methods and compositions for modulating enteroendocrine cells
|
WO2023039164A2
(en)
|
2021-09-09 |
2023-03-16 |
Flagship Pioneering Innovations Vi, Llc |
Methods and compositions for modulating goblet cells and for muco-obstructive diseases
|
CN117957234A
(zh)
|
2021-09-10 |
2024-04-30 |
吉利德科学公司 |
噻吩并吡咯化合物
|
EP4402281A2
(en)
|
2021-09-14 |
2024-07-24 |
Flagship Pioneering Innovations VI, LLC |
Methods and compositions for perturbing monocyte and neutrophil lineages
|
AU2022349463A1
(en)
|
2021-09-24 |
2024-03-14 |
Xenon Pharmaceuticals Inc. |
Pyridinyl derivatives as sodium channel activators
|
MX2024003645A
(es)
|
2021-09-24 |
2024-06-04 |
Xenon Pharmaceuticals Inc |
Derivados de piridinilacetamida como activadores de canales de sodio.
|
MX2024003647A
(es)
|
2021-09-24 |
2024-05-29 |
Xenon Pharmaceuticals Inc |
Derivados de piridina y su uso como activadores del canal de sodio.
|
WO2023055457A1
(en)
|
2021-09-29 |
2023-04-06 |
Amneal Pharmaceuticals Llc |
Baclofen-containing granule formulations and reduced patient exposure to metabolite variations
|
WO2023060134A1
(en)
|
2021-10-06 |
2023-04-13 |
Global Blood Therapeutics, Inc. |
Lactam pyrrolidine-pyrazoles as pyruvate kinase activators
|
EP4162933A1
(en)
|
2021-10-08 |
2023-04-12 |
Algiax Pharmaceuticals GmbH |
Compound for treating non-alcoholic fatty liver disease and related diseases
|
IL311885A
(en)
|
2021-10-08 |
2024-06-01 |
Harvard College |
Ionic liquids for drug delivery
|
WO2023069770A1
(en)
|
2021-10-22 |
2023-04-27 |
Prosetta Biosciences, Inc. |
Novel host-targeted pan-respiratory antiviral small molecule therapeutics
|
WO2023076404A1
(en)
|
2021-10-27 |
2023-05-04 |
Aria Pharmaceuticals, Inc. |
Methods for treating systemic lupus erythematosus
|
WO2023081730A1
(en)
|
2021-11-03 |
2023-05-11 |
Teon Therapeutics, Inc. |
4-hydroxy-2-oxo-1,2-dihydro-1,8-naphthyridine-3-carboxamide derivatives as cannabinoid cb2 receptor modulators for the treatment of cancer
|
AU2022391767A1
(en)
|
2021-11-22 |
2024-07-04 |
Solarea Bio, Inc. |
Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
|
WO2023097230A1
(en)
|
2021-11-23 |
2023-06-01 |
Genentech, Inc. |
Spirocyclic bicyclic modulators of cholesterol biosynthesis and their use for promoting remyelination
|
WO2023097233A1
(en)
|
2021-11-23 |
2023-06-01 |
Genentech, Inc. |
Spirocyclic cyclic modulators of cholesterol biosynthesis and their use for promoting remyelination
|
CN118510783A
(zh)
|
2021-11-23 |
2024-08-16 |
基因泰克公司 |
胆固醇生物合成的螺环调节剂及其用于促进髓鞘再生的用途
|
TW202327590A
(zh)
|
2021-11-30 |
2023-07-16 |
美商庫拉腫瘤技術股份有限公司 |
大環化合物及組合物以及其製備及使用方法
|
IL312718A
(en)
|
2021-12-03 |
2024-07-01 |
Gilead Sciences Inc |
Therapeutic compounds for HIV infection
|
TW202342447A
(zh)
|
2021-12-03 |
2023-11-01 |
美商基利科學股份有限公司 |
用於hiv病毒感染之治療性化合物
|
CN118355020A
(zh)
|
2021-12-03 |
2024-07-16 |
吉利德科学公司 |
Hiv病毒感染的治疗性化合物
|
KR20240116826A
(ko)
|
2021-12-10 |
2024-07-30 |
글로벌 블러드 테라퓨틱스, 인크. |
헤모글로빈의 조정제의 투여 방법
|
US20230190834A1
(en)
|
2021-12-21 |
2023-06-22 |
Solarea Bio, Inc. |
Immunomodulatory compositions comprising microbial entities
|
EP4433040A2
(en)
|
2022-01-03 |
2024-09-25 |
Lilac Therapeutics, Inc. |
Acyclic thiol prodrugs
|
WO2023129577A1
(en)
|
2022-01-03 |
2023-07-06 |
Lilac Therapeutics, Inc. |
Cyclic thiol prodrugs
|
WO2023137178A1
(en)
|
2022-01-17 |
2023-07-20 |
Chandrasekhar Satishchandran |
Combinations of vitamin d3, niacinamide and lipoic acid for use in the maintenance of healthy blood glucose levels
|
WO2023147135A1
(en)
|
2022-01-31 |
2023-08-03 |
Acer Therapeutics, Inc. |
Nk receptor antagonists for treatment of prostate cancer
|
WO2023147134A2
(en)
|
2022-01-31 |
2023-08-03 |
Acer Therapeutics, Inc. |
Methods for treating patients having low estrogen with nk3 antagonists
|
WO2023168426A1
(en)
|
2022-03-03 |
2023-09-07 |
Enosi Therapeutics Corporation |
Compositions and cells containing mixtures of oligo-trap fusion proteins (ofps) and uses thereof
|
WO2023178283A1
(en)
|
2022-03-18 |
2023-09-21 |
Epicentrx, Inc. |
Co-crystals of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone and methods
|
WO2023192817A1
(en)
|
2022-03-28 |
2023-10-05 |
Isosterix, Inc. |
Inhibitors of the myst family of lysine acetyl transferases
|
TW202342070A
(zh)
|
2022-03-30 |
2023-11-01 |
美商拜奧馬林製藥公司 |
肌萎縮蛋白外顯子跳躍寡核苷酸
|
WO2023192506A1
(en)
|
2022-03-31 |
2023-10-05 |
Rarified Biosciences, Inc. |
Malt1 modulators and uses thereof
|
GB2619907A
(en)
|
2022-04-01 |
2023-12-27 |
Kanna Health Ltd |
Novel crystalline salt forms of mesembrine
|
TWI843506B
(zh)
|
2022-04-06 |
2024-05-21 |
美商基利科學股份有限公司 |
橋聯三環胺甲醯基吡啶酮化合物及其用途
|
TW202406901A
(zh)
|
2022-04-14 |
2024-02-16 |
美商必治妥美雅史谷比公司 |
新穎gspt1化合物以及新穎化合物之使用方法
|
WO2023201348A1
(en)
|
2022-04-15 |
2023-10-19 |
Celgene Corporation |
Methods for predicting responsiveness of lymphoma to drug and methods for treating lymphoma
|
WO2023211990A1
(en)
|
2022-04-25 |
2023-11-02 |
Siteone Therapeutics, Inc. |
Bicyclic heterocyclic amide inhibitors of na v1.8 for the treatment of pain
|
WO2023215229A1
(en)
|
2022-05-02 |
2023-11-09 |
Epicentrx, Inc. |
Compositions and methods for treatment of pulmonary hypertension
|
WO2023215227A1
(en)
|
2022-05-02 |
2023-11-09 |
Epicentrx, Inc. |
Systems and methods to improve exercise tolerance
|
WO2023215220A1
(en)
|
2022-05-02 |
2023-11-09 |
Esperion Therapeutics, Inc. |
Macrocyclic inhibitors of atp citrate lyase
|
WO2023215781A1
(en)
|
2022-05-05 |
2023-11-09 |
Biomarin Pharmaceutical Inc. |
Method of treating duchenne muscular dystrophy
|
WO2023225162A1
(en)
|
2022-05-20 |
2023-11-23 |
Gilead Sciences, Inc. |
Antiviral indolinyl compounds and uses thereof
|
WO2023230524A1
(en)
|
2022-05-25 |
2023-11-30 |
Flagship Pioneering Innovations Vi, Llc |
Compositions of secretory and/or catalytic cells and methods using the same
|
TW202404583A
(zh)
|
2022-06-08 |
2024-02-01 |
加拿大商再諾製藥公司 |
吡啶胺衍生物及其作為鉀通道調節劑之用途
|
WO2023240186A1
(en)
|
2022-06-08 |
2023-12-14 |
Auspex Pharmaceuticals, Inc. |
Osmotic dosage forms comprising deutetrabenazine and methods of use thereof
|
TW202408485A
(zh)
|
2022-06-13 |
2024-03-01 |
美商埃皮辛特瑞科斯公司 |
用於減少癌症治療中不良副作用之組合物及方法
|
WO2023244563A1
(en)
|
2022-06-14 |
2023-12-21 |
Amygdala Neurosciences, Inc. |
Aldh-2 inhibitor compounds and methods of use
|
WO2023244574A1
(en)
|
2022-06-14 |
2023-12-21 |
Amygdala Neurosciences, Inc. |
Aldh-2 inhibitor compounds and methods of use
|
WO2024015827A1
(en)
|
2022-07-12 |
2024-01-18 |
Hotspot Therapeutics, Inc. |
Solid forms of a triazine derivative as cbl-b modulator
|
WO2024015372A1
(en)
|
2022-07-14 |
2024-01-18 |
Teon Therapeutics, Inc. |
Adenosine receptor antagonists and uses thereof
|
WO2024015416A1
(en)
|
2022-07-15 |
2024-01-18 |
Celloram Inc. |
Celastrol derivatives
|
TW202410893A
(zh)
|
2022-08-31 |
2024-03-16 |
日商大塚製藥股份有限公司 |
用於治療t細胞淋巴瘤之結合治療
|
US20240158370A1
(en)
|
2022-09-09 |
2024-05-16 |
Innovo Therapeutics, Inc. |
CK1 alpha AND DUAL CK1 alpha / GSPT1 DEGRADING COMPOUNDS
|
WO2024073473A1
(en)
|
2022-09-30 |
2024-04-04 |
Boulder Bioscience Llc |
Compositions comprising 3,3'-diindolylmethane for treating non-hemorrhagic closed head injury
|
WO2024086246A2
(en)
|
2022-10-18 |
2024-04-25 |
Eluciderm Inc. |
2-substituted 3,4 a, 5, 7, 8, 8 a-hexahydro-4h-thiop yrano [4,3- djpyrimidin-4-ones for wound treatment
|
WO2024091863A1
(en)
|
2022-10-25 |
2024-05-02 |
Starrock Pharma Llc |
Combinatorial, and rotational combinatorial therapies for obesity and other diseases
|
WO2024092037A1
(en)
|
2022-10-26 |
2024-05-02 |
Protego Biopharma, Inc. |
Spirocycle containing pyridone compounds
|
US20240174673A1
(en)
|
2022-10-26 |
2024-05-30 |
Protego Biopharma, Inc. |
Spirocycle Containing Pyridine Compounds
|
WO2024092040A1
(en)
|
2022-10-26 |
2024-05-02 |
Protego Biopharma, Inc. |
Spirocycle containing bicyclic heteroaryl compounds
|
WO2024089668A1
(en)
|
2022-10-28 |
2024-05-02 |
Basecamp Bio Inc. |
Somatostatin receptor 2 agonists and uses thereof
|
WO2024098009A1
(en)
|
2022-11-04 |
2024-05-10 |
Epicentrx, Inc. |
Rrx-001 for minimizing post-infarct adverse ventricular remodeling and complications
|
US20240165112A1
(en)
|
2022-11-04 |
2024-05-23 |
Bristol-Myers Squibb Company |
Therapy for the treatment of cancer
|
WO2024118810A1
(en)
|
2022-11-30 |
2024-06-06 |
Protego Biopharma, Inc. |
Cyclic pyrazole diamide ire1/xbp1s activators
|
WO2024118801A1
(en)
|
2022-11-30 |
2024-06-06 |
Protego Biopharma, Inc. |
Linear heteroaryl diamide ire1/xbp1s activators
|
WO2024124152A1
(en)
|
2022-12-08 |
2024-06-13 |
Epicentrx, Inc. |
Rrx-001 for the treatment of a hemoglobinopathy
|
US11931224B1
(en)
*
|
2022-12-19 |
2024-03-19 |
Robert Parker |
Tooth pod
|
WO2024145662A1
(en)
|
2022-12-30 |
2024-07-04 |
Altay Therapeutics, Inc. |
2-substituted thiazole and benzothiazole compositions and methods as dux4 inhibitors
|
WO2024186690A2
(en)
|
2023-03-03 |
2024-09-12 |
Enosi Therapeutics Corporation |
Oligo-trap fusion proteins (ofps) and uses thereof
|